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Abstract 
 
The mitochondrion is the energy producing factory of cells and it has long been thought 
that disruption to mitochondrial systems is linked to energy metabolism dysfunction.  
Sequence variants in the mitochondrial genome are plausible candidate risk factors for 
numerous human diseases, and research has identified specific mitochondrial DNA 
(mtDNA) variants associated with metabolic disorders such as obesity and type-2 
diabetes.  As part of the Rakaipaaka Health and Ancestry Study (RHAS) it has been 
observed that the Maori community of Nuhaka (Ngati Rakaipaaka) have a high 
incidence of certain metabolic diseases, namely obesity and diabetes.  The reason for 
this is not well understood, but is likely to be a combination of both current lifestyle 
(e.g. dietary) and ancestral genetic factors.  This study set out to sequence the entire 
mitochondrial genome in a sample of RHAS Maori participants.  The aim was to 
discover genetic variation that might be specific to this Maori community and test 
whether such variants are associated with diabetes and other metabolic traits. 
 
This study used a novel RFLP assay to screen the mtDNA control region for Polynesian 
mtDNA ancestry.  This established an initial group (n=30) with high levels of Maori 
mtDNA. Hypervariable (HVRI) sequencing was then used to generate a large dataset of 
sequences (n=94).  This dataset was representative of individuals showing high Maori 
ancestry and aided the selection of 20 mtDNA’s for Mitochip analysis.  Combining the 
RHAS Maori HVRI sequences with those from previous studies indicated elevated 
variation in Maori mtDNA.  Haplotype analysis identified 17 unique Maori haplotypes, 
10 more than previously recorded.  Mitochip resequencing has provided the first 
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complete Maori mtDNA sequences to date.  When compared to other mtDNA 
sequences it was identified that RHAS Maori share similar haplotype markers with 
Polynesians.   
 
Seven novel undocumented variants were found, as well as four variants that had 
previously been associated with various metabolic disorders.  Mitochip analysis of 
mtDNA sequences revealed three variants which created a RHAS Maori specific 
signature; C1185T, G4769A, and T16126C.  These variants also defined 3 unique 
mtDNA haplotypes within RHAS Maori, which are the first Maori specific haplotypes 
reported.  Variant genotyping and correlation with metabolic traits identified significant 
associations within the wider RHAS Maori community.  It was identified that RHAS 
Maori with T16189C showed elevation in both vitamin B12 levels and mean diastolic 
blood pressure.  Individuals with the G4769A variant were shown to have significant 
increases in specific metabolic risk factors for cardiovascular disease.  Conversely 
individuals with the more common A4769G variant were 2 times less likely to be 
diagnosed with diabetes. 
 
The findings from this study have identified a series of potential markers of metabolic 
disease within the RHAS Maori community.  The goal now is to understand how these 
markers interact with environmental variables to increase the risk of metabolic 
syndrome.  Such an outcome may open the way to designing personalised intervention 
strategies (e.g. dietary) to increase the health and well-being of at risk individuals. 
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Chapter 1  Introduction 
1.1 Rationale 
As part of the Rakaipaaka Health and Ancestry Study (RHAS) it has been observed that 
the Maori community of Nuhaka, New Zealand (i.e. Ngati Rakaipaaka) have quite a 
high prevalence of certain metabolic traits such as obesity and type II diabetes.  In a 
recent community health survey it was shown that the rate of self-reported diabetes in 
the Rakaipaaka community was 12%, which is approximately 3 times greater than the 
New Zealand (NZ) average (NZ Health Survey 02/03).  The reason for this is not well 
understood, but will no doubt be explained by both current lifestyle (e.g. dietary), and 
ancestral genetic factors, including perhaps underlying dysfunction in energy 
metabolism systems. 
 
The mitochondrion is the energy producing factory of cells and it has long been thought 
that disruption to mitochondrial systems is linked to metabolic disorders.  The objective 
of this study was to screen the entire mitochondrial genome in a sample of RHAS Maori 
using novel high-throughput sequencing technologies to identify mitochondrial genome 
(mtDNA) variants that might be specific to this Maori community and that might be 
correlated with metabolic-related traits such as diabetes.  
 
 The goal of this project was to identify genetic markers for metabolic syndrome in this 
Maori community and to understand how these markers interact with environmental 
variables to increase risk of metabolic disorders.  Such an outcome should allow for 
more personalised intervention strategies (e.g. dietary) to be designed to increase the 
health and wellbeing of people with those genetic markers.  
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1.2 Hypothesis and Objectives 
 
It is hypothesised that Maori have distinctive DNA sequence patterns (or signatures) in 
the mitochondrial genome, which have been shaped by a unique population history.  It 
is suspected that these specific mtDNA signatures modify the risk of developing 
metabolic disorders such as diabetes and obesity in this population. 
 
This project aims to utilise a new high-throughput microarray technology (Mitochip™ 
resequencing assay 2.0) to sequence the entire mitochondrial genome in subjects from 
the RHAS, and identify novel genetic markers of metabolic disease traits such as 
diabetes and obesity. 
 
The specific objectives of this study are as follows: 
 
1. Design and optimisation of an RFLP assay and HVRI PCR to aid with subject 
selection for Mitochip array analysis. 
2. Obtain entire mtDNA sequence information from a subsample of Rakaipaaka 
individuals with Maori ancestry (n=20) using the Affymetrix Mitochip. 
3. Align and compare this sequence information with independent worldwide 
sequences to identify group differences, i.e. a mtDNA signature that is specific to 
Rakaipaaka Maori. 
4. Validate the signature in a larger community sample of the RHAS Maori 
population (n=400). 
5. Correlate the validated mtDNA signature with metabolic traits (eg. BMI and 
diabetes). 
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1.3 The Mitochondrion 
 
Type 2 diabetes and obesity are prevalent in the Maori community of Ngati Rakaipaaka 
(Lea 2009, Paper in prep).  Metabolic traits such as these are known to be influenced by 
inherited genetic factors.  As the mitochondrion is the metabolic powerhouse of the cell 
and contains its own genetic information, it was deemed that this research would 
concentrate on identifying unique variants within mtDNA that could possibly be 
contributing to certain metabolic disorders.  This section provides an overview of the 
mitochondrion. 
 
1.3.1 Mitochondrial Structure 
Mitochondria are double membrane organelles are ~1 μm in size and located in the 
cytoplasm of eukaryotic cells (Kakkar et al., 2007).  The basic structure of a 
mitochondrion consists of; outer membrane, intermembrane space, inner membrane, 
cristae, and matrix (Figure 1.1).  The outer membrane is very similar in structure and 
composition to that of a eukaryotic cell membrane (Voet et al., 2004).  This outer 
membrane contains large amounts of the protein porin, which creates transport pores for 
the diffusion of small molecules (Ryan 2005).  Any large proteins that enter the 
mitochondrion must be labelled at the N-terminus and actively transported by the 
protein translocase of the outer membrane (Ryan 2005).  As small molecules are free to 
diffuse through pores, the intermembrane space is similar in content to the cytoplasm.  
Larger molecules however, are actively transported and reside in the intermembrane 
space, an example being cytochrome c (Lister et al., 2005).  The inner membrane 
contains all the proteins required for electron transport and production of ATP, as well 
as specific transport proteins and others that are needed for fusion and fission (Hansford 
2002; Voet et al., 2004).  The cristae are the invaginating folds of the inner membrane 
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that extend into the matrix of a mitochondrion.  These increase the surface area of the 
inner membrane, which effectively increases the amount of oxidative phosphorylation 
(OXPHOS) proteins (Voet et al., 2004).  Mitochondria that reside in tissue with higher 
energy requirements have many cristae, while those in less energy dependent areas have 
fewer cristae.  The mitochondrial matrix contains the bulk of all mitochondrial proteins, 
and is the major site of aerobic metabolism (Hansford 2002).  It also contains several 
copies of mtDNA and the ribosomes and associated proteins required for mtDNA 
transcription and translation (Voet et al., 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1:  Overview of the mitochondrial electron transport chain (ETC) and other 
complexes.  Flow of electrons through ETC complexes is indicated by the red dotted 
line.  ANT, adenine nucleotide translocator; Cyt C, cytochrome C; mPTP, 
mitochondrial permeability transition pore; PDH, pyruvate dehydrogenase complex; 
VDAC, voltage-dependent transition pore.  Adapted from Wallace (2006).  
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1.3.2 Mitochondrial Function 
The mitochondrion is the energy producing factory of the cell (Wallace 2006).  It is 
inside mitochondria that the conversion of metabolic energy into adenosine triphosphate 
(ATP) takes place (Figure 1.1).  ATP powers all cellular processes, and it is the 
mitochondrion’s job to ensure that oxygen consumption is correctly coupled to ATP 
production.  The system put in place is known as oxidative phosphorylation (Hansford 
2002).  This requires the passing of electrons (via electron transport chain, ETC) 
through specific protein complexes, the OXPHOS proteins (Hansford 2002).  Electron 
transport through this system enables the pumping of protons (H+) from the 
mitochondrial matrix into the intermembrane space, generating a proton motive gradient 
(Schultz et al., 2001).  It is this gradient that drives the production of ATP.  The 
mitochondrion has roles other than energy production, including cell signalling, 
programmed cell death (apoptosis), and control of the cell cycle (Wallace 2006; Kakkar 
et al., 2007). 
 
1.3.3 Oxidative Phosphorylation 
Oxidative phosphorylation (OXPHOS) is the metabolic pathway that uses energy 
released from the oxidation of nutrition resources to produce ATP (Voet et al., 2004).  
This process occurs inside mitochondria, with the initial energy being supplied in the 
form of the nutrient pyruvate.  Glycolysis breaks down glucose producing the metabolic 
product pyruvate, which is an essential component of aerobic respiration (Hansford 
2002).  Pyruvate is transported into the mitochondria (Figure 1.1) via pyruvate 
dehydrogenase (PDH), where it is then converted via a series of reactions to acetyl CoA.  
Acetyl CoA is the first substrate essential for Krebs cycle (Hansford 2002).  The Krebs 
cycle (citric acid cycle) provides several electron donors required for the ETC.  The 
ETC pertains to a series of 5 enzymes (Complex I-V) located within the mitochondrial 
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inner membrane (Figure 1.1).  These enzymes mediated the passage of electrons along 
the ETC via redox centers (Schultz et al., 2001).  The passage of electrons in this 
manner induces various charges which allow the pumping of protons from the matrix to 
the intermembrane space. 
 
The first enzyme in the ETC is NADH dehydrogenase (complex I).  This is a very large 
protein (~1000 kDa), in humans consisting of 46 subunits (Voet et al., 2004).  Complex 
I receives electrons from NADH supplied via the Krebs cycle, which it then transfers to 
ubiquinone (coenzyme Q10).  During this transfer 4 protons (H
+
) are pumped across the 
membrane (Hansford 2002).  The second enzyme succinate dehydrogenase (complex II) 
also transfers electrons to Q10.  Complex II is unique as it is the only ETC complex 
which has no mtDNA encoded subunits.  It is also the only complex enzyme that has a 
role in the Krebs cycle (Horsefield et al., 2004).  In the Krebs cycle, complex II oxidises 
succinate to fumarate, transferring these electrons to Q10.  Coenzyme Q10 when fully 
reduced becomes ubiquinol (Voet et al., 2004).  Ubiquinol is oxidised by cytochrome 
bc1 complex (complex III), resulting in the transfer of electrons and pumping of more 
protons.  Complex III contains several cytochrome subunits; proteins that contain 
hemegroups and transfer electrons (Kakkar et al., 2007).  Oxidisation of ubiquinol 
allows complex III to transfer electrons to a mitochondrial associated protein, 
cytochrome c (Schultz et al., 2001), which in turn transfers electrons to the final ETC 
complex, cytochrome c oxidase (complex IV).  It is in this complex that the terminal 
electron receptor resides in the form of oxygen (Voet et al., 2004).  A series of 
hemegroups and metal co-factors in complex IV are utilised to transfer electrons to 
oxygen, ultimately reducing it to H2O.  Again potential energy created at this step 
allows for the pumping of protons (Hansford 2002).  The net pumping of protons by 
ETC creates a chemiosmotic gradient, which allows the passage of protons, via proton-
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motive force, through the enzyme ATP synthase (Schultz et al., 2001).  As these 
protons pass back down into the matrix, a conformational change in the ‘head’ of ATP 
sythase forces ADP and Pi (inorganic phosphate) to bind, resulting in the production of 
ATP (Dimroth et al., 2000).  This ATP is transported out of the mitochondrion and used 
to power cellular processes. 
 
1.3.4 The Mitochondrial Genome 
The human genome stretches over a total of 3 billion base pairs, and codes for 
approximately 20,000-25,000 genes (Venter et al., 2001).  In contrast, the human 
mitochondrial genome is ~16,600 base pairs in size with only 37 genes in total 
(Anderson et al., 1981).  However, while smaller in size there are far more protein 
coding genes per base in the mtDNA (~69%) than in the human nuclear genome 
(~1.5%).  Essentially the entire human mtDNA encodes products; there is no ‘junk’ 
DNA.  Unlike nuclear DNA which is only present in two copies per autosome, there can 
be in excess of thousands of mtDNA copies per cell (Chen et al., 2005).  Mitochondrial 
DNA (mtDNA) has a mutation rate that is ~15 times that of the nuclear genome 
(Wallace 2006).  It is believed that this could be due to the apparent lack of mtDNA 
repair mechanisms and error checking, the lack of histones, as well as the constant 
production of reactive oxygen species (ROS), a by-product of ATP production 
(Chinnery et al., 2000; Hoffman et al., 2006).   
 
The mtDNA is located within the matrix of mitochondria, typically exhibiting usually 2-
10 copies per organelle (Kakkar et al., 2007).  Nuclear DNA and mtDNA are commonly 
thought to be of separate evolutionary origins, with mtDNA believed to have originated 
from the genomes of bacteria which were engulfed by an early eukaryotic cell ancestor 
(Davidov et al., 2006).  Together these organisms formed a symbiotic relationship, 
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allowing the flow of genes from the bacterial DNA into the host nuclear DNA.  Human 
mtDNA is a double stranded, circular molecule (Anderson et al., 1981).  Within this are 
coded 37 genes; 13 dedicated to OXPHOS subunits, 22 to tRNAs, and 2 for rRNAs 
(Figure. 1.2).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2:  The human mitochondrial genome is a circular molecule that is 16.569bp 
in size.  Human mtDNA contains 37 genes; 13 protein coding (green), 22 transfer 
RNA’s (yellow; single letter code indicates coded amino acid), and 2 rRNA (orange).  
In the control region there are two hypervariable regions, HVRI and HVRII (pink).  
Origins of replication for each strand (red) and directions of transcription are detailed. 
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Being solely maternally inherited (Giles et al., 1980; Chen et al., 2005), mitochondrial 
genetics do not follow simple Mendelian laws (DiMauro et al., 2007).  In each cell there 
are potentially hundreds to thousands of mitochondrial genomes (Hoffman et al., 2006).  
This means that instead of dealing with two alleles of every gene, as in Mendelian 
genetics, there are hundreds to thousands of gene copies within each cell, all of which 
may have variable mutations (Chinnery et al., 2000).  During cell proliferation, 
mitochondria are randomly segregated to the two new daughter cells at cytokinesis.  
Due to this random distribution of mtDNA segregating to daughter cells, the frequency 
of mutant mtDNA within a daughter cell can increase or decrease in frequency 
(Chinnery et al., 2000).   
 
1.3.5 Mitochondrial OXPHOS Genes 
The majority of the OXPHOS proteins are encoded by the nuclear genome, with only 13 
OXPHOS subunit proteins stemming from the mtDNA (Figure 1.4).  These 13 subunits 
form integral components within four of the protein complexes essential for electron 
transport and OXPHOS (Kakkar et al., 2007).  A brief overview of the complexes 
containing mtDNA encoded subunits and an overview of their function will be given for 
reference: 
 
 NADH Dehydrogenase (Complex I) 
(mitochondrial genes: NAD1, NAD2, NAD3, NAD4, NAD4L, NAD5, NAD6) 
NADH dehydrogenase catalyzes the transfer of electrons from NADH to coenzyme Q.  
Four protons are translocated per NADH, helping build the electrochemical gradient. 
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 Cytochrome b (subunit of Complex III) 
(mitochondrial gene: cyt b – solely encoded by mtDNA) 
The mitochondrial gene that codes for cytb subunit of the cytochrome bc1 complex 
(complex III).  This complex non-covalently binds two heme groups.  Four conserved 
histidine residues are postulated to be the ligands of the iron atoms of these two heme 
groups.  Complex III passes electrons on to cytochrome c and pumps protons out of the 
matrix.   
 
 Cytochrome c Oxidase (Complex IV) 
(mitochondrial genes: COI, COII, COIII ) 
Cytochrome c Oxidase accepts electrons from cytochrome c, and uses them to convert 
molecular oxygen into water and in the process translocates protons across the 
innermembrane helping establish the electrochemical gradient. 
 
 ATP Synthase (Complex V) 
(mitochondrial genes: ATP6, ATP8) 
ATP Synthase is an enzyme that can create ATP from ADP and an inorganic phosphate 
(Pi) and energy.  In mitochondria this energy is supplied via the protons moving against 
the electrochemical gradient set up via electron transport. 
  
1.3.6 mtDNA Markers of Ancestry 
Over the last 30 years mtDNA has shown considerable potential in the revealing of 
evolutionary secrets.  Mitochondrial DNA is uniparently inherited; it is only passed 
down the maternal line (Giles et al., 1980).  Male mtDNA is either lost during the 
fusion of the sperm and ovum, or targeted for destruction within the oocyte (Giles et al., 
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1980).  While there is scarce evidence of male mtDNA inheritance (Schwartz et al., 
2002), it appears to be at a very diminutive level.  The fact that mtDNA is haploid and 
does not exhibit the recombination seen in nuclear genes, means that markers 
(mutations) are conserved in blocks and passed on to future generations.  These unique 
blocks are termed haplogroups.  Haplogroups are defined by specific variants that create 
major branching points in the mitochondrial phylogenetic tree (van Oven et al., 2009).  
They can be broken down into more specific haplotypes, which refer to an individual 
group of variants found on top of the core haplogroup defining variants (a collection of 
potential haplotypes belong to a broader haplogroup).  Due to the nature of mtDNA 
inheritance and the path of early human evolution specific haplogroups have become 
established in varying parts of the world (for a review see Forster [2004]).  These 
properties make mtDNA an ideal candidate for investigating the evolutionary 
relationship between inherited variants and among human sub populations. 
 
Founder effects and bottlenecks have shaped the Polynesian mitochondrial genome in a 
unique way that allows it to be used as a powerful tool for identification.  It was 
discovered that a 9-bp deletion existed in moderate frequencies in the mitochondrial 
haplotypes of Southeast Asia and Papa New Guinea, and later in Taiwan and the Pacific 
Island (Polynesia) populations (Hertzberg 1989).  Alongside this was discovered a 
transition (T16189C), and two transversions, which create a homopolymeric tract 
(Poulton 1998).   A few years later a unique set of transition mutations termed the 
‘Polynesian Motif’ were identified in high frequencies in the mitochondrial control 
regions of Polynesians (Redd et al., 1995).  This motif includes three separate transition 
mutations; T16217C, A16247G, and C16261T. An individual with maternal Polynesian 
descent will most likely show the motif ‘CGT’.  It is also important to note that the 
Polynesian Motif is only found in haplogroup B, in the presence of the 9-bp deletion.  
Introduction 
 
12 
 
1.3.6.1  Restriction Fragment Length Polymorphism’s (RFLP) 
It was in 1968 that Meselson and Yucan discovered a group of enzymes that recognised 
and cut specific sequences of DNA (Meselson et al., 1968).  These were termed 
restriction endonucleases’, now more commonly known as restriction enzymes.  Owing 
to the nature of these enzymes specificity a simple mutation, such as a substitution of a 
single nucleotide (e.g. single nucleotide polymorphisms or SNPs), can create or destroy 
a restriction site, thus leaving larger or smaller fragments of digested DNA.  This 
recognised change in fragment size was first noticed in human β globin with the 
restriction enzyme Hpa I (Waikan et al., 1978).  The presence of the specific 
polymorphism was coined a restriction fragment length polymorphism (RFLP).  It was 
later realised that restriction sites could be used to investigate genetic affinities within 
and between specific human ethnicities.  Different mitochondrial haplogroups were 
found to contain unique restriction sites (Figure 1.3) which are seen to be continent 
specific (Ruiz-Pesini 2007). 
 
The high mutation rate and population specific properties of mtDNA lend itself well to 
the nature of RFLP investigation.  Early studies investigated mitochondrial 
polymorphisms with various restriction enzymes (Cann et al., 1987), ultimately 
generating a group of RFLP based haplogroups (Francalacci et al., 1999).  Figure 1.3 
shows the restriction sites and corresponding enzymes distributed around the mtDNA, 
haplogroups are indicated using alphabetic nomenclature.   
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Figure 1.3:  The position of haplogroup specific restriction sites in the human mtDNA.  
(+) indicates a restriction site is created by respective variant,  (-) indicates a restriction 
site is lost.  Restriction site labelled in red was discovered in this study and will be 
explored in more detail later.  This figure has been modified from Francalacci et al. 
(1999).  
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1.3.6.2  mtDNA Haplogroup B 
Haplogroup B is believed to have arisen in Asia some 50,000 years before present 
(YBP), stemming from the ancestral haplogroup R (van Oven et al., 2009).  Present day 
haplogroup B is spread over all of Asia, the Americas, Melanesia and Polynesia 
(Hertzberg 1989; Melton et al., 1995).  An important characteristic that defines mtDNA 
of this group is a 9-base deletion at 8281-8289 (Hertzberg 1989).  Haplogroup B is 
broadly distributed in Asian populations.  Recent population expansions associated with 
the spread of Austronesian languages appear to have brought these haplotypes from 
Southeast Asia into Polynesia around 5000-1000 YBP (Sykes et al., 1995).  The vast 
majority of Polynesian haplogroup B mtDNA’s exhibit a set of polymorphisms that 
distinguishes them from similar types in other Asian populations (Lum et al., 1994; 
Melton et al., 1995; Redd et al., 1995; Melton 1998).  This set of mutations, which 
includes the T16217C, A16247G, and C16261T transitions (or "CGT"), has been called 
the "Polynesian motif" because of its uniqueness to Polynesian and related populations 
(Hagelberg and Clegg 1993; Hagelberg et al. 1994; Lum et al. 1994).  The Polynesian 
motif is believed to have descended from mtDNAs bearing an ancestral origin in 
Taiwan, and continued as populations spread south into the Philippines, Indonesia, and 
Melanesia (Melton et al. 1995, 1998; Redd et al. 1995), although some favour an 
Indonesian source for this lineage (Richards et al. 1998).  Melton et al. (1995, 1998) 
observed the Polynesian Motif at the highest frequency in Polynesians and coastal 
Papua New Guineans, and at modest frequencies in East Indonesians and Malays, with 
the intermediate form (CAT) occurring at the highest frequencies in Taiwanese 
aborigines and moderate frequencies in Filipinos and east Indonesians (Trejaut et al., 
2005).    
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1.3.6.3  9bp-deletion 
Haplogroup B is found in several places around the world; Southeast Asia, South 
America, and the Pacific region (van Oven et al., 2009).  The major B haplogroup 
defining mutation is the intergenic 9-bp deletion between cytochrome oxidase II and 
tRNA lysine (Figure 1.4).  Population frequencies of the 9-bp deletion have nearly 
reached 100% in much of the island Oceania region (Hertzberg 1989; Sykes et al., 
1995) and appear to have reached fixation Maori mtDNA of Polynesian ancestry 
(Whyte et al., 2005).  A complete phylogenetic tree of mitochondrial haplogroups and 
their individual haplotypes can be found on the PhyloTree database (van Oven et al., 
2009).   
 
 
 
 
 
 
 
 
 
 
Figure 1.4:  Mitochondrial markers of haplogroup B.  1. (a) the Cambridge Reference  
Sequence mtDNA showing the position of the 9-bp deletion (indicated in red text).  (b) 
the deleted region in mtDNA of haplogroup B.  2. (a) the mtDNA HVRI of the 
Cambridge Reference Sequence.  (b) the required transitions for the formation of the 
Polynesian motif.  The 16189 transition creates a poly-cytosine tract.  The two adenines 
often undergo A to C transversions in many Polynesian and Maori (indicated by blue 
text and arrows).  This figure has been adapted from Whyte et al. (2004).  
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1.3.6.4  Hypervariable Region I and the Polynesian ’CCGT’ motif 
The hypervariable region of the human mitochondrial genome is divided in two parts: 
hypervariable region I (HVRI), and hypervariable region II (HVRII).  Both HVRI and 
HVII are located within the D-loop (Anderson et al., 1981; Andrews et al., 1999).  
These regions are named such because they exhibit a higher mutation rate than any 
other genes within mtDNA (Stoneking 2000).  Both regions are believed to contain 
sections of DNA that are involved in the initiation and regulation of mtDNA replication 
and transcription.  There are mutational hotspots within the hypervariable regions, and 
the HVRI mutates faster than HVRII (Stoneking 2000). 
 
Haplogroup B is of predominantly higher frequency within the Polynesian peoples of 
Oceania (Hertzberg 1989).  The majority of Polynesian mitochondrial haplotypes are 
specifically B4a1a1 (Ingman 2001).  This haplotype is represented by a specific set of 
variants located within the HVRI of the mitochondrial D-loop (Hagelberg et al., 1993; 
Lum et al., 1994; Redd et al., 1995).  This has been colloquially termed the Polynesian 
motif (Redd et al., 1995), for the reason that frequencies are extremely high in all 
Polynesian populations.  The Polynesian motif consists of three transition mutations 
which are all found within the HVR of the mtDNA.  The transitions are as follows; 
T16217C, A16247G, and C16261T (Figure 1.4).  As mentioned previously, haplogroup 
B is also typified by a T→C transition at position 16189 which creates a 
homopolymeric C tract.  This is often referred to as the forth transition within the 
Polynesian motif (Whyte et al., 2005).  For the purpose of this thesis from this point on 
the Polynesian motif will be represented as ‘CCGT’ for the four transitions.  This 
‘CCGT’ motif defines the haplotype B4a1a1a. 
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In 2005 it was identified that there existed a possible pre-Polynesian motif in the coastal 
regions of Taiwan, the aboriginal Taiwanese Amis tribe (Trejaut et al., 2005).  This pre-
Polynesian motif is again represented by the same four HVRI positions, yet it only 
exhibits three of the transitions (T16189C, T16217C, and C16261T).  This then is 
‘CCAT’, missing the A→G transition at 16247.  Interestingly the researchers found that 
when they ran several phylogenetic tests, Polynesian mitochondrial sequences grouped 
within the Amis sequences (Trejaut et al., 2005).  Not only this, other sequences from 
areas in Miconesia and Melanesia (including the PNG coast) also grouped within these 
aboriginal Taiwanese samples.  This supports the theory that present day Polynesians 
are decedents of Austronesian speaking migrants from coastal Taiwan, who moved 
down through coastal regions of PNG and surrounding islands, finally branching out 
into the Pacific region.  It appears that it was during this migration into the Pacific 
region that the 16247 transition occurred, as it is at its highest frequencies in and around 
the Pacific countries (Redd et al., 1995; Cann 2004). 
 
1.3.6.5  Hypervariable Region II 
Previous research has shown that the HVRII shows little to no variation within 
Polynesian and NZ Maori populations (Ingman 2001; Whyte et al., 2005).  The only 
informative markers within this region are shared by numerous different haplogroups, 
thus analysing the HVRII region is not as informative as the HVRI.  Studies have also 
discovered that there is a high mutation rate within HVRI, explaining the increased 
variation (Stoneking 2000).  It has been postulated that this could be due to the fact that 
the HVII contains vital DNA segments that are related to the functional aspects of 
replication and translation of mtDNA (Chang et al., 1985).   
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1.3.7 A New Era of mtDNA Sequencing 
Historically the mitochondrial genome has been investigated using RFLP and targeted 
polymerase chain reaction (PCR) and sequencing, mainly of the HVR’s (Cann et al., 
1984).  The last few years have seen a dramatic increase in number and availability of 
complete mitochondrial genomes, see databases such as Mitomap, mtDBA, and 
Phylotree (the latter having a curetted database of 6729 as of October 2009).  Bar the 
recent rise there were a limited number of complete sequences, due to the fact that using 
traditional methods (numerous overlapping PCR fragments and traditional Sangar 
sequencing) was expensive and time consuming.  Recognising the need for more cost 
effective and less labour intensive mtDNA sequencing analyses there have been the 
recent release of several new technologies. 
 
1.3.7.1  Affymetrix Mitochip™ 
Affymetrix have designed an alternative method based on their GeneChip technology.  
The Mitochip is a resequencing array that binds mtDNA fragments and interrogates 
each position of the mitochondrial genome (Figure 1.5).  The design and first 
documented use of Mitochip technology was in detection of head and neck cancer 
(Maitra et al., 2004).  Information of positional variation is determined and a complete 
mtDNA sequence generated.  This method has several benefits, the first being that it is 
very quick and requires little preparation in the way of PCR’s and sequencing (the 
human contact time is reduced).  One of the major technical developments was the 
introduction of the long-range PCR method.  Using a set of specially designed primers 
and Takara LA Taq polymerase, the entire mitochondrial genome can be amplified in 
only three overlapping fragments, far less than traditional PCR methods. The Mitochip 
process takes no more than 48 hours and 8 chips can be processed at the same time.   
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Figure 1.5:  Overview of the Affymetrix Mitochip™.  Extracted DNA is used as 
template for long range PCR.  Three sets of primers are used to amplify the mtDNA.  
The PCR products are then fragmented, labelled with biotin, and hybridised to the 
Mitochip.  The chip is then washed with streptavidin-phycoerythrin which binds to the 
biotin.  A signal amplification step is carried out by washing the chip with anti-
streptavidin antibody (goat), followed with biotinylated goat IgG antibody, and a final 
wash with streptavidin.  This procedure ensures an ample signal is present when the 
chip is scanned with a confocal laser.  When scanned the chip creates a distribution 
pattern, which is read by Affymetrix GeneChip Operating Software (GCOS).  Data can 
then be analysed using GeneChip Sequence Analysis Software (GSEQ).  
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1.3.7.2  mitoSEQr™ 
Applied BioSystems have recently developed a resequencing assay which is able to 
identify sequence variants in entire mitochondrial genomes (including the control 
region).  This new plate PCR method uses a set of specific universal primer pairs, which 
generate 46 overlapping mtDNA fragments covering the complete mitochondrial 
genome.  These fragments are used as templates for sequencing using universal M13 
primers.  The assay design allows all primer pairs to anneal and operate at the same 
temperature, making it faster and less labour intensive.  Being a direct sequencing assay 
makes the mitoSEQr protocol very accurate at detecting areas of heteroplasmy, as well 
as in-dels.  Further details on mitoSEQr can be found on the Applied BioSystems 
website (https://products.appliedbiosystems.com/). 
 
1.3.7.3  High-Resolution Melt Profiling 
High-Resolution Melt (HRM) profiling has recently been proven as a method for 
accurately detecting specific mtDNA mutations (Dobrowolski et al., 2009).  It has the 
benefits of being a fast, simple, and low cost screen that looks to become widely 
adopted as a mutational diagnostic tool.  It is also less labour intensive as the PCR 
amplification and melting curve are able to be run from the same plate.  Other 
advantages include high levels of accuracy for detection of heteroplasmy, indels, and 
SNPs.  High resolution melt profiling is however not an ideal method for complete 
reconstruction of the mtDNA, as this would end up being expensive and time 
consuming. 
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1.4 The Role of Mitochondrial DNA in Disease 
 
Faults in the mtDNA can cause around 50 known diseases, some of which lead to 
disability and death (Hoffman et al., 2006).  About one in every 6500 people is affected 
by such conditions, which include fatal liver failure, stoke-like episodes, blindness, 
muscular dystrophy, diabetes and deafness.  Metabolic syndrome comprises of 
numerous ‘component’ disorders, such as; insulin resistance, hyperglycemia, high blood 
pressure, visceral obesity, elevated triglycerides, and decreased HDL.  Together these 
increase the risk of developing heart disease (cardiovascular disease) and diabetes.  
Several diseases are in fact directly related to specific mtDNA mutations, such as the 
large scale deletion Kearns-Sayre Syndrome (Puoti et al., 2003). 
 
The effects of mitochondrial disorders vary greatly.  Due to the nature of mtDNA it is 
possible that the expression of mutant mtDNA can differ from tissue to tissue.  It is 
evident that many mitochondrial diseases are tissue dependent.  Muscle and nervous 
tissue are generally accepted as being most vulnerable to deleterious mutations due to 
the high energy requirement of these tissue types.  Many mtDNA mutations have been 
associated with myopathy and neurological disorders such as Parkinson’s disease (van 
der Walt et al., 2003; Gaweda-Walerych et al., 2008).  It is now clear that mtDNA plays 
a role in many other diseases, with metabolic disorders such as insulin resistance 
(Poulton et al., 1998), type-II-diabetes mellitus (Kim et al., 2002), deafness (Ballana et 
al., 2008), and obesity being some of the most important (Figure 1.6).  It is however, 
not always easy to attribute disease phenotype to mitochondrial dysfunction.  The major 
reason for this is that mtDNA can also vary inside the mitochondrion itself, a state 
known as heteroplasmy.  
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Figure 1.6:  The mitochondrial genome and disease association.  The position in 
mtDNA of the disorders is indicated along with variant type (i.e. transition/transversion, 
or insertion/deletion).  LHON, leber’s hereditary optic neuropathy; MELAS, 
mitochondrial encephalopathy lactic acidosis with stroke-like episodes; MERRF, 
myoclonic epilepsy and ragged-red fiber; T2DM, type II diabetes mellitus.  Adapted 
from Wallace (2006).   
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1.4.1 Heteroplasmy and Mutational Threshold Effect 
Heteroplasmy is the state of having two variant mtDNA populations within a cell 
(Acton et al., 2007).  This means that mitochondria can contain varying levels of two 
different types of mtDNA, one set being ‘normal’ the other being ‘mutant’.  Different 
levels of heteroplasmy, also the tissue type, can mask the disease phenotype (Figure 
1.7).   The relative frequency of mutant to wild-type mtDNA within a cell, a tissue, or 
even an organism, determines whether an altered phenotype will be observed clinically 
(Ballana et al., 2008).  Thus, a specific threshold of mutations are required within each 
cell to alter metabolism, and a threshold of mutant cells within a tissue are required for 
the phenotype to be observed clinically (DiMauro et al., 2007; Ballana et al., 2008). 
 
 
 
Figure 1.7:  The role of mitochondrial heteroplasmy and disease.  Varying degrees of 
heteroplasmy are shown, along with possible outcomes to cell survival.  Wild-type 
mtDNA is represented in blue, mutant mtDNA in green. 
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Heteroplasmy can also be useful when tracing mtDNA ancestry.  The most famous 
documented example of mtDNA heteroplasmy is the historical case of the Romanov’s, 
the Russian royal family that were brutally murder during the Russian revolution.  
Independent lab testing of mtDNA extracted from exhumed remains identified a 
position of heteroplasmy shared between close maternal relatives (Ivanov et al., 1996).  
Using this positional variation it was determined that over several generations the 
heteroplasmic variant had segregated to homoplasmy in living relatives that had 
supplied DNA.  This was most likely attributed to a mtDNA bottleneck effect over the 
several generations of mtDNA transmission. 
 
1.4.2 Reactive Oxygen Species and Mitochondrial Disease 
Reactive oxygen species (ROS) are free radicals that contain the oxygen atom (Voet et 
al., 2004).  They are very small molecules that include oxygen ions and peroxides and 
can be either inorganic or organic (Brand 2007).  They are highly reactive due to the 
presence of unpaired valence shell electrons.  ROS form as a natural by-product of the 
normal metabolism of oxygen and have important roles in cell signalling (Figure 1.8).  
Many of mitochondrial functions actually rely on specific forms of ROS, such as 
apoptosis (Cadenas 2004).  Raqual Moreno-Loshuertos and colleagues reported that 
ROS could also act homeostatically (Moreno-Loshuertos et al., 2006).  Their research 
shows that ROS can control processes such as increasing mtDNA replication, the 
activation of uncoupling proteins, and growth factor signalling.  These properties of 
ROS may be a contributing factor towards the masking of phenotypic consequences of 
mtDNA variation (Baughman et al., 2006).  However, during times of environmental 
stress (e.g. UV or heat exposure) ROS levels can increase dramatically, which can result 
in significant damage to cell structures.  This cumulates into a situation known as 
oxidative stress. 
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Figure 1.8:  Possible routes to metabolic disease in the pancreatic β cell.  Effecting the 
production of ATP can ultimately alter the amount of insulin released by the β cells.  
Decreasing ATP production favours ADP, which opens the membrane potassium 
channels.  Extracellular potassium can feed back, inhibiting calcium uptake, which is 
directly related to insulin release.  Other outcomes to errors in mitochondrial function 
include the increased production and build up of reactive oxygen species (ROS), which 
can be harmful to the cell.  Adapted from Wallace (2006). 
 
 
Recent studies have been investigating the relationship between certain mtDNA variants 
and increased ROS levels (Brand 2007; Gaster 2007).  One of the major correlations 
seems to be that increasing ROS levels lead to increased instances of insulin resistance 
(Lin et al., 2005; Houstis et al., 2006).  Insulin resistance occurs when the normal action 
of insulin is impaired, leading to muscle, fat and liver cells unable to illicit an insulin 
response (Stannard et al., 2004).  Production of insulin increases to try and combat 
sensitisation of cells, this leads to increased insulin in blood plasma.  Ultimately the 
action of insulin decreases leading to increased blood glucose (Gaster 2007).  High 
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plasma insulin levels and high blood glucose owing to insulin resistance is believed to 
be the precursor and primary cause of type II diabetes and many metabolic disorders.   
 
Researchers are still debating as to how insulin resistance actually occurs (Taubes 
2009).  Numerous reports are putting forth specific mtDNA variants as contributing or 
possibly having a causal role in insulin resistance (Poulton et al., 1998; Evans et al., 
2003; Petersen et al., 2003; Bhat et al., 2007).  Significance of the mutation T16189C 
having a role in insulin resistance has been discussed in many studies (Poulton et al., 
1998; Kim et al., 2002; Lin et al., 2005; Weng et al., 2005; Bhat et al., 2007; Liou et 
al., 2007).  This mutation is found within the non-coding control region (HVRI), it is 
also a marker for haplogroup B alongside the intergenic 9-bp deletion.  It is 
hypothesised mitochondria with this mutation become less competent in dealing with 
oxidative stresses (Bhat et al., 2007).  Research has associated this variant with 
increased levels of oxidative damage, not only in diabetic patients but also in non-
diabetic patients harbouring the mutation (Lin et al., 2005; Bhat et al., 2007).  One 
possible pathway is via mitochondria containing this mutation being prone to producing 
higher than normal levels of ROS.  A build up of ROS in the mitochondria can have 
many pathologic effects, including DNA damage, inhibition of glucose metabolism, and 
promotion of apoptosis (Figure 1.8).   
 
ROS levels appear to be a trigger for insulin resistance in numerous settings (Houstis et 
al., 2006).  Houstis et al., (2006) found they were able to induce ROS levels with either 
cytokine TNF-α or glucocorticoid dexamethasone.  They noticed that as ROS levels 
increased so did insulin resistance.  They then tested whether ROS has a causal effect in 
insulin resistance by applying pharmacological and genetic interventions.  While these 
treatments did not fully prevent the development of insulin resistance, they did ease it.  
Introduction 
 
27 
 
1.4.3 mtDNA Haplogroups Associated with Metabolic Diseases 
Phylogenetic studies have shown that human populations can be divided into mtDNA 
haplogroups which are defined by specific single nucleotide polymorphisms (SNP’s) 
(van Oven et al., 2009).  These haplogroups are representative of accumulated 
mutations which have been inherited along discrete lineages.  Some of these specific 
inherited variants might be predisposing factors in numerous diseases; insulin resistance 
(Poulton et al., 1998) and diabetes (Chinnery et al., 2005; Lin et al., 2005; Bhat et al., 
2007), cancer (Bai et al., 2007; Ray et al., 2009), Alzheimer’s disease (van der Walt et 
al., 2004; Santoro et al., 2006), and Parkinson’s disease (Van Der Walt et al., 2002; 
Ghezzi et al., 2005; Gaweda-Walerych et al., 2008). 
 
The variant T16189C, common to haplogroup B (Polynesian motif, this variant is 
heavily conserved in Polynesian and Maori populations) has been associated in 
numerous studies with insulin resistance and a possible role in type II diabetes (Poulton 
et al., 1998; Kim et al., 2002; Livesey et al., 2004; Bhat et al., 2007; Liao et al., 2008).  
Other markers from haplogroup B have also been associated with metabolic traits.  The 
previously mentioned 9-bp deletion has a role in disease.  It has been reported that there 
is a high prevalence of 9-bp in Taiwanese populations with MELAS or MERRF (Liu et 
al., 2005).  
 
Some haplogroups have been shown to provide a certain degree of protection from 
certain diseases.  The Asian haplogroups N9a and N9b appears to offer protection from 
specific metabolic disorders.  N9a has been associated with protection against type 2 
diabetes in Asian females (Fuku et al., 2007), while N9b has been associated with 
protection against myocardial infarction in Asain males (Nishigaki et al., 2007).  
Protection is also seen in arctic populations. Several non-synonymous mitochondrial 
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mutations appear to be advantageous in Arctic populations (Mishmar et al., 2003; Ruiz-
Pesini et al., 2004).  These two studies suggest that non-synonymous mutations in 
mtDNA encoded OXPHOS proteins might disturb ATP production in a way that leads 
to the production of extra heat.  These mutations could then be viewed as adaptive 
features. 
 
The A10398G has been found to be both protective and harmful.  In Irish populations 
(mutation is associated with haplotype J) this mutation has been associated with 
longevity, found to be well represented in haplotypes of centenarians (Ross et al., 
2001).  The same variant in Northern Indian populations has been correlated with 
increased ROS levels and insulin resistance, possibly also predisposing individuals to 
type 2 diabetes (Bhat et al., 2007).   
 
1.4.4 Coupling and Thrifty Genes 
As humans migrated out of Africa they came in contact with varying environmental 
conditions and challenges (Forster 2004).  Mitochondrial DNA is theorised to have 
played a large role in the survival and success of migrating human populations (Wallace 
2006).  This advantage revolves around the process of coupling.  Coupling explains the 
efficiency of the joint effort of OXPHOS complexes and electron transport to produce 
ATP (Schultz et al., 2001).  This is an indirect process, being maintained via the 
generated proton electrochemical gradient.  Loosely coupled mitochondria are able to 
disengage the processes of OXPHOS ETC and ATP production (Malmgren et al., 
2009).  Using either uncoupling proteins (UCPs) or nonspecific leak pathways, they 
have the ability to usurp potential redox energy and dissipate it as heat rather that 
synthesising ATP.  This property therefore allowed certain populations the ability to 
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persevere in colder climates, and forced those with tightly coupled mitochondria to the 
warmer more temperate climates (Wallace 2006). 
 
Tightly coupled mitochondria have increased efficiency for using available calories to 
produce ATP.  Fewer calories are need in a tightly coupled system as the mitochondria 
are able to generate a larger electrochemical potential, thus produce more ATP.  This 
would have been an advantage in warmer climates (Wallace 2006).  Not being able to 
uncouple however, can have draw backs.  Over eating can lead to outcomes other than 
fat storage.  An excess of calories can overload OXPHOS, effectively stalling electron 
transport.  Overloaded electron transport causes the electron carriers to become highly 
reduced, which in turn leads to the increased production of ROS in an attempt to utilise 
some of the surplus electrons (Wallace 2006).  ATP production decreases due to the 
stalling of electron transport, thus the ATP:ADP ratio changes to favour ADP (Maechler 
et al., 2006).  An increase of ADP within the cell activates the potassium ATP (KATP) 
channel which inhibits the cellular influx of Ca2+ (Section 1.4.2, Figure 1.8).  This is 
important to consider in the context of the β-cells of the pancreas (Maassen et al., 
2006).  Decreasing the amount of Ca
2+
 taken up by the pancreatic islet cells, directly 
affects insulin release.  Less insulin release means higher blood glucose.  This is one 
hypothesised route to insulin resistance (Maassen et al., 2006; Maechler et al., 2006).   
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1.4.5 mtDNA Disease Detection and Future Therapies 
In the past sequencing mtDNA used to be relatively difficult and very expensive for 
complete mitochondrial genomes.  The majority of the earlier mtDNA research focused 
on RFLP (Restriction Fragment Length Polymorphism) analysis and sequencing of the 
hypervariable regions (Francalacci et al., 1999).  Slowly it has been recognised that 
complete mtDNA sequences offer the ability to analyse more fully the role and function 
of mitochondria (Zhou et al., 2006).  Complete mitochondrial sequencing has provided 
an advanced resolution for phylogenetic studies (Torroni et al., 2006), and is going to be 
of great benefit for further investigation into how metabolic disorders effect not only 
individuals but also specific populations (so effectively improve how we understand the 
mitochondrion).   
 
One such example of technology that has evolved for analysing the mtDNA is the 
Mitochip, designed by Affymetrix (Maitra et al., 2004).  This is a gene array chip that is 
able to resequence the entire mtDNA, provide additional information for the control and 
hypervariable regions (HVR), as well as a host of common known variants.  A simple 
PCR recoups the mtDNA from a genomic preparation, then it is fragmented and 
hybridised to the Mitochip.  Not only does the Mitochip lend itself to provide complete 
mtDNA sequence information, it has several other novel uses.  Several groups have 
found a potential use for the Mitochip in the early detection of cancers (Maitra et al., 
2004; Zhou et al., 2006).  In fact one group have managed to successfully identify 
breast cancer patients by just using mtDNA from nipple aspirate (Jakupciak et al., 
2008).  This process offers much faster results than traditional sequencing, and is very 
non-intrusive as nipple aspirate fluid is easy and painless to collect.  This technique 
could then be utilised for other cancers such as prostate or urinary tract cancers by 
analysing mtDNA from cells in urine.   
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Another Mitochip application is forensic identification (Vallone et al., 2007).  
Previously HVR data has been used for forensics, but now the ability to increase the 
resolution of mtDNA means that it becomes an even more potent and accurate tool 
(Vallone et al., 2007).  Therefore the next few years should see the amount of available 
complete mtDNA sequences increase dramatically (~6729 online, PhyloTree).  The off-
shoot of this in terms of metabolic disorders means that more mtDNA sequences from 
an extended variety of population backgrounds will become available online, and will 
allow for increased interrogation.   
 
Due to the maternal inheritance of mtDNA, mitochondrially inherited disorders are 
nearly impossible to treat (Dimauro et al., 2001).  Recently the first viable treatment for 
mitochondrial disorders was explored in monkeys (Tachibana et al., 2009).  This 
procedure has been termed the three-parent embryos.  The principle is to effectively 
transfer a healthy nucleus from a mitochondrial defected cell into an embryonic cell that 
has had its nucleus removed (Tachibana et al., 2009).  This new cell has a healthy 
mitochondrial background.  The procedure has been tested recently in monkeys, and 
some have given birth to healthy offspring (Tachibana et al., 2009).  The offspring show 
nuclear DNA from the donor female and male, and mtDNA from the cytoplast donor.  If 
the three-parent embryo procedure became a viable option for humans, it would be the 
ideal treatment for mothers with metabolic syndrome who wished to one day have 
children. 
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1.5 Genomics and Polynesian Ancestry 
 
When thinking about RHAS and the study being conducted it is important to consider 
the effect that ancestry and migration have on the subsequent origin of specific variants 
and genes (in this case the mtDNA).  Ancestry has shaped the mitochondrial genome in 
all human populations and this holds true for RHAS.  Recounting ancestral history is 
valuable not only from an evolutionary perspective, but also for identifying associations 
between mtDNA and disease, with the goal of being able to deliver the best possible 
diagnosis and treatment.   
 
1.5.1 The Settlement of Remote Oceania by Polynesians 
Now that the ‘out of Africa’ model is generally accepted (Vigilant et al., 1991; Forster 
2004), the question becomes re-orientated on the process of how we got to where we are 
now.  The vast majority of populations around the world are able to be traced back 
through their ancestral intermediates to Africa, but one region has perplexed 
evolutionary scientists for nearly 50 years.  This area is Oceania. 
 
Oceania encompasses the Pacific Islands and New Zealand, and is thought to have been 
the last place in the world to be populated.  As such there is great interest in discovering 
where pre-Polynesian populations originated from (Cann 2004). This interest has 
sparked major debate within the scientific community.  It is generally accepted that 
Oceania was populated by Austronesian speaking peoples (Bellwood 1991).  The debate 
centres on where these people originally came from, and how they reached their final 
destinations.  Early evidence arose in the form of linguistic (Bellwood 1991; Gray et al., 
2000) and archaeological information (Kirch et al., 1988), and recently genetic analysis 
has been used to reinforce the picture.  Genetic markers have been invaluable tools in 
Introduction 
 
33 
 
the attempt to elucidate the facts about the settlement of Oceania.  Analyses of the Y-
chromosome are pointing towards a Melanesian origin, or a stopover in this area for a 
longer period of time (Hagelberg 1999; Kayser et al., 2000).  More recent research on 
ALDH points towards a South East Asian origin, with NZ Maori sharing the many of 
the same allele’s as some Asian populations (Chambers et al., 2002).  The plausible 
theories incorporate a combination of these pieces of evidence, suggesting models that 
provide a variety of answers.   
 
There are three main theories that have previously emerged to try and explain the 
origins of Polynesians: the Slow Boat model (Oppenheimer 2001), the Express Train 
model (Bellwood 1991), and the Entangled Bank model (Terrell 1988).  The Slow Boat 
model proposes Island Southeast Asia as the ‘melting pot’ for early Polynesian culture.  
It assumes that migrants from southern China travelled down into island Southeast Asia, 
where they resided for many years (~15000).  Gradual, complex interactions with 
neighbouring islands additionally shaped the Polynesian culture and genome, before 
populations began travelling further abroad, finally reaching Polynesia (Oppenheimer 
2001).  The Express Train model suggests that the migration into Oceania occurred 
rapidly, in the space of ~6000 years.  This theory assumes Taiwan as the original birth 
place of Polynesian migration.  Early ancestors migrated from mainland China and 
Southeast Asia to colonize Taiwan, and from there rapidly spread out into the Pacific 
(Diamond 1988).  The Entangled Bank model supposes a long history of cultural and 
genetic interactions amongst south-east Asians, Melanesians, and already-established 
Polynesians.  This model suggests that these Melanesian and Polynesian peoples were 
in constant contact with each other, making a complex social and trade network (Terrell 
1988).  
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This is a brief overview as it stands today from all the available evidence (Figure 1.9).  
Between 3000-1000 BC speakers of Austronesian languages migrated through island 
Southeast Asia.  Current linguistic (Bellwood 1991; Lum 1998; Gray et al., 2009) and 
archaeological evidence (Kirch et al., 1988) suggest that these people originated from 
Taiwan (Figure 1.9).  Carbon dating has placed the appearance of Lapita culture in the 
Bismarck Archipelago, northwest Melanesia, ~3000 years BC (Kirch et al., 1988).  This 
culture is likely to have spread from China/Taiwan.  The Lapita culture has been found 
as far as 6000 km east of the Bismarck Archipelago (Kirch et al., 1988).  According to 
dating its spread occurred rapidly, between 1300 and 900 BC, ultimately reaching as far 
as Fiji, Tonga and Samoa (Kirch et al., 1988).  It is calculated that these islands were 
populated about 2000 years ago.  It was during this time that the Polynesian culture 
began to develop and, around 300 BC, spread further out into remote Oceania 
populating the Cook Islands, Tahiti, the Marguesas Islands, and the Tuamotus.  Easter 
Island was settled by the Polynesians around 300 AD.  Around AD 1200 a grouping of 
Polynesian peoples migrated to and settled New Zealand (Aotearoa), these people are 
known as the New Zealand Maori (Cann 2004). 
 
One major genetic clue that has proven to be important to the elucidation of this 
migration is the variation that exists within the genome of the human mitochondrion 
(Cann et al., 1984; Cann et al., 1987; Lum et al., 1994).  As mentioned previously, 
mitochondria are found within cells and are unique in the fact that they have their own 
genomic material.  Mitochondrial DNA is only passed down via the maternal line, in 
contrast to nuclear DNA which is obtained from both parents (Giles et al., 1980).  This 
property of mtDNA allows it to be traced back to a single common ancestor.  As such, 
all human mtDNA should be an exact copy of this original, but this is not the case.  
Mutation plays a major role in the mtDNA, which exhibits a mutational rate ~15 times 
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higher than that of the nuclear genome (Stoneking 2000).  As human populations have 
migrated from Africa different mutations have arisen within the mtDNA.  Those that 
persist for long enough will be passed down the maternal line to descendents (Forster 
2004).  Over time as human populations have moved apart, the number of mutations has 
grown, creating very different mtDNA (haplogroups) when compared to the original 
population.  These haplogroups can be compared, and relationships established between 
populations.  Mitochondrial haplogroups have been used to trace migration and 
settlements of populations (Figure 1.10).   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10:  Map of continent specific mitochondrial haplogroups.  Haplogroups are 
indicated with a letter, +/- indicates the presence or absence of specific restriction sites.   
Estimates of migration time are in years before present.  This figure has been modified 
from the MITOMAP website: http://www.mitomap.org/WorldMigrations.pdf  
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1.6 The Rakaipaaka Health and Ancestry Study 
 
Ngati Rakaipaaka is a Maori iwi (tribe) located predominantly on the east coast 
(Hawke’s Bay) of the North Island of Aotearoa (New Zealand).  This iwi is rich in 
history, with the living descendents of Rakaipaaka now extending into the 15
th
 
generation.  The iwi have extremely well documented whakapapa (family) and a 
comprehensive family tree.  It has been observed that within the iwi there are high 
incidences of serious diseases.  This has been one of the driving forces behind the 
development of the Rakaipaaka Health and Ancestry Study (RHAS).  The RHAS has 
been designed to utilise whakapapa to understand patterns of genetic and disease 
variation within the Rakaipaaka community (Appendix One – Community Factsheet).  
The RHAS is a large-scale, long-term epidemiological project revolving around the 
genetic variation observed within the iwi.  There are several main aims to the RHAS:  
i)  utilise genetics to understand the serious diseases that affect the community. 
ii)  understand the heritability of these diseases through the use of whakapapa. 
iii)  identify genetic and environmental factors that influence these diseases.   
The ultimate goal of the RHAS is to generate an understanding of these diseases at the 
genetic level, and to use this to develop treatment strategies to benefit Rakaipaaka.  All 
individuals enrolled in the RHAS are informed consenting participants.  Each has 
provided detailed health information in the form of a questionnaire, undergone physical 
assessment, and given blood samples for analysis.  Detailed whakapapa information has 
also been given where available.  All this will be used to successfully track patterns of 
disease with particular genetic markers. Already genetic research is providing a better 
understanding of disease pathways within the Maori community, with the goal of 
offering enhanced treatment strategies.  Recent research conducted in Rakaipaaka Maori 
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explored the association of DNA variants within several genes, including CYP2A6 (Lea 
et al., 2005; Lea et al., 2008), and ADH2/ALDH2 (Chambers et al., 2002).  These 
studies investigated variation within drug metabolising genes between Maori and 
Caucasian genomic backgrounds.  It was found that Maori have a very different 
genomic background when compared to Caucasians  (Hall et al., 2007).  One region of 
common Maori genetic variation that contains several single nucleotide polymorphisms 
(SNPs) is found within cytochrome P450 (specifically CYP2A6).  This variation has 
been associated with slower nicotine metabolism, and appears to be more prevalent in 
Maori (Lea et al., 2005).  Further research identified important differences in drug 
metabolism between Maori and Caucasians (Lea et al., 2008).  These differences could 
possibly influence the manor by which Maori respond to specific treatments, i.e. slower 
nicotine metabolism could require an alteration of the cessation therapy.  Identifying 
such differences between groups with varying ancestry is the first step to offering 
personalised treatment based on an individual’s genetic background. 
 
Studies suggest that this Maori iwi has a distinguishable genomic background when 
compared to Caucasians  (Hall et al., 2007; Lea et al., 2007) and preliminary work on 
mtDNA variation in New Zealand Maori has shown different frequencies compared to 
other groups worldwide (Murray-McIntosh et al., 1998; Whyte et al., 2005).  This 
apparent uniqueness of genomic patterns in Maori is probably the result of genetic 
bottlenecks and founder effects that occurred during the Polynesian migrations (Lea et 
al., 2007).  Because of these unusual population genetic forces, it cannot be assumed 
that the genetic factors for metabolic traits in other worldwide populations are the same 
as in groups with Maori heritage.  Identifying the specific genetic factors that influence 
risk of metabolic disorder in Rakaipaaka community, and understanding how these 
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interact with environmental (eg. dietary) factors, will contribute to better treatment 
strategies, reducing this problem.   
 
Mitochondria are the energy producing factories of cells.  It has long been thought that 
disruption to mitochondrial systems is linked with metabolic disorders.  The 
mitochondrion has its own distinct genome.  Mitochondrial DNA sequence variants 
have been linked to diabetes risk in several epidemiological studies (Poulton et al., 
2002; Tanaka et al., 2007). As part of the RHAS (Hudson et al., 2007) it has been 
observed that the Maori community of Nuhaka (Ngati Rakaipaaka) have a high 
incidence of certain metabolic diseases such as diabetes and obesity. These disorders are 
thought to be influenced by a combination of ancestry specific genetic predisposition 
and environmental exposures (envirogenomics). 
 
It is important to begin to understand the ancestry of a population when we come to the 
creation of treatments, whether pharmaceutical or interventional.  It is this ancestry that 
has shaped population genomics, meaning that individualised population treatment 
should be explored, what works for one group does not mean that it will work for 
another.  As such, ancestry is starting to be considered in the development of 
personalised medicine (pharmacogenomics).  Pharmacogenomics attempts to explain 
the influence of genetic variation on the response and efficacy of a drug treatment in 
patients.  The aim is to develop a means of optimising the manufacture and delivery of 
drugs based on the patient’s genotype.  So this is replacing the ‘one size fits all’ 
approach with a more tailored treatment that should be effective with minimal risk of 
adverse effects. 
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It is hypothesised that Maori from Ngati Rakaipaaka have distinctive DNA sequence 
patterns (or signatures) in the mitochondrial genome, which have been shaped by 
unique population history, and that specific mtDNA signatures modify the risk of 
developing metabolic disorders such as diabetes in this population.  This study aimed to 
screen the mitochondrial genome using the Mitochip™ in selected RHAS participants 
to highlight genetic variants that might be specific to this community and subsequently 
correlate these particular variants with metabolic traits such as diabetes, cardiovascular 
disease, and obesity.  These metabolic conditions are a significant health issue in New 
Zealand, with the rates being especially high in the Rakaipaaka community.  A 
successful outcome of this research may allow for more personalised intervention 
strategies (e.g. dietary) to be designed, with the ultimate goal of reducing metabolic 
disease and increasing health and wellbeing within the Rakaipaaka iwi, and perhaps 
Maori and Polynesians more generally. 
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1.7 Specific Research Objectives 
 
The objectives of this thesis are as follows: 
 
1. Design and optimisation of an RFLP assay and HVRI PCR to aid with subject 
selection for Mitochip array analysis. 
 
2. Obtain entire mtDNA sequence information from a subsample of Rakaipaaka 
individuals with Maori ancestry (n=20) using the Affymetrix Mitochip. 
 
3. Align and compare this sequence information with independent worldwide 
sequences to identify group differences, i.e. a mtDNA signature that is specific 
to Rakaipaaka Maori. 
 
4. Validate the signature in a larger community sample of the RHAS Maori 
population (n=400). 
 
5. Correlate the validated mtDNA signature with metabolic traits (eg. BMI and 
diabetes). 
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Chapter 2  Materials and Methods 
2.1 Study Population Characteristics 
 
DNA was collected either from blood or buccal samples for ~400 adults enrolled in the 
RHAS.  Extensive clinical data was also obtained, including BMI, lipid profiles (LDL, 
HDL, etc.), cardiovascular disease makers, and disease history.  Autosomal ancestry has 
been used to investigate population structure within RHAS Maori (Hall 2009) and is 
shown in Figure 2.1.  This autosomal ancestry score will be used to identify those 
individuals most likely to contain the mitochondrial Polynesian motif, hence Maori 
mtDNA.  This eliminates any admixture of European mtDNA present and provides a 
Maori specific mtDNA sample group with which to screen for sequence variation.  
 
 
 
 
 
 
 
 
 
 
Figure 2.1:  The figure shows genomic clustering of individuals with Maori and 
European ancestry.  The X axis shows individuals for whom DNA has been genotyped 
using 300K SNP chips.  Y axis shows estimates for % of European ancestry 
(1.0=100%).  The 30 RHAS Maori individuals highlighted have been selected for this 
study because little, if any, of their genome is of European origin.  Figure reproduced 
from Hall (2009).  
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2.2 Overview of Experimental Design 
 
This study was designed as pioneer research, an exploration of complete mitochondrial 
genome sequences in New Zealand Maori community.  This next section aims to give a 
general summary of the methodology and experimental design of the research 
conducted in this thesis.  A workflow diagram has been included to give an overview of 
experimental structure (Figure 2.2).   
 
The research was conducted with DNA samples kindly supplied to ESR as part of the 
Rakaipaaka Health and Ancestry Study (RHAS).  As far as is known this is the first 
research of its kind in New Zealand Maori.  Twenty Mitochip arrays were purchased 
due to budget limitations and the expense of the technology.  This then became a proof 
of principle study, with the goals of testing the Mitochip technology and gaining an 
indication from a smaller sample of mtDNA sequences if there was anything worth 
following up.  This meant that much care had to be shown in the selection of individual 
mtDNA sequences for Mitochip analysis; the final 20 had to be a good representation of 
the RHAS mtDNA pool.  Using autosomal ancestry data supplied by David Hall (Figure 
2.1), 30 RHAS individuals were identified as having very high Maori ancestry. 
 
In testing the mtDNA for Polynesian ancestry two approaches have been designed and 
optimised (Figure 2.2).  The first is the more traditional PCR and sequencing of the 
HVRI region.  This protocol was used to generate the first 30 HVRI sequences.  The 
second analysis was the designing of an RFLP assay, which was very useful as a quick 
screen for a specific marker of Polynesian mtDNA.  This was a novel RFLP assay, the 
restriction site being first documented in this research.  
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Figure 2.2:  Workflow schematic detailing experimental layout.  
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After confirmation that the PCR protocol was working for the HVRI region, the RFLP 
assay was used as a quick survey to determine if the majority of RHAS Maori PCR 
products were of Polynesian ancestry.  The RFLP assay interrogated a Polynesian 
mtDNA marker, A16247G.  The presence of this marker indicated mtDNA as being 
Polynesian in ancestry.  This eliminated the chance of wasting resources on sequencing 
unwanted products.  This analysis proved useful, with some samples showing digestion 
and others not.   
 
When all 30 HVRI PCR products were sequenced and analysed, it was observed that all 
sequences were in fact Polynesian, regardless of the RFLP results.  To make completely 
sure the best representative group of mtDNAs was selected a further 64 HVRI 
sequences were added, making the final cohort 94.  This created a larger pool of 
candidate sequences for final Mitochip resequencing.  Based on the frequency of 
reported haplotypes and specific variants of interest the 20 RHAS Maori products were 
chosen.  
 
Once the complete mitochondrial sequence data had been acquired, it was aligned 
against the Cambridge Reference Sequence (CRS).  This is the human mitochondrial 
reference sequence which all variants are identified against.  This data was then collated 
in Microsoft Excel and MEGA 4.1, providing the major dataset of this project.  
Obtaining this dataset was one of the primary objectives, which lead to further analysis 
experiments.  These were; phylogenetic testing, protein modelling, ribosomal RNA 
secondary structure prediction, and genotyping.  Genotyping several signature SNPs in 
the larger RHAS Maori cohort group (n=400) allowed for disease association statistics 
to be calculated. 
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2.3 Source of DNA and Ethics Approval 
 
Being a genetic study involving Maori participants, the RHAS has taken several years 
to develop in terms of ethical and cultural clearance.  The study is directed and hosted 
by Te Iwi o Rakaipaaka (TIORI) in Nuhaka and has received full ethical approval from 
the Multi-regional ethics committee (MEC/05/12/174).  All individuals have signed a 
consent form acknowledging they understand the genetic nature of this health research 
and wish to participate.  All blood samples were sent to Aotea pathology, where plasma 
was removed the plasma for testing.  The remaining blood samples and buccal swabs 
were sent to ESR Ltd.  Te Iwi o Rakaipaaka are consulted and kept updated in respect to 
major findings, manuscripts and presentations. 
 
2.3.1 Blood Extraction 
Genomic DNA was extracted from blood using QIAGEN FlexiGene DNA extraction kit 
and a modified extraction procedure.  Briefly, 4ml of blood was collected in an EDTA 
vacutainer. The sample was sent to Aotea pathology who removed the plasma for 
testing and sent the remaining sample to ESR where it was stored at -20 before 
extraction.  The 4ml tube was topped up with sterile phosphate buffered saline. Blood 
suspension was decanted into a 50ml falcon containing 20ml FG1 Buffer, and then 
mixed by inversion.  Tubes were centrifuged at 2500 x g in a swing out rotor for 10 
minutes.  The supernatant was discarded and the tubes inverted on absorbent paper for 2 
minutes, care was taken to ensure the pellet remained in the tube.  4 ml of FG2 Protease 
was added and the tubes immediately vortexed until the pellet was completely 
homogenised.  The tubes were then inverted 3 times and placed in a heat block at 65°C 
for 10 minutes.   4 ml of isopropanol (100%) was added each tube and mixed by 
inversion, causing the DNA to precipitate and become visible.  At this stage the 
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clumped DNA was removed using a pipette tip and transferred to clean labelled 1.5 ml 
microcentrifuge tubes.  1 ml of 70% ethanol was added and tubes were vortexed.  Tubes 
were then centrifuged at 10000 rpm for 2 minutes then vortexed.  Tubes underwent a 
final centrifugation for 2 minutes, the supernatant was discarded and tubes inverted and 
pellet allowed to air dry.  The DNA pellet was resuspended in 1 ml dH2O.  Where 
necessary the tube was incubated 65°C to aid in resuspension.  DNA yield was 
quantitated by pico-green (Section 2.4.5) and samples stored at -20°C. 
 
2.3.2 Buccal Swabs Extraction 
DNA extraction from these was performed using BuccalAMP™ DNA Extraction Kit 
(Epicentre
®
).  Briefly, the subject’s mouth was rinsed thoroughly with water and tissue 
was collected by rolling the Catch-All sample collection swab firmly on the inside of 
both cheeks.  Swabs were sent to ESR and stored at -20 until extraction.  The swabs 
were placed into tubes containing QuickExtract DNA extraction solution and then 
rotated a minimum of 5 times.  Swabs were removed and screw caps applied to the 
tubes, which were then vortexed for 10 seconds.  They were then incubated at 65°C for 
1 minute before a further vortex of 15 seconds before incubation at 98°C for 2 minutes.  
Tubes were then vortexed for 15 seconds then incubated at 98°C for 2 minutes.  Tubes 
were then vortexed for 15 seconds, centrifuged for 5min at 14,000rpm and the extract 
removed to a fresh tube with care not to carry over any pelleted material.  DNA yield 
was quantitated by pico-green (Section 2.4.5) and samples stored at -20°C.  
 
2.4 Mitochondrial Control Region (HVRI) Analysis 
 
The HVRI area of the mitochondrial genome was amplified for each sample (94 in total) 
using the Polymerase Chain Reaction (PCR). The expected product size of the HVRI 
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target region was ~543bp.  The presence of the 16189 T→C transition in the majority of 
samples made sequencing the complete product using one primer impossible.  Therefore 
products were sequenced in both the forward and reverse directions, generating a 
consensus HVRI sequence for each.  Additionally any nucleotide variants from the 
Cambridge Reference Sequence (CRS) were confirmed by generating independant PCR 
amplicons of PCR product and resequencing. 
 
2.4.1 Primers 
The HVRI target region was amplified by polymerase chain reaction (PCR), using 
primers that complemented the flanking regions.  The primer pair used for this reaction 
were L15975 (5’-CTC CAC CAT TAG CAC CCA AAG C-3’) and H16517 (5’-CCT 
GAA GTA GGA ACC AGA TG-3’).  See Appendix Two for primer information. 
 
2.4.2 HVRI PCR Protocol 
The standard 30 μl double stranded PCR reaction contained: 
16.1 μl  sterile double distilled water (sddH20) 
3.0 μl  10X PCR Buffer with MgCl2  
6.0 μl  GC-rich Buffer (10x) 
1.2 μl 2.5 mM dNTPs (deoxynucleotide triphosphate mix with dATP, dTTP, 
dCTP, dGTP at 2.5 mM each) 
1.2 μl  Forward (F) Primer (10 μm, Invitrogen) 
1.2 μl  Reverse (R) Primer (10 μm, Invitrogen) 
0.3 μl  FastStart Taq Polymerase  
1.0 μl  Template DNA (~20 ng/μl) 
 
Due to the small amount of Taq required for each reaction a master mix was prepared 
beforehand.  Each master mix was made by multiplying the PCR reagents above by the 
number of samples to be amplified (Taq was added to the master mix just before use).  
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The master mix was made up in a 1.5 ml microcentrifuge tube and kept on ice until 
required.  1 μl Template DNA was pipette into sterile strip tubes, and then 29 μl of 
master mix was added to each tube.  Negative controls contained 1 μl ddH20 instead of 
template DNA, and were also PCR amplified to check for contamination.  The target 
region was amplified in an Eppendorf Mastercycler ep. Thermal Cycler under the 
following profile: initial denaturation at 95°C for 5 minutes,  35 cycles of denaturation 
at 94°C for 30 seconds, primer annealing at 60°C for 30 seconds, extension at 72°C for 
60 seconds, a final extension at 72°C for 60 seconds, then held at 4°C. 
 
2.4.3 Agarose Gel Electrophoresis 
Successful amplification of PCR products was assessed using agarose gel 
electrophoresis.  A 5 μl aliquot of loading dye was added to each PCR product 
containing strip tube, and then a 5 μl aliquot of each PCR product was loaded onto a 1% 
agarose, 1 x TBE gel containing SYBR safe (1µl of 1/10 dilution [Invitrogen]) for DNA 
visualisation (Appendix Three).  5 μl of 1 kbp ladder (Invitrogen) to gauge the size of 
PCR products was used as reference.  The gel was run in Tris Borate Buffer (TBE) at 
110V for 60 minutes.  Gel photographs were taken under UV illumination. 
 
2.4.4 Purification of PCR Products 
Manufacturer’s (Qiagen®) instructions were followed using the QIAquick PCR 
Purification kit.  Briefly, 5 volumes of Buffer PB (kit) were added for every 1 volume 
of PCR sample and mixed.  The DNA was bound by applying each sample to a 
QIAquick column, which was then centrifuged for 60 seconds at ~13000 rpm.  Flow-
through was then discarded and 750 μl of wash buffer (buffer PE) added to each 
column.  Columns were then centrifuged for 60 seconds.  Flow-through was again 
discarded and columns underwent an additional centrifugation for 60 seconds.  In the 
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final step columns were placed into labelled 1.5 ml plastic microcentrifuge tubes.  To 
elute DNA product 30 μl of dH2O was applied to each column which was then 
centrifuged for 60 seconds.  The columns were then discarded and the 30 μl DNA 
samples were stored at -20°C. 
 
2.4.5 DNA Quantitation: Pico Green assay 
A Quant-iT PicoGreen dsDNA quantitation kit (Invitrogen) was used to quantify PCR 
products.  Briefly, 96-well flat-bottomed (Nunc) plates were used.  Standard solutions 
were prepared in duplicate in the first two rows of the plate wells using 1 μl DNA 
standard stock (Appendix Four) and 99 μl TE buffer to a total of 100 μl.  The standard 
preparations used were 200 ng, 100 ng, 50 ng, 25 ng, 12.5 ng, 1 ng, 0.5 ng total DNA.  
The blank wells contained 1 μl dH2O and 99 μl TE buffer.  1 μl of DNA samples were 
added to wells in duplicate, then 99 μl TE buffer was added to each well.  Pico Green 
quantitation reagent was diluted 1:200 in dH2O, 100 μl was added to each well used, the 
plate was then covered and mixed gently, before reading with a FLUOstar OPTIMA 
microplate reader after 1-5 minutes.  The excitation wavelength used was 484 nm and 
the emission was 538 nm.  A curve was created from the standard solutions.  The 
standard curve and the sample values corrected for the blank were used to calculate the 
amount of DNA present in each sample. 
 
2.4.6 Sequencing of HVRI Products 
Sequencing of the HVRI product was difficult due to the homopolymeric cytosine tract 
present in all but one of the 94 RHAS samples.  Therefore both the forward and reverse 
strands were sequenced to generate a consensus HVRI sequence.  Sequencing was 
conducted at the Allan Wilson Centre of Molecular Biology.  Sequencing reactions 
were prepared in accordance to specifications detailed on the Allan Wilson Centre 
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(AWC) website (http://awcmee.massey.ac.nz/genome-primer.htm).  Sequencing 
reactions were set up with 13 ng template PCR product, 3.2 pmol primer (forward or 
reverse) and then made up to 15 µL total volume with PCR grade dH2O.   DNA 
sequencing was primed with the following sequencing primers: forward strand sequence 
5’-CTCCACCATTAGCACCCAAAGC-3’ and reverse strand sequence 5’-
CCTGAAGTAGGAACCAGATG-3’.  The BigDyeTM Terminator Version 3.1 Ready 
Reaction Cycle Sequencing kit was used and samples were run on an ABI3730 DNA 
Analyzer.  Sequences were made available from AWC via web drop off using an AWC 
user profile.  Sequence data was interpreted using FinchTV software v1.4.0 (Geospiza, 
Inc.; Seattle, WA, USA). 
 
2.5 Restriction Fragment Length Polymorphism Analysis 
 
The 50 μl restriction digest reaction contained: 
38 μl  dH2O 
4.0 μl  10x Buffer (NEB) 
0.5 μl  BSA 
0.5 μl  Pst I 
7.0 μl  DNA (HVRI PCR product at 15 ng/μl) 
 
A master mix was made by multiplying the reagents by the number of samples.  7 μl of 
each DNA sample was pipette into individual 0.2 ml strip tubes, and then 43 μl of 
master mix was added to each tube. The samples were incubated in an Eppendorf 
Mastercycler ep. Thermal Cycler under the following parameters: 2 hours at 37°C, 80°C 
inactivation for 20 minutes, then held at 4°C.  Restriction products were run on a 2% 
agarose, 1 X TBE gel (containing SYBR safe) at 100V for 2 hours, then viewed under 
UV illumination.  
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2.6 Mitochip Analysis 
 
The Mitochip Resequencing Array was conducted offsite by the Centre for Genomics 
and Proteomics at the University of Auckland.  The Mitochip Resequencing protocol 
(Affymetrix, Santa Clara, CA) laid out by Affymetrix was followed (Affymetrix 
GeneChip CustomSeq Resequencing Array Protocol version 2.1.), and the chips were 
run on Affymetrix GeneChip equipment (GeneChip Hybridization Oven, GeneChip 
Fluidics Station, and GeneChip Scanner 3000).  Briefly, the Mitochip has array tiles for 
both strands of the complete human mtDNA (~16,550 bp), as well as an additional 
12,935 bp arrayed in duplicate.  The assay required 100ng of DNA from 20 selected 
RHAS individuals as template for mtDNA specific long range PCR.  Two sets of long 
range primers were used to amplify the mtDNA: Mito1-2 forward primer 5’-
ACATAGCACATTACAGTCAAATCCCTTCTCGTCCC-3’ and Mito1-2 reverse 
primer 5’-ATTGCTAGGGTGGCGCTTCCAATTAGGTGC-3’, Mito3 forward primer 
5’-TCATTTTTATTGCCACAACTAACCTCCTCGGACTC-3’ and Mito3 reverse 
primer 5’-CGTGATGTCTTATTTAAGGGGAACGTGTGGGCTAT-3’ (Appendix 
Five).  The PCR products were then fragmented, labelled with biotin, and hybridised to 
the Mitochip.  The chip with bound mtDNA was washed with streptavidin-
phycoerythrin, which binds to the biotin.  A signal amplification step was conducted by 
washing the chip with anti-Streptavidin antibody, followed with biotinylated goat IgG 
antibody, and a final wash with streptavidin.  This procedure ensures an ample signal is 
present when the chips are scanned with a confocal laser.  The raw data from the 
scanned Mitochips was uploaded and made available for collection via the University of 
Auckland web-dropoff system.  These files were then analysed using the GeneChip 
Sequence Analysis Software 4.1 (GSEQ 4.1). 
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2.7 Software Packages 
 
2.7.1 DNA Sequence Alignment and Phylogenetic Tree Creation 
MEGA4 was used to align both partial HVRI sequences and complete mtDNA 
sequences.  All sequences were aligned against the human mitochondrial reference 
sequence (CRS) to preserve historic positional information.  The default ClustalW 
alignment was implemented, with final alignment checked manually for error or 
discrepancies.  A phylogenetic reconstruction was created in MEGA4 using Tamura-
Nei neighbour-joining method (Tamura 2007).  All 20 complete RHAS mtDNA 
sequences were added to a data set containing complete sequences from various B 
haplogroups (Trejaut et al., 2005). 
 
2.7.2 Mitochip Data Analysis in GSEQ 4.1  
The Mitochip data received from the University of Auckland was in .CEL format.  
These files were analysed using GeneChip® Sequence Analysis Software 4.1 
(Affymetrix).  The CEL files store the probe intensity data for each nucleotide position 
tiled on the Mitochip array.  There are 8 probes for each position (4 each strand) which, 
depeding on probe binding, will give various fluorescent levels.  These levels are 
interpreted by the GSEQ 4.1 software by running a resequencing algorithm.  This 
algorithm consists of specific parameters which when adjusted can alter the overall 
accuracy and base calling ability of the array.  The final algorithm determined to give 
the highest call rate in this study is as follows:  
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Probe Array Type - Mitochip_2 
Number of Bases per Array = 37756 
Number of Samples = 20 
Parameters Used By Algorithm:       
No Signal Threshold (probe signal/noise ratio) = 1 
Weak Signal Fold Threshold (mean/probe ratio) = 10 
Large SNR Threshold (probe signal/noise ratio) = 20 
Perfect Call Quality Threshold (quality score) = 3 
Model Type (0=Heterozygote, 1=Homozygote) = 0 
Min Fraction of Calls of Samples (0-1) = 0.5 
Trace Threshold = 1 
Sequence Profile Threshold = -0.175 
 
 
2.7.3 rRNA secondary structure modelling 
Structures for the wild type and mutated human mitochondrial 12S rRNAs were 
generated using the RNAfold webserver software (http://rna.tbi.univie.ac.at/cgi-
bin/RNAfold.cgi) from the Vienna RNA package (Hofacker 2003).  RNAfold predicts 
RNA secondary structure based on minimum energy requirements and pair 
probabilities.  Parameters used were adapted from models found in Ballana et al. 
(2006).  Parameters used are as follows: minimum free energy (MFE) only = selected, 
avoid isolated base pairs = selected, unpaired bases can participate in at most one 
dangling end = selected, RNA parameters (Turner Model) = selected, rescale energy to 
given temperature (C) = 37.  The same parameters were used to predict secondary 
structure of 16SrRNA models.  Amino acid conservation at positions of interest was 
examined by aligning 12SrRNA sequences of five different species (idea adapted from 
Ballana et al. (2006)).    
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2.7.4 Protein Modelling with Sirius 
Models were found for those proteins which contained amino acid changes: (model 
numbers listed, all models can be found at http://swissmodel.expasy.org/repository/) 
Human Cytochrome b: P00156 
Human ATP Synthase subunit 6: P18859 
Human Cytochrome Oxidase subunit I: P00395 
Human Cytochrome Oxidase subunit III: P00414 
Sirius v1.2 was used to view and render the protein models.  It also allowed for the 
substitution of specific amino acids.  Using this feature wild-type amino acids could be 
substituted for their respective variant, which allowed the examination of what effects 
amino acid change had on the possible structure and interactions within the proteins.  
(Sirius can be found at http://sirius.sdsc.edu/index.php) 
 
2.7.5 mtPhyl: software for mtDNA analysis and phylogeny reconstruction 
Haplotype identification and amino acid conservation indexes were generated using the 
human mitochondrial DNA software suite mtPhyl (Eltsov 2009).  Sequences can be 
imported into mtPhyl in either text or fasta format.  Once the 20 complete RHAS Maori 
mtDNA’s were loaded into the program a variation report with conservation analysis 
was conducted.  This tests all sequences against the Cambridge Reference Sequence 
(CRS) and generates a table that can be exported and edited in Microsoft Excel.  
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2.8 Genotyping and Statistical Analysis 
 
Samples were sent for genotyping to a service provider, Australian Genome Research 
Facility Ltd. (AGRF, www.agrf.org.au).  Three mitochondrial SNPs were included in a 
Genotyping assay alongside selected RHAS nuclear SNPs (in collaboration with ESR).  
These were positions 4769, 16189, and 16519.  AGRF's Sequenom custom SNP 
genotyping service is run on the Sequenom MassARRAY system and utilises a 
homogenous MassExtend (hME – single base extension) reaction termed iPLEX 
GOLD, for analysis of up to 36 SNP's in a single multiplex.  SNP assays are designed 
by the AGRF based on provided SNP sequences (RS Numbers). Oligonucleotides are 
then obtained by the AGRF and used to process samples in multiplex format.  
Following the MassExtend reaction, oligonucleotides are printed onto specialised 
Spectro CHIPs and anaylsed by the Sequenom mass spectrometer.  This platform has 
the ability to replex SNP panels so SNPs can be dropped or added at a later date. 
 
Results from genotyping were entered into an SPSS database which contained all 
recorded information for participants enrolled in the RHAS project.  Statistical analysis 
was therefore performed using the SPSS statistical package (www.spss.com).  Possible 
correlations between metabolic traits and mitochondrial SNP’s were tested using 
Spearman’s two-tailed Bivariate test for correlation.  Traits that showed a P=0.05 (95%) 
level of significance were then investigated using appropriate statistical tests, either an 
Independent-Samples T test or Chi squared test.  As data for the diabetes trait was 
nominal in nature (either diabetic or non-diabetic) risk association was explored using 
the Chi-squared test. 
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Chapter 3  Results 
3.1 DNA Extraction 
Genomic DNA was extracted from ~400 Maori individuals who had given consent to be 
part of the RHAS research project.  These individuals donated DNA in one of two 
forms, either as a buccal swab or as a small blood sample (4 ml).  Total genomic DNA 
(includes mtDNA) was extracted using the respective protocol; blood extraction 
(QIAGEN
®
; Section 2.3.1), or buccal swab extraction (Epicentre
®
; Section 2.3.2).  
Rakaipaaka Maori DNA was then PCR amplified, purified (Chapter 2, Section 2.4), and 
quantitated to approx. 15 ng/μl (see Appendix Six for an example Pico-Green output). 
 
OBJECTIVE 1: Design and optimisation of an RFLP assay and HVRI 
PCR to aid with subject selection for Mitochip array analysis. 
3.2 Mitochondrial DNA HVRI Target Amplification 
Due to budget constraints there was only enough funding for 20 Mitochip assays.  As 
such it was determined that preliminary work would involved screening HVRI 
sequences of an initial RHAS Maori group (n=30) identified to be of high Maori 
autosomal ancestry (Methods, Figure 2.1).  The goal of this initial screen was to identify 
mtDNA sequences that were of Polynesian, and thus Maori, ancestry.  The initial 30 
RHAS Maori selected revealed high autosomal ancestry which was a good predictor of 
mtDNA ancestry.  As such, an extended group of HVRI sequences was generated 
(n=94) consisting of another 64 RHAS Maori based on ancestry score (Figure 3.1).   
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Figure 3.1: shows the 2 HVRI subgroups and the overall Mitochip sample selection 
pool (n-94).  The Y axis has ancestry fraction (Q) based on autosomal data (Hall 2009), 
while the X axis shows RHAS Maori individuals. 
 
RHAS Maori were selected for HVRI analysis based on autosomal ancestry (Hall 
2009).  Figure 3.1 details the selection pool; subgroup A consisted of the inital 30 
RHAS Maori, and subgroup B (n=64) extended this to a larger pool (n=94) of HVRI 
sequences to allow for Mitochip selection.  Having this pool of HVRI sequences meant 
that the 20 sequences chosen were a good representation of RHAS Maori mtDNA.  The 
mitochondrial HVRI control region was successfully PCR amplified from a total of 94 
RHAS Maori DNA solutions, using the primers and protocol outlined in Methods 
Section 2.4.  All PCR products were validated for size and quality using agarose gel 
electrophoresis (Figure 3.2).  An agarose calibration curve was calculated to verify that 
products of the correct size were being amplified (Figure 3.3).  The expected PCR 
product size was 543 bp based on primer design software (Primer Blast; 
http://www.ncbi.nlm.nih.gov/).  A successful PCR amplification should appear as a 
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single band of this size when run through an agarose gel.  Figure 3.2 shows an agarose 
gel electrophoresis of four HVRI PCR products (specimen ID’s; mt3, mt6, mt12, and 
mt20).  In each of the lanes loaded with PCR product in this figure there is a single 
bright band of approximately ~550 bp (when compared the 1 Kb Plus DNA Ladder; 
Invitrogen
®
).  The lanes containing negative reaction controls show no bands, indicating 
there is no PCR product present.   
Figure 3.2 also shows the reaction used to find the optimal primer annealing 
temperature for further HVR1 PCR reactions.  A thermal cycle was designed to set the 
annealing temperature across the heat block in three sections as follows: 55°C, 60°C, 
and 65°C.  As all three temperatures yielded acceptable products of the correct size, the 
central temperature (60°C) was selected as the final annealing temperature.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2:  Gel showing electrophoresis of amplified mtDNA HVRI target region.   
PCR amplicons of the same four DNA specimens were used in replicate for each 
temperature gradient, as loaded from left to right; mt3, mt6, mt12, and mt20.  Lanes 1 
and 20 contain a 1 Kb Plus DNA Ladder (Invitrogen
®
; Appendix Three).  Lanes 2, 3, 8, 
9, 14, and 15 were negative reaction controls used to identify if contamination was 
present.  
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The size of the amplified products was inferred to be ~550 bp, as indicated by the DNA 
ladder fragments.  To confirm the fragment size of the PCR product bands from Figure 
3.2 an agarose gel calibration curve was calculated (Figure 3.3).  This curve was created 
by plotting the log10 of the ladder fragment sizes against the distance the fragment bands 
migrated.  A trend line established a linear relationship allowing the calculation of the 
‘unknown’ PCR product size.  The PCR product band was measured to have migrated 
45.5 mm from the origin.  When this distance was input into the equation generated by 
the trend line, a product size of 550 bp was inferred (Figure 3.3).  This correlates well 
with both the size estimated from the DNA ladder and also the size given by in silico 
analysis (543 bp). 
 
 
 
 
 
 
 
 
 
 
Figure 3.3:  Calibration curve of Log (fragment size, bp) versus the migration distance 
(mm) of 1 Kb Plus DNA Ladder (Invitrogen
®
) fragments, as seen in Figure 3.2.  The 
blue dashed line on the graph represents the migratory distance of PCR products in 
Figure 4.1.  These products had migrated 45.5 mm through the gel giving an estimated 
product size of 550 bp.  This size is an approximation of the PCR product size expected 
(543 bp). 
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3.3 Identification of Pst I Restriction in RHAS Maori mtDNA 
 
An online restriction digest program (http://insilico.ehu.es/restriction/two_seq/) allowed 
the comparison of ~300 bp of Maori HVRI sequence (Whyte et al, 2005, GENBANK 
No. AY604073.1) and the same section from the Cambridge Reference Sequence (CRS: 
NC_012920).  The online web server analysed both sequences and identified several 
restriction sites.  The only enzyme found to digest specifically within Maori HVRI 
sequenmces was Pst I.  The restriction site was found to be formed by the transition at 
16247, A→G, (Figure 3.4).   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4:  Restriction enzyme site created by the A16247G transition within the 
HVRI of haplogroup B4a1a1 individuals.  When a G (blue) is present at position 16247 
it creates a restriction site that is specific for Pst I.  When treated with Pst I digestion 
occurs creating DNA fragments which can be identified via agarose gel electrophoresis.  
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For the restriction analysis 30 RHAS PCR products were investigated.  Two Amis 
Taiwanese Aboriginal samples were HVRI PCR amplified and used as positive controls 
in the digest.  These Amis products were used as they were known lack the 16247 
A→G transition.  The negative controls contained dH2O instead of PCR product.  
Figure 3.5 shows the agarose gel electrophoresis of the restriction digest, a total of 32 
individual PCR products were tested for the 16247 A→G transition (2 Amis and 30 
RHAS).  The gel was set up so each HVRI product had 2 lanes; the first lane lacked Pst 
I restriction enzyme, the second lane contained Pst I.  If the A→G transition was 
present the product in the second lane would show differing band size to that in the first 
lane.  The positive controls (lanes 4-8) do not exhibit any sign of restriction, confirming 
that Amis Taiwanese lack the transition that creates the restriction site.  The negative 
controls (lanes 2, 3 and 72, 73) do not contain any bands, indicating that there was no 
contamination.  Some of the restriction lanes contain faint bands around the 500-600 bp 
mark, this is possibly due to partial digestion of the original ~540 bp product.  As this 
restriction analysis was used to quickly identify mitochondrial sequences which belong 
to haplogroup B4a1a1a it was not further optimised, all that was needed was proof of 
principle.  Further optimisations could include; adjusting the amounts of PCR product, 
the concentration of the enzyme, and the length of restriction reaction. 
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Figure 3.5:  Gel Picture of restriction enzyme digest of 32 HVRI regions.  Shown 
above, DNA ladder, negative controls, 2 Taiwanese HVRI samples, and 30 RHAS 
HVRI samples.  Uncut product is ~540 bp, cut product is ~270 bp.  Each sample has 
two lanes, the first lane contains PCR product only, while the second lane contains PCR 
product and Pst I restriction enzyme.  Shown in red are the sample numbers of those 
PCR products that did not undergo restriction. 
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It can be seen from Figure 3.5 that 23 (77%) of the 30 RHAS HVRI PCR products 
underwent restriction indicating the presence of the Polynesian motif.  This is identified 
by the smaller digested fragments migrating further in the second lane than the original 
product in the first lane.  The original product was ~550 bp; the fragments formed by 
restriction are ~270 bp, exactly half of the original size.  This explains why there is only 
one visible band present in the lanes that have undergone restriction; the fragments are 
the same size.  There were 7 RHAS HVRI PCR products that did not digest.  This 
indicates that these samples did not contain the 16247 A→G transition, or that there was 
another mutation within the restriction site that stops the enzyme from digesting.  This 
became clear once the results from sequencing were returned (Section 3.5).  It was 
assumed that the samples that did not digest were of different mitochondrial haplotype, 
most likely European introduced through genetic admixture. 
 
3.4  Mitochondrial DNA Sequencing 
 
As this is a discovery project, and the Mitochip technology is still very novel, only 20 
chips were available for complete mtDNA sequence analysis.  This meant that from the 
final pool of HVRI sequences a candidate group of 20 RHAS mtDNA had to be selected 
as a representative.  It was an important requirement that these mtDNA sequences be of 
the haplotype B4a1a1a, as this indicates mtDNA of Maori origin.  A sampling pool of 
94 individual RHAS mitochondrial HVRI sequences was generated from PCR products.  
This pool was used, along with a selection criterion based on individual variants of 
particular interest, to select the 20 mtDNA candidate group.  It was hoped that this 
candidate group would provide information regarding a Maori specific signature within 
the coding region of the mitochondrial genome.  This signature could possibly prove 
valuable not only in disease association studies, but also in evolutionary genetics.  At 
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the time of writing these are the only documented complete Maori mitochondrial 
genomes. 
 
The exact sequences of all 94 PCR amplified HVRI samples were determined using an 
ABI3730 DNA Analyzer (Methods, Section 2.4.6).  All HVRI sequences were viewed 
and edited in the FinchTV software (primer cleanup and base read corrections).  They 
were then aligned with the Cambridge Reference Sequence (CRS) in MEGA4, which 
verified that all products were human mitochondrial HVRI (see Table 3.1).  After 
primer cleanup and alignment the DNA sequences were ~470 bp long.  This size is due 
to the presence of the C variant at 16189, which creates a homopolymeric C-tract.  
Automated sequencing is unable to proceed past this point.  Therefore complete HVRI 
sequence was obtained by sequencing in both 5’ and 3’ directions.  Table 3.1 shows 
four HVRI sequences (mt6, mt3, mt13, and mt20) have been aligned in MEGA and 
exported to indicate comparison to the CRS.  The incredibly high degree of similarity 
with the CRS indicates that the correct PCR product has been amplified, and is homo 
sapien in nature.  Over the 450 bp sequence shown in Table 3.1, there are 8 variants 
(highlighted in yellow).  An insert of A at position 8 in the table is represented as dashes 
in the other sequences. 
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Initially sequencing of the RHAS HVRI samples was conducted using the 5’ L15975 
primer (Forward).  Figure 3.6 shows example electropherograms produced by the 
sequencing protocol employed in this experiment.  These revealed the nucleotide 
sequence for each sample.  The first sequencing reaction used to test the primers was 
conducted on several Taiwanese Aboriginal HVRI samples.  Sequence returned from 
the initial forward primer reactions was of exceptional quality (Figure 3.6 A).  The 
sequence shown in this figure is the HVRI of Amis Taiwanese specimen AM011.  This 
electropherogram shows little to no background ‘noise’, and very clear consistent 
nucleotide peaks.  Coverage of the HVRI is also shown to be good with sequence 
covering the majority of this region; once edited HVRI sequences were 498 bp in 
length.  These results confirmed that the forward primer was in fact selecting for the 
correct region of the mtDNA, and was also giving quality sequence data. 
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Upon confirmation of the sequencing protocol, 30 RHAS HVRI specimens were sent to 
the AWC for analysis.  When the data was returned the HVRI sequences were viewed in 
FinchTV, a sample RHAS HVRI sequence is shown in Figure 3.6 B.  All 30 RHAS 
sequences were of good quality for the first 190 bp, after which they became ‘noisy’ and 
could not be reliably interpreted.  Several attempts were made to sequence through this 
area.  First by using the reverse, 3’ H16517 primer (Figure 3.6 B shows the reverse 
complement of this data for mt3).  The reverse primer had the same problem, giving 
readable sequence to a point.  A modified sequencing protocol (dGTP BigDyeTM 
Terminator Version 3.0) was then trialled to make sequencing of GC rich regions easier.  
None of the employed methods allowed for sequencing through this region.  As all but 1 
of the 94 RHAS HVRI samples contained this T16189C transition (Section 3.4.2) the 
decision was made to use the forward primer (L15975) to generate the 5’ region of the 
sample, up to the C-tract, and the reverse primer (H16517) was used to provide the 3’ 
region after the C-tract (Figure 3.6 B).  Sequences were then joined and aligned using 
MEGA4.  Therefore both primers were used to acquire the final HVRI sequences.  The 
HVRI sequences generated in this study will be entered in to GenBank, for access by 
the scientific community, after this thesis has been submitted. 
 
As noted in previous work  (Lum et al., 1994; Redd et al., 1995; Whyte et al., 2005) 
most Polynesian subjects have additional C-tract length variation introduced by two 
transversions (A→C) at positions 16182 and 16183 (Figure 3.6 B).  This combined with 
the 16189 transition inevitably made it impossible for the complete sequencing in one 
direction.  After close examination of both forward and reverse sequences, as well as 
other available Polynesian sequence data, the majority of the RHAS HVRI samples 
(again all but one) were found to have a C-tract length of 12 C’s.  This was later 
confirmed by Mitochip analysis (Section 3.5)  
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3.4.1 30 RHAS HVRI Sequences 
These were the first 30 RHAS individuals that had been identified as prime candidates 
for Mitochip analysis.  These individuals were chosen on the basis of their genetic 
Maori ancestry (Hall 2009).  Accordingly they all exhibited very high autosomal Maori 
ancestry (Figure 3.1).  It was suggested that by selecting individuals with high nuclear 
ancestry individuals with Maori mtDNA would also be selected, which was crucial for 
this project.  The variability in the HVRI sequences was evaluated in 94 RHAS mtDNA 
by analysing the difference between RHAS sequences and the CRS.  The sequence data 
was complied and variants were documented in Table 3.2. 
 
Of the 30 sequences, 24 exhibited the classic Polynesian CCGT Motif (T16189C, 
T16217C, A16247G, and C16261T; CCGT), while the other 6 lack the transition, 
A16247G (Motif being CCAT).  From these sequencing results we are able to explain 
the restriction digest pattern seen in Figure 3.5.  As seen in this figure 7 of the 30 
samples did not undergo restriction digest (mt6, mt10, mt11, mt12, mt21, mt23, and 
mt26).  Now using the sequence information in Table 3.2 we can see that mt6, 10, 11, 
12, 21, and 23 all lack the A→G transition required to create a Pst I restriction site, 
explaining why they did not digest.  As for the seventh undigested sample, mt26, the 
sequence for this individual shows a T→C transition at position 16243.  This mutation 
falls within the recognition site of the restriction enzyme, and alters it so that Pst I will 
no longer cut.  Individual mt26 therefore has the classic Polynesian Motif, but another 
mutation interferes with the restriction by Pst I.  This is then a novel restriction assay 
for identifying mtDNA that contains the 16247 transition, making the assay specific for 
haplotype B4a1a1 as shown by Figure 3.5. 
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Table 3.2:  Table showing HVRI sequence data for 30 RHAS individuals 
 
 
 
 
 
 
 
 
 
 
 
 
 
The above table shows the mitochondrial HVRI sequence data for 32 HVRI products.  
Shown in blue are 2 Taiwanese Amis HVRI sequences, 30 RHAS Maori HVRI 
sequences are shown in green.  All sequences are aligned to the CRS with positions 
shown across the top.  The four positions of the Polynesian Motif are highlighted; 
16189, 16217, 16247, and 16261.  Nucleotides that differ to the CRS are represented by 
their single letter code.  All HVRI sequence ID’s are listed in numerical order with the 
prefix mt, these ID’s are maintained through-out this study.  Sequences that did not 
undergo restriction are underlined.  A dash at 16295 represents no nucleotide insertion.  
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m t1 . . . . A . C . . . . . . . . . . . . . . T — . . C . . . C .
m t2 . . . C A . . . . . . C . T . . . . . . . . — C T . C . . . .
m t3 . . . . . . . C C C . . C . . G . T . . . . — . . . . . . . .
m t4 . . . . . . . C C C . . C . . G . T . . . . — . . . . . Y . .
m t5 . . . . . . . C C C . . C . . G . T . A . . — . . . . . . . .
m t6 . . . C . . . C C C . . C . . . . T . . . . — . . . . . . . .
m t7 . . . . . . . C C C . . C . . G . T . . . . — . . . . . . . A
m t8 . . . . . . . C C C . . C . . G . T . . . . — . . . . . . . .
m t9 . . . C . . . C C C . . C . . G . T . . . . — . . . . . . . .
m t10 . . . . . . . C C C . . C . . . . T . . . . — . . . . . . . .
m t11 . . . C . . . C C C . . C . . . . T . . . . — . . . . . . . .
m t12 . . . . . . . C C C . . C . . . . T . . . . — . . . . . . . .
m t13 . . . . . . . C C C . . C . . G . T . . . . A . . . . . . . .
m t14 . . . . . . . C C C . . C . . G . T . . . . — . . . . . . . .
m t15 . . . . . . . C C C . . C . . G . T . . . . — . . . . . . . .
m t16 . . . . . . . C C C . . C . . G T T . . . . — . . . . . . . .
m t17 . . . . . . . C C C . . C . . G . T . . . . — . . . . . . . .
m t18 G . C . . . . C C C . . C . . G . T . . . . — . . . . . . . .
m t19 . . . C . . . C C C . . C . . G . T . . . . — . . . . . Y . .
m t2 0 . . . . . . . C C C . . C . . G . T . . . . — . . . . . Y . .
m t2 1 . . . C . . . C C C . . C . . . . T . . . . — . . . . . . . .
m t2 2 . . . . . . . C C C . . C . . G . T . . . . — . . . . . . . .
m t2 3 . . . C . . . C C C . . C . . . . T . . . . — . . . . . . . .
m t2 4 . . . . . . . C C C . . C . . G . T . . . . — . . . . . . . .
m t2 5 . . . . . . . C C C . . C . . G . T . . . . — . . . . . . . .
m t2 6 . . . . . . . C C C . . C . C G . T . . . . — . . . . . . . .
m t2 7 . . . . . . . C C C . . C . . G . T . . G . — . . . . . . . .
m t2 8 . . . . . . . C C C . . C . . G . T . . . . — . . . . . . . .
m t2 9 . . . . . . . C C C . . C . . G . T . . . . — . . . . . . . .
m t3 0 . . . . . . . C C C . . C . . G . T . . . . — . . . . . . . .
m t3 1 . . . . . . . C C C . . C . . G . T . . . . — . . . . . . . .
m t3 2 . . . . . . . C C C . . C . . G . T . . . . — . . . . . . . .
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Nucleotide heteroplasmy is represented as Y in the table (in this case C/T 
heteroplasmy). 
 
All RHAS mtDNA sequences lacking the A16247G transition were independently PCR 
amplified a second time, with this PCR product being sequenced allowing the validation 
of this variant (Figure 3.7 A).  This procedure was replicated for all HVRI sequences 
containing a variant to the CRS.  The 6 sequences lacking the final Polynesian motif 
marker (underlined in Table 3.2), were the same sequences which did not undergo 
restriction digest detailed in Section 3.3.  This again proved that the restriction assay 
was working correctly.  However HVRI sequencing had identified that the 6 sequences 
were definitely not European as was originally suspected from restriction results.  
 
There are several other mutations of note among these sequences, the first being an 
insertion of A at position 16295 in individual mt13.  Insertions are not uncommon in the 
D-loop of the mitochondria, but none have been documented in previous work with 
Polynesian and Maori HVRI samples.  As such this mutation was identified as genuine 
(Figure 3.7 B), and a database search suggested that this is a novel undocumented 
mutation.  
 
Another point of interest is that 3 individuals demonstrated nucleotide heteroplasmy at 
the same position, 16354 (Figure 3.7 C).  The sequence chromatograms were examined 
to ensure the position had been called correctly, and then validated by independent PCR 
of a new HVRI sequence from the same sample, followed by sequencing.  All areas of 
heteroplasmy were identified and replicated in sequences this way, and were deemed to 
be genuine. 
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Figure 3.7: Positional variants of the mitochondrial HVRI in RHAS individuals.   
A) Shows the presence (Pst I +ve) or absence (Pst I –ve) of the restriction site created 
by A16247G.  B) Demonstrates the insertion of A at 16295 in two RHAS HVRI.  C) 
Shows C/T heteroplasmy in 3 RHAS HVRI sequences at position 16354.   
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3.4.2 94 RHAS HVRI Sequences 
Following on from the sequencing of the first 30 RHAS HVRI samples it was decided 
that we would validate the frequency of these haplotypes in a larger cohort before 
making the final selection for the Mitochip analysis.  The reasoning for this is that we 
wanted to select 20 individual mitochondrial haplotypes as a wide representative of the 
RHAS mtDNA pool as a whole.  So another 64 individual RHAS DNA samples were 
PCR amplified for the HVRI region, and then added to the original 30 sequences, giving 
us a total of 94.  Again any novel variants were confirmed by preparing separate PCR 
amplicons and resequencing these. 
 
All sequences were collated into a haplotype table (Table 3.3).  From this table it can be 
seen that there are three major haplotypes; those that contain the full Polynesian 
‘CCGT’ Motif, those that have the ‘CCAT’ motif lacking the 16247 A→G transition, 
and one individual (haplotype MB21) that shares the European haplotype H (Helena) 
with the CRS.  This in itself is interesting as all samples were selected on autosomal 
DNA ancestry, which makes finding a European mitochondrial haplotype on a 
predominantly Maori genome peculiar.   
 
All RHAS mtDNA sequences lacking the A16247G transition were independently PCR 
amplified a second time, with this PCR product being sequenced allowing the validation 
of this variant (Figure 3.7 A).  There were 18 individuals in the RHAS Maori cohort 
lacking this transition (20%).  This proportion seems to correlate well with those found 
in other HVRI studies that have been conducted in Polynesian and Maori (see position 
16247 in Table 3.6). 
  
Results 
 
76 
 
Table 3.3:  Table showing HVRI sequence data for 94 RHAS individuals 
 
 
Table 3.3 shows the mitochondrial HVRI sequence data for all 94 RHAS HVRI 
products.  All sequences are aligned to the CRS with the positions shown across the top.  
Nucleotides that differ to the CRS are shown.  Three major haplogroups are shown; 
CCGT (green, 80%), CCAT (violet, 19%), and TTAC (orange, 1%).  Positions shaded 
in grey indicated Polynesian motif transitions.  A dash at 16295 represents no 
nucleotide insertion.  Nucleotide heteroplasmy is represented as Y in the table (in this 
case C/T heteroplasmy).  These three major haplotypes have been broken down into 21 
sub-haplotypes in Table 3.3 (MB01-MB21).  This is based on individual variants 
contained within the sequenced region.  Being the Hyper Variable Region of the 
mitochondrial D-loop it comes as no surprise that such a high rate of mutation was 
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M B 0 1 45 . . . . C C C . C . G . T . . . . - . . . .
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M B 0 3 1 G . . . C C C . C . G . T . . . . - . . . .
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M B 0 6 1 . . . Y C C C . C . G T T . . . . - . . . .
M B 0 7 5 . . C . C C C . C . G . T . . . . - . . . .
M B 0 8 2 . . C . C C C . C . G . T . . . . - . . Y .
M B 0 9 2 . . . . C C C . C . G . T . . . . - . . Y .
M B 10 2 . . . . C C C . C . G . T . . . . A . . . .
M B 11 2 . . . . C C C . C . G . T . . . G - . . . .
M B 12 1 . . . . C C C T C . G . T . . . G - . . . .
M B 13 1 . . . . C C C . C C G . T . . . . - . . . .
M B 14 1 . . . . C C C . C . G . T . . . . - C . . .
M B 15 1 . . . . C C C . C . G . T C . . . - . . . .
M B 16 1 . . . . C C C . C . G . T . . . . - . . . A
M B 17 7 . . . . C C C . C . . . T . . . . - . . . .
M B 18 9 . . C . C C C . C . . . T . . . . - . . . .
M B 19 1 . . C . C C C . C . . . T . . . . - Y . . .
M B 2 0 1 . . . . C C C . C . . . T . . . . - . G . .
M B 2 1 1 . . . . . . . . . . . . . . . T . - . . . . 1
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detected.  As mentioned in Section 3.4.1 there are several positions that show 
heteroplasmy; one more individual that shows the previously mentioned position 
(16354), and two other individuals showing heteroplasmy at positions 16147 and 16311 
respectively.  These positions were validated as being genuine heteroplasmy, and tend 
to show varying degrees between individuals.  Another individual sequence contains the 
same insertion seen in individual mt13 (Table 3.2), insertion of A at 16295.  This could 
indicate that these two individuals are related.  The insertion was validated by 
generating separate amplicons and resequencing, and was confirmed in both individuals 
(Figure 3.7 B).  Searching online databases yielded no result for this polymorphism, 
leading us to believe it is undocumented. 
 
The variant at position 16126 (T→C) is present in 18% HVRI sequences (17/94).  It is 
interesting to note that this C transition at 16126 is present in 7 sequences exhibiting the 
traditional Polynesian ‘CCGT’ motif, as well as in 10 sequences which have the 
‘CCAT’ motif.  This could indicate two separate mutational events involving both 
variant 16126 as well as the variant 16247.  Variant 16126 could well be a RHAS Maori 
specific signature marker worth validating in the larger Maori community.  
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OBJECTIVE 2: Obtain entire sequence information from a subsample of 
Rakaipaaka individuals with Maori ancestry (n=20) using the Mitochip. 
 
3.5 Complete mtDNA sequence data for 20 RHAS Maori individuals 
 
One of this project’s primary objectives was to ascertain whether a RHAS Maori 
specific mtDNA signature existed.  This was determined by utilising the Affymetrix 
Mitochip assay and resequencing 20 entire RHAS Maori mitochondrial genomes.  The 
previous section demonstrates the design and optimisation of a specific RFLP assay and 
HVRI PCR protocol.  These were used to generate a selection pool of HVRI sequences, 
from which 20 Maori mtDNA could be selected for Mitochip resequencing.  After the 
successful PCR amplification and sequencing of RHAS Maori HVRI the selection pool 
was n=94.  These sequences were interrogated for variation and the results collated into 
haplotypes (Table 3.3).  These 94 sequences became a informative representation of the 
mitochondrial variation within the Rakaipaaka community.  From this cohort 20 
individuals were selected to undergo Mitochip analysis.  This chip analysis is a 
resequencing assay that interrogates each nucleotide position of a selected 
mitochondrial genome (Introduction, Section 1.3.7.1), with the final result being a 
reconstructed complete genome sequence (~16540 bp).  It was hypothesised that by 
investigating and comparing the complete mtDNA sequences of RHAS Maori 
individuals against available databases a specific ‘signature’ motif common to RHAS 
Maori would be identified.  This signature could potentially be useful as a genetic 
marker for the early diagnosis of specific metabolic disorders, and could provide an 
invaluable insight into the early maternal ancestry of not only Rakaipaaka, but also 
other New Zealand Maori.  The selected 20 individuals are shown in Appendix Seven.  
Results 
 
79 
 
3.5.1 Mitochip Analysis 
Once results from the Mitochip analysis were made available from the University of 
Auckland Centre for Genomics and Proteomics it was analysed using Affymetrix 
GSEQ4.1 software.  The GSEQ4.1 software package allows the user to run a series of 
algorithms to gain ‘base calls’ for each position of the mitochondrial genome (see 
Methods, Section 2.7.2 for algorithm parameters).  The algorithms restrict or relax 
decisions to make a call based on the intensity (fluorescence) of four separate probes at 
each nucleotide position.  Therefore the highest intensity indicates which nucleotide is 
present at each position.  This way the entire mitochondrial genome can be resequenced 
base by base, and interpreted by the software GSEQ4.1.  Due to the nature of the 
mitochondrial genome and the chemistry involved in the Mitochip probe design, areas 
that contain runs of 4 or more C’s sometimes result in miss calls.  These miss calls are 
indicated by n’s in the sequence.  Adjustment of the GSEQ4.1 algorithm parameters 
allowed the number of miss calls to be limited to a minimum.  It was also discovered 
that by setting the ‘model type’ parameter to ‘heterozygote’ the chip was better able to 
detect areas of nucleotide heteroplasmy.   Once the software was calling accurately, 
consensus sequence was obtained for 20 ‘complete’ Maori mitochondrial genomes.  
These sequences were exported as FASTA files and then imported and aligned in 
MEGA4. 
 
3.5.2 Variation in 20 Maori mitochondrial genomes 
Once the sequence data was exported from GSEQ4.1 it was aligned in MEGA4.  
FASTA files were then imported into the program mtPhyl (Eltsov 2009).  MtPhyl is a 
new piece of software that can be used to analyse and compare mtDNA, and can be 
used to create tables and phylogenetic trees.  Table 3.4 was created by mtPhyl and 
edited in Microsoft Excel.  This table summarises all the information gained from the 
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Mitochip analysis of 20 mitochondrial genomes RHAS Maori individuals.  The 
individual sequences are listed down the left of the table, with positional information 
listed across the top.  All sequences are aligned against the CRS; mutations to the CRS 
are shown as the respective nucleotide at the given position.  Blank squares indicate the 
nucleotide at that position is identical to that within the CRS.  Position numbers bolded 
indicate rare polymorphisms found within the CRS (Andrews et al., 1999).  Map locus 
refers to the region of the mitochondrial genome a given variant is found in (i.e. the 
HVR, or a specific protein coding gene).  For the protein coding regions there is extra 
information included in the table; Amino acid change indicates whether there has been a 
substitution and if so what amino acid, the Conservation Index represents how many (in 
percentage) of 39 species have the same amino acid in that position as human wild type 
does, and the Protein Position indicates where in the protein the specific amino acid is 
located.  Areas of common variation within the RHAS Maori sequences can clearly be 
seen highlighted green in Table 3.4.  These positions were found in all 20 RHAS Maori 
sequences.  Positions that are highlighted in purple are variants that appear to form 
unique Maori haplotypes.  The rare CRS polymorphisms (positions bolded) were 
excluded from the suggested RHAS Maori signature.  This is due to the fact that they 
are present in high frequency in other mtDNA’s.  The rest of the variant positions 
became our candidate mitochondrial signature for RHAS Maori mtDNA.  It is 
interesting to note that the 7 individuals that exhibit the C1185T transition, lack the 
A4769G transition which all other individuals contain, indicating some form of genetic 
linkage.  
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3.5.3 Variants within Protein Coding Genes 
Amino acid information is included in the data generated by the mtPhyl software (see 
Table 3.4).  Information is provided regarding any variant within a protein coding gene, 
as well as respective conservation indexes where applicable.  These values represent 
how many (in percentage) of 39 species have the same amino acid in that position 
relative to the human CRS (Ruiz-Pesini et al., 2004; Eltsov 2009).  A confidence index 
of 100 indicates that the site is highly evolutionarily conserved.  This provides 
information about the predicted mutation rate of specific amino acid positions.  The 
positions of the amino acid in the protein, as well as the type of mutation (synonymous, 
non-synonymous), are listed in the table.   
 
There are 13 synonymous mutations and 8 amino acid substitutions.  Of the 8 
substitutions it is interesting to note that 4 occur within the gene for cytochrome b; 
C14766T, T15014C, A15326G, and A15746G.  Of these A15326G can be accounted 
for as one of the 7 rare polymorphisms of the CRS.  Extended variant analysis of protein 
coding and rRNA genes was conducted and explored in Sections 3.7 and 3.8. 
 
This study identified six novel variants within the coding region, and one within the 
control region (Table 3.5).  An extended database search of Mitomap (Ruiz-Pesini 
2007) and mtDB (Ruiz-Pesini 2007) returned no hits, thus these positions are deemed to 
be unidentified in previous literature.  Upon the submission of this thesis these variant 
positions will be entered into the respective databases for the general use of the 
scientific community. 
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Table 3.5: Novel mtDNA variants documented in 20 RHAS individuals* 
Gene Nucleotide Change Protein Change No. Individuals 
Percentag
e 
          
16SrRNA     m.1806T>C NA 1 (20) 5 
ND1     m.3909C>T syn 3 (20) 15 
COXI     m.6782T>C syn 1 (20) 5 
COXIII     m.9255C>T p.MT-COXIII:Pro17Ser 1 (20) 5 
COXIII     m.9722T>C syn 1 (20) 5 
Cyt b     m.15014T>C p.MT-Cyt b:Phe90Leu 1 (20) 5 
HVRI**     m.16295C insA NA 2 (98) 2 
*Reference sequence is the revised Cambridge Sequence (www.mitomap.org/mitoseq.html) 
**HVRI is non-coding and the variant was investigated in a group of 94 individuals, the 6 novel coding 
variants have been investigated in a group of 20. 
 
NA, not applicable; 16SrRNA, 16S ribosomal RNA; ND1, NADH dehydrogenase subunit 1; COXI, 
cytochrome c oxidase I; COXIII, cytochrome c oxidase III; Cyt b, cytochrome b; HVRI, mitochondrial 
hyper variable region I. 
 
 
The main reason behind obtaining 20 complete mtDNA sequences was to identify if a 
RHAS Maori signature was present and, if so, to validate this in a larger global dataset.  
The common variants are highlighted green in Table 3.4.  There are 22 variants to the 
CRS which are shared by all 20 RHAS Maori over their entire mtDNA sequence.  It is 
these variants that will form the basis of the RHAS Maori mtDNA signature.  It must be 
noted that these 22 variants are those ancestral to, and therefore shared by, Polynesian 
mtDNA.  Highlighted in purple (Table 3.4) however, are 3 other variants (C1185T, 
A4769G, and T16126C) that form unique haplotypes, which appear to be RHAS Maori 
specific.  Together all these variants become the specific RHAS mtDNA signature.  It is 
the 3 ‘unique’ variants that will be of interest for validation in the larger RHAS Maori 
population.  Another point of interest is the fact that position 16247 (indicative of 
Polynesian ancestry) appears to be variable among these sequences, this will be 
reflected on in discussion.  This newly defined Maori mtDNA signature is explored and 
validated within a global dataset in the following section (Section 3.6).  
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OBJECTIVE 3: Align and compare the sequence information with 
independent worldwide data to identify a RHAS Maori specific signature. 
 
 
3.6 Population analysis 
These 20 RHAS Maori sequences are the only entire Maori mtDNA’s currently 
available (at time of writing).  As such this project provides the first opportunity to 
investigate the evolutionary similarities between Polynesian and Maori mtDNA.  It has 
been speculated that they are identical, with little to no diversity, based on HVR I & II 
data (Hertzberg 1989; Lum et al., 1994; Sykes et al., 1995).  It is currently suggested 
that there is very limited mtDNA variation in Polynesians in general, and even less in 
Maori.  As such, no Maori informative genetic mtDNA markers have yet been 
identified, and excluding novel variants, most Maori are expected to share the same 
mtDNA lineage.  
 
By utilising RHAS HVRI and entire mtDNA sequence data this study aims to answer 
several important questions: 
- How does Maori mtDNA compare with other global ethnicities mtDNA? 
- Can this be used to establish a specific RHAS Maori mtDNA profile signature? 
- What does this tell us about Maori mtDNA ancestry? 
 
3.6.1 Variant Frequency Tables - Identification of a RHAS signature? 
Online databases (Mitomap, mtDB, and PhyloTree) were used to gather global mtDNA 
sequence data from various ethnic groups; European, Chinese, Japanese, Taiwanese, 
Melanesian, and Polynesian.  Additional HVRI sequence data was also obtained for 100 
New Zealand Maori sequences (see Appendix Eight for accession numbers).  All 
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sequences were combined with the 20 RHAS Maori mtDNA sequences.  Frequency 
tables were generated to validate the possible RHAS specific mtDNA signature (see 
Appendix Nine for raw data).  Frequency data was collated and compared to RHAS 
Maori variant data gained from both HVRI sequencing and Mitochip analysis (see 
Table 3.6).  This table shows all RHAS Maori variants that exhibit a high frequency 
(nearly 100% in all cases) when compared to differing ethnic groups.  These groups are; 
European, Chinese, Japanese, Taiwanese, Melanesian, Polynesian, and Maori (RHAS 
for complete mtDNA, and includes other NZ Maori HVRI sequences where applicable).  
Variant position and the mitochondrial region containing it is shown, with wild-type and 
respective variant nucleotide given for each position.  Each nucleotide is represented by 
a percentage, with the number of sequences investigated in brackets next to it.  In some 
cases only partial mtDNA sequence information was available.  Also some positions 
show low sequence count due to the lack of complete mitochondrial genomes available 
for certain ethnic groups (e.g. Taiwanese and Polynesian). 
 
Table 3.6 shows the comparison and validation of a proposed Maori mtDNA signature.  
It is not yet RHAS Maori specific as, with the exception of 1185 and 4769, all the other 
included variants are common in Polynesian mtDNA sequences.  This is the signature 
that can be used to identify Polynesian and Maori mtDNA, an ‘extended’ Polynesian 
motif that covers the entire mtDNA.  This correctly suggests that Maori mtDNA has 
come from Polynesia.  Yet the RHAS sequences are not identical.  Positions 1185 and 
4769 have been included as they show high frequency in RHAS Maori relative to other 
included ethnic groups, including Polynesians, and are suspected to be RHAS Maori 
specific.  The frequencies seen in other populations support this theory, with both 
1185>T and 4769>A being present in 35% of the RHAS Maori sequences.  
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Again from Table 3.6 it was noted that the C→T transition at position 1185 is quite 
interesting.  This variant demonstrates a 35% frequency in the RHAS Maori cohort, 
while the other ethnic groups investigated do not contain this mutation at all (with the 
exception of 2; an Indian [AY71401] and a Melanesian [DQ137401] individual).  As 
can be seen in Table 3.6 this is also the case for the variant A4769G.  These two 
variants appear to exhibit a form of genetic linkage and are present together in 7 RHAS 
Maori.  
 
As this study is the first to sequence and document entire Maori mtDNA sequences , 
there was no available Maori coding region data for comparison.  There is also 
unfortunately little coding region information available for other Polynesian mtDNA 
sequences, with only 9 complete Polynesian sequences listed in mtDB (Ingman 2006).  
As such the possible RHAS Maori specific variants identified in Section 3.5 were 
unable to be incorporated into this analysis.  A database screen of Mitomap (Ruiz-Pesini 
2007) and mtDB (Ingman 2006) however, provided information about the global 
frequencies of these variants.  As mentioned, 1185>T exhibits a frequency of 0.07% 
(2/2800).  The other two RHAS signature variants show marginally higher global 
frequencies; 4769>A = 1% (30/2800) and 16126>C = 6% (166/2800).  All comparisons 
were made using mtDB (Ingman 2006).  It is obvious that all three variants exist at very 
low frequencies globally, and an extended search returned no catalogued sequence 
containing all three.  This further confirmed that these markers would be useful in 
defining a RHAS Maori mtDNA specific signature.   
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3.6.2 Haplotype analysis: New Zealand Maori mtDNA HVRI 
Previous research using Maori HVRI sequences has attempted to shed light on the 
possible size of the Maori female founding population.  Earlier work in 1998 used 3’ 
HVRI haplotypes to test migration patterns, and estimated the founding population size 
of NZ Maori to be ~70 (Murray-McIntosh et al., 1998).  This was later expanded when 
Whyte et al. (2005) identified that additional unique HVRI haplotypes were present in 
Maori.  These findings increased the total number of haplotypes from 3 to 7.  When 
simulations of the combined data sets were conducted the estimated number of founding 
females was greatly expanded to ~190 (Whyte et al., 2005).  With the discovery of 
numerous unique HVRI haplotypes in Rakaipaaka HVRI sequences, it was decided to 
investigate how these affect the total amount of Maori haplotypes.  In Section 3.4.2, 21 
different HVRI haplotypes were reported from 94 Rakaipaaka Maori HVRI sequences.  
These were combined with the two existing data sets, AW (Whyte et al., 2005) and 
MM98+ (Murray-McIntosh et al., 1998), and collated in Table 3.7. 
 
Table 3.7:  3' HVRI Control Region mtDNA Haplotypes: New Zealand Maori 
 
 
 
 
 
 
 
 
† samples within these categories are known to contain variation outside np 16189-16365, the region of 
interest.  ‡ observations in these categories/groups are all singlton haplotypes. 
NB data exclude all mtDNA haplotypes that are European-like. 
Haplotype RHAS Maori AW MM98+ Combined Data Set
MB1/AW1† 54 44 47 145
AW3 0 1 1 2
MB15/AW7 1 1 0 2
MB02 4 0 0 4
MB05† 5 0 0 5
MB08† 4 0 0 4
MB10 2 0 0 2
MB11 2 0 0 2
MB17/AW2† 16 5 5 26
Others‡ 5 3 0 8
N  (samples) 93 54 53 200
N  (haplotypes) 13 7 3 17
Number Found in Each Data Set
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Table 3.7 details all three data sets, and the number of sequences within each haplotype.  
It can be clearly seen that the MB1/AW1 haplotype is the most common found in NZ 
Maori, showing the highest numbers in all three data sets and 73% of total sequences 
(145 out of 200).  All sequences within MB1/AW1 contain the ‘CCGT’ Polynesian 
motif.  The second most common haplotype is MB17/AW2, which is present in 
approximately 8% (16 out of 200) of the surveyed sequences.  All sequences in this 
haplogroup have the pre cursor ‘CCAT’ motif.  The addition of the RHAS HVRI data 
has greatly expanded the previous number of recorded haplotypes, from 7 to 17.  Re-
running population simulations is outside the scope of this study, however implications 
of the expanded haplotype diversity will be discussed. 
 
The previous research used 3’ HVRI sequences between nucleotide position 16189-
16365. However in this study there were several unique variants identified outside of 
this range.  This was also the case with the AW data set.  To expand on this the RHAS 
haplotypes have been combined with the AW data set (Table 3.8), which increases the 
number of detected HVRI haplotypes in Maori. 
 
In Table 3.8 the length of HVRI sequence included is extended past the range set by 
Murray-McIntosh (1998).  It can be seen that variation outside of this range is relatively 
high, when included in the analysis it increases the number of haplotypes from 17 to 25.  
This is nearly three times the number of previous calculated Maori mtDNA haplotypes 
(Whyte et al., 2005). 
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Table 3.8:  HVRI Control Region mtDNA Haplotypes: 2 New Zealand Maori Data Sets 
 
 
 
 
 
 
 
 
 
‡ observations in these categories/groups are all singlton haplotypes. 
NB data exclude all mtDNA haplotypes that are European-like. 
 
 
So with this haplotype analysis the number of distinct Maori mtDNA haplotypes had 
been greatly expanded upon.  It must be taken into account that this number is actually 
still an underestimate of the total haplotype diversity likely to be observed.  This is due 
to the fact that the RHAS dataset has come from one Maori community, the Rakaipaaka 
iwi.  As such there are family members enrolled in the study who would share the same 
mtDNA, thus underestimating the total diversity within the community. 
  
Haplotype RHAS Data Set AW Data Set Combined Data Set
MB1/AW1 45 44 89
MB18 9 0 9
MB17/AW2 7 4 11
MB07 5 0 5
MB02 4 0 4
MB05 4 0 4
MB04 2 0 2
MB08 2 0 2
MB09 2 0 2
MB10 2 0 2
MB11 2 0 2
MB15/AW7 1 1 0
Others‡ 8 5 13
N  (samples) 93 54 147
N  (haplotypes) 20 8 25
Number Found in Each Data Set
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3.6.3 Phylogenetic Analysis 
To further investigate the phylogenetic structure of the RHAS Maori sequences, a 
neighbour-joining tree was created in MEGA4.  The tree with the highest parsimony is 
shown in Figure 3.8.  A selection of complete mtDNA sequences that represent various 
haplogroup were downloaded from mtDB (Ingman 2006).  These included sequences 
from Africa, Aboriginal Australia, Highland and Coastal PNG, Europe (CRS), 
Aboriginal Taiwan, Japan, Korea, Polynesia, and NZ Maori.  Figure 3.8 shows the 
neighbour-joining tree, with bootstrap values.  The tree was rooted on the oldest 
mtDNA lineage, deemed to be L from Africa.  It can be clearly seen that the two RHAS 
Maori sequences are grouped well within the major haplogroup B, showing close 
association with other Polynesian mtDNA sequences.  These in turn group within the 
broader B haplogroup, grouping within Coastal PNG and Aboriginal Taiwanese 
sequences.  This is supported by previous work (Trejaut et al., 2005). 
 
Maori and Pacific Islanders mitochondrial haplotypes belong to the haplogroup B.  
Haplogroup B arises from haplogroup R on the base of two mutations, 8271-9bp 
deletion and 16189 T→C.  B4 is created by 16217 T→C, B4a is typified by 16261 
C→T. Three transitions, 146 T→C, 6719 T→C, and 10238 T→C, create B4a1a, this is 
the sub-haplotype that the Taiwanese Amis Tribe belong to (Trejaut et al., 2005).  
Another transition mutation at 14022 A→G forms B4a1a1, then another at 16247 A→G 
forms B4a1a1a.  It is these haplotypes, B4a1a1 and B4a1a1a, which form the bulk of 
Rakaipaaka mitochondrial genomes.  It is also these haplotypes which are directly 
attributed to by variants of the Polynesian motif; the ‘CCGT’ motif is B4a1a1a, while 
the ‘CCAT’ motif is B4a1a1 (van Oven et al., 2009). 
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Figure 3.8:  A neighbour-joining tree showing haplotype mapping across a selection of 
complete mitochondrial genome sequences.  The tree was created in MEGA4 using 
1000 bootstrap replicas and the Tamura-Nei model of base pair substitution.  All 
GENBANK Accession numbers are listed for each sequence.  Sequences are grouped 
and coloured according to mitochondrial haplogroup.  The tree was rooted on the 
African mtDNA sequence AF346969. 
 
It was established within the software suite mtPhyl (Eltsov 2009) that all 20 RHAS 
Maori sequences belonged to haplogroup B.  This was the expected outcome as 
previous studies have detailed that the majority of Polynesian mtDNA belong to 
haplogroup B (Hertzberg 1989; Lum et al., 1994; Redd et al., 1995; Sykes et al., 1995), 
as well as work previously conducted on Maori HVRI sequences (Murray-McIntosh et 
al., 1998; Whyte et al., 2005).  This was further validated in MEGA4 by generating a 
phylogenetic tree to demonstrate haplotype structuring (Figure 3.8).  It was decided to 
investigate the extent of haplotypes within the RHAS mtDNA pool.  To further explore 
the phylogenetic relationship Figure 3.9 shows a reconstruction based on the sequences 
from Trejaut et al., (2005).  The 20 complete RHAS mitochondrial genomes were 
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combined with Trejaut’s dataset.  This analysis was conducted to investigate where the 
complete RHAS Maori mtDNAs would fit in the overall structure of haplogroup B.  
Figure 3.9 clearly demonstrates RHAS sequences grouping within the subhaplogroup 
B4a1a1, this was determined by using the complete mitochondrial haplogroup tree 
available from PhyloTree (van Oven et al., 2009).  The individual sequence mt18 was 
found to be of subhaplogroup B4a1a1a1, owing to the presence of the variant A6905G. 
 
This tree clearly shows the presence of 2 clades which contain a large portion of the 
RHAS sequences; one with 7 sequences, the other with 8 (15 out of the total 20).  In the 
previous section it was eluded to the fact that within the 20 RHAS Maori sequences 
there markers that defined distinct haplotypes within Maori.  This tree confirms a new 
haplotype within the B4a1 grouping, defined by the presence of the C1185T variant 
(and the absence of A4769G).  Going from the naming system implemented in the 
Phylotree database this would be termed B4a1a1a2.  This is a group of 7 sequences 
clearly seen separated and underlined on the tree (Figure 3.9).  The clade of 8 RHAS 
sequences are grouping due to the presence of the T16126C variant found within the 
HVRI.  This variant could also indicate the presence of another Maori specific 
haplotype.  
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3.7 Secondary structure analysis of 12S and 16S rRNA 
 
With information gathered from the Mitochip data, we have noted 3 12S rRNA variants 
occurring within the 20 individuals; A750G, C1185T, and A1438G.  Two of these 
variants (A750G and A1438G) have been previously identified as rare European 
polymorphisms within the CRS (see Andrews et al., 1999 for a complete list of rare 
polymorphisms).  This means that variants at these positions are actually the most 
globally common base, but appear as variation when compared to the CRS.  All 20 
individuals had these two variants, creating the 12S rRNA motif ‘GCG’.  The third 
variant that is present within the Mitochip group is C1185T.  This variant is of great 
interest as it was identified in 7 of the 20 complete mtDNA sequences (35%), and is not 
a known B haplogroup mutation.  It also seems to share linkage association with the 
variant at position 4769 (previously reported in Section 3.5.4, Table 3.4).  The presence 
of this variant creates a sub-haplotype within the 12S rRNA sequences; with 13 
individuals having the 12S motif ‘GCG’, while the 7 containing C1185T are ‘GTG’.  To 
further explore this variation at 1185 two tests were conducted; prediction of 12S rRNA 
secondary structure models, and a conservation analysis. 
 
To determine if any of these 12S rRNA variants had an effect on the possible secondary 
structure, a series of modelling predictions were generated.  These predictions were 
made using RNAfold (Vienna RNA web servers; http://rna.tbi.univie.ac.at/website) by 
utilising minimum free energy (MFE) parameters adapted from those in Ballana et al. 
(2006).  Three separate 12S rRNA sequences were used to predict the final models 
(Figure 3.10); A) CRS to predict a wild-type model, B) mt6 (represents ‘GCG’ motif), 
and C) mt3 (represents ‘GTG’ motif).  
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Figure 3.10:  Predicted secondary structure models of human mitochondrial 12S rRNA.   
A) wild-type model predicted from CRS, showing the location of all 3 RHAS variants 
(750, 1185, and 1438).  B) ‘GCG’ model was predicted from 12S rRNA sequence from 
mt6, this represents 13 of the 20 RHAS 12S rRNA sequences.  Two variants are present 
in this sequence, A750G and A1438G.  12S rRNA secondary structures were predicted 
using RNAfold webserver.  
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Figure 3.10:  Predicted secondary structure models of human mitochondrial 12S rRNA.     
C) ‘GTG’ model was predicted from 12S rRNA sequence from mt3, this represents the 
7 of the 20 RHAS 12S rRNA sequences.  All three variants are present in this model.  
The arrow indicates a significant conformational change induced by the presence of the 
C1185T variant.  D) a conservation analysis comparing 12S sequences between 5 
different organisms; Homo sapiens, Mus musculus, Rattus norvegicus, Bos Taurus, and 
Danio rerio.  A consensus sequence surrounding each variant position is shown. 12S 
rRNA secondary structures were predicted using RNAfold webserver.  
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The wild-type 12S rRNA model generated by CRS sequence (Figure 3.10 A) shows the 
MFE predicted model.  This model was used to identify any structural differences due 
to 12S rRNA variants.  As variants at A750G and A1438G are actually rare 
polymorphisms found in the CRS, it was expected that there would be little influence of 
these variants on secondary structure.  This was proven to be the case as seen in both 
models B and C from Figure 3.10.  However a noticeable structural change is seen in 
the 12S rRNA sequence containing the C1185T variant (Figure 3.10 C).  In this model it 
appears that C1185T causes a shortening of an RNA ladder and a disassociation of a 
small hairpin from a larger loop (indicated by arrow in Figure 3.10 C).  A database 
search for other C1185T variants returned only 2 other sequences (DQ137401, 
AY714047).  MEGA4 analysis revealed that while these 2 sequences contained 
C1185T, they did not have the same association with position 4769 as observed in these 
7 RHAS sequences.  This suggests that C1185T is a rare mutation, even more so when 
in combination with 4769A, which could possibly define a unique haplotype in RHAS 
Maori. 
 
The C1185T variant was found in 7 of the 20 mtDNA sequences.  A conservation 
analysis was used to determine the evolutionary significance of each of the 3 variants 
(adapted from Ballana et al. (2006)).  Five different organism’s 12S rRNA sequences 
were aligned and a consensus sequence was generated for the areas directly surrounding 
each of the 3 variants (Figure 3.10 D).  The conservation analysis showed that all 3 
positions appear to be highly conserved through evolution, with the exception of 
position 1185.  All other sequences show a T at 1185, but the human sequence has a C.   
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Four variants were also identified within the 16S rRNA of the 20 complete mtDNA’s; 
A1692G, T1806C, T2416C, and A2706G.  Again RNAfold webserver was used to 
predict secondary structure models for the 4 separate 16S motifs.  The same MFE 
parameters utilised in the 12S analysis were used as a starting point (see Methods 
Section 2.7.3 for detailed parameters).  These parameters were adjusted until a 
consensus model was generated for all 4 sequences.  It is important to note that these are 
predicted models based on MFE, as yet the secondary structure model of human 
mitochondrial 16S rRNA is yet to be elucidated.  The predicted secondary structure 
models are shown in Figure 3.11.  In this figure A is the wild-type model, based on CRS 
16S sequence, predicted by the RNAfold webserver.  This figure indicates the 4 
separate positions identified as variable within RHAS mtDNA from the complete 
sequence data; A1692G, T1806C, T2416C, and A2706G.  So the wild-type 16S motif is 
‘ATTA’ (Figure 3.10 A).  The other 3 16S motifs are; B) ‘ATTG’ the most common 
(85%), C) ‘ACTG’ only 1 individual (5%), and D) ‘GTCG’ (10%).  Comparing these 3 
models to the wild-type shows no significant change to the secondary structure due to 
the variation within the 16S rRNA gene.  There is a slight change in the due to the 
A2706G, the loss of a small loop as seen in the wild-type model.  By looking at the 
position of each variant on the wild-type model, they all seem to be in structural regions 
that are ‘flexible’ in terms of base conservation – a transition mutation won’t affect the 
structure so conservation appears to be relaxed.   
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Figure 3.11:  Predicted secondary structure of human mitochondrial 16S rRNA. 
16S rRNA secondary structures were predicted using RNAfold webserver.  A) wild-
type model predicited from CRS, showing the location of all 4 RHAS variants (1692, 
1806, 2416, and 2706).  B) was predicted from 16S rRNA sequence from mt3, this 
represents 17 of the 20 RHAS 16S rRNA sequences. Figure generated using the 
RNAfold webserver software (http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi).   
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Figure 3.11:  Predicted secondary structure of human mitochondrial 16S rRNA. 
C) was predicted from 16S rRNA sequence from mt29, this represents the 1 of the 20 
RHAS 16S rRNA sequences.  D) was predicted from 16S rRNA sequence from mt10, 
this represents 2 of the 20 RHAS 16S rRNA sequences.  The arrows indicate the loss of 
a small loop due to the A2706G transition in all 3 variant models. Figure generated 
using the RNAfold webserver software (http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi).  
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3.8 Protein modelling 
 
While the mitochondrial genome only encodes 13 proteins, they are all crucial subunits 
of the OXPHOS system.  Hence any mutations that detrimentally alter proteins can 
disrupt production of ATP, increase ROS levels, and be associated with diseases such as 
exercise intolerance, cancer, neurological disorders, and deafness.  These proteins are 
vital to the correct functioning of OXPHOS, and much has been discovered about their 
functions, molecular structure, and interactions.  Elucidated structural models for 
mitochondrial encoded OXPHOS proteins have been created and can be freely 
download from databases such as SwissProt (Kopp et al., 2004; Kiefer et al., 2009).  
 
The aim of this modelling analysis was to identify if any of the substituting variants 
within the mtDNA encoded OXPHOS proteins of the 20 RHAS sequences affected 
structure or interactions.  In Section 3.5, the variation of the 20 RHAS mtDNA’s was 
described.  There were 21 mutations within 9 protein coding genes.  Of these 8 
mutations resulted in a change in the respective amino acid, the other 13 mutations were 
synonymous.  The protein coding genes containing amino acid changes were; COI, 
ATP6, COIII, and Cyt b.  It should be noted that two of the eight amino acid 
substitutions are in fact variants that have been found to be rare polymorphisms to the 
CRS.  As such these positional variants are not indicative of a conserved wild-type 
position, but have been included for historical purposes.  Another two of the eight 
amino acid substitution variants are haplogroup B markers that result in favoured 
substitutions.  The last four variants are of the most interest as they are found in very 
low frequency in the 20 complete mtDNA’s.  It is these variants that may benefit from 
the structural analysis conducted within the modelling software. 
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The Complex III subunit cytochrome b (cyt b) exhibited the most amino acid variation 
across all RHAS sequences interrogated.  All four variants identified within the cyt b 
gene were substitutions; C14766T Threonine to Isoleucine, T15014C Phenyalanine to 
Leucine, A15326G Threonine to Alanine, and A15746G Isoleucine to Valine.  Figure 
3.12 A shows the 3D structural model for cyt b, amino acids implicated in substitutions 
are displayed.  The variant A15326G is one of the 7 rare polymorphisms found in the 
CRS, as such the G allele at this position is common to most mtDNA’s.  As is expected 
all 20 RHAS individuals had this variant in reference to the CRS.  All sequences also 
shared C14766T and A15746G which have been identified as haplogroup B specific 
markers.  Also highlighted in this figure are two regions which anchor redox prosthetic 
groups found within cyt b.  These are two b heme groups; heme bL, and heme bH 
(Figure 3.12 A).  This area is of interest as the forth variant found within the cyt b gene, 
T15014C, resides between both heme groups.  The variant (C) allele at this position was 
only identified in one individual sequence (mt16).  The wild-type amino acid at this 
position, phenylalanine (UUC), is substituted in the T15014C variant by leucine (CUC).  
From interaction models within Sirius, this substitution appears to leave a somewhat 
more open pocket where the aromatic group of the phenylalanine would have been.  
Implications of this will be covered in discussion. 
 
Within ATP6 there were 4 variants, two of these resulting in amino acid substitutions; 
A8860G Threonine to Alanine, and G9145A Alanine to Threonine.  Again it is noted 
that variant A8860G is one of the 7 rare CRS polymorphisms identified by Andrews et 
al. (1999).  Hence all 20 mtDNA’s contained this ‘variant’ as would be expected.  The 
other variant causing amino acid substitution, G9145A, was present only in one 
individual sequence (mt18).  Alanine (GCC) to threonine (ACC).  Figure 3.12 B 
outlines the structure of ATP6 showing positional information of variants identified.  
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Figure 3.12:  Protein modelling of human mitochondrial respiratory chain proteins.   
A) Human Cytochrome b  B) Human ATPase subunit 6.  All positions rendered in blue 
are wild-type amino acids that have been modified in some or all of the 20 RHAS 
individuals.  Amino acids are given their three letter code and the corresponding 
position within the protein.  Underlined AA positions indicate an AA change.  Protein 
models generated in Sirius (http://sirius.sdsc.edu/index.php).   
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Figure 3.12:  Protein modelling of human mitochondrial respiratory chain proteins.   
C) Human Cytochrome c Oxidase I  D) Human Cytochrome c Oxidase III.  All 
positions rendered in blue are wild-type amino acids that have been modified in some or 
all of the 20 RHAS individuals.  Amino acids are given their three letter code and the 
corresponding position within the protein.  Underlined AA positions indicate an AA 
change.  Protein models generated in Sirius (http://sirius.sdsc.edu/index.php).   
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Within COI there were 5 variants, however only one of these resulted in an amino acid 
substitution; G6261A Alanine to Threonine.  The wild-type alanine is (GCC) is 
substituted for threonine (ACC).  Figure 3.12 C shows the 3D structure for the modelled 
COI protein subunit, and highlights the areas of variation.  A database search was also 
conducted to identify if this variant had previously been reported, and if so, to 
investigate its frequency in recorded sequences.  This variant had been reported in 20 
individual sequences, out of 6729 (as of time of writing) that were available in the 
database.  It had also been associated with prostate cancer and LHON.  
 
Within COIII there were two variants, with one resulting in an amino acid substitution; 
C9255T Proline to Serine.  This was identified as an unfavoured amino acid substitution 
(Betts et al., 2003).  In the C9255T variant the wild-type proline (CCC) is substituted 
for serine (UCC).  This variant was again only identified within one of the 20 RHAS 
mtDNA sequences (mt26), and as mentioned is also novel.  Figure 3.12 D shows the 3D 
structure for the modelled COIII protein subunit, and highlights the areas of variation. 
 
From the structural modelling analysis of these four OXPHOS proteins several variants 
of interest have been discovered.  Predicted models have been used to identify 
substitutions of interest.  The A15746G (Phe→Leu) variant appeared to impact on 
predicted protein structure the most.  Also the properties of serine make the variant 
C9255T (Ser→Pro) interesting to discuss.  As mentioned in previous sections these two 
variants are also novel, making them prime candidates for further study.  A database 
search for the Ala→Thr (G6261A) substitution identified it being associated in other 
research with prostate cancer and LHON.  Further research would need to be conducted 
into these variants to elucidate whether they have any implication on final protein 
structure or function.  
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OBJECTIVE 4: Validate the signature in a larger community sample of 
the RHAS Maori population (n=400 adults). 
 
3.9 Genotype Results and Metabolic Trait Correlation 
 
Selected mitochondrial SNPs were included in a Genotyping assay alongside numerous 
RHAS nuclear SNPs (in collaboration with ESR ltd.).  These were variant positions 
1185, 16189, and 16519.  Position 1185 was an obvious selection for screening in the 
larger RHAS group due to the noted high frequency (Section 3.5.2, Table 3.4).  The 
variant at 16189 was selected as this position has been associated with disease in several 
prior studies (Poulton et al., 1998; Lin et al., 2005; Bhat et al., 2007).  It is also a 
marker of Polynesian mtDNA and would therefore provide an indication of the total 
frequency of Polynesian/Maori mtDNA within the RHAS population.  As this variant 
forms the C-tract which causes sequencing problems it was unsure if genotyping this 
position would be possible.  In anticipation of this position 16519 was selected, also 
another marker of interest already highlighted in previous work.  This assay was 
conducted offsite by AGRF, and results were made available by email.  Unfortunately 
position 1185 was excluded from the assay as it was found to be flanked by regions that 
showed high copy number within genomic DNA.  As noted in Section 3.5, position 
1185 appeared to be linked to another variant at position 4769.  It was decided that 
another genotyping assay would use this variant as a possible surrogate marker for the 
variant at 1185.  
 
Results from both genotyping assays were inputted into an SPSS database which 
contained all recorded information for participants enrolled in the RHAS project.  The 
information was gathered in a questionnaire, and includes extensive clinical data. Table 
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3.9 shows all mitochondrial SNPs screened and the resulting genotypes.  Final totals 
exclude samples that failed the genotype assay at the given position. 
 
 
Table 3.9:  Frequencies of three mitochondrial SNP’s in large RHAS cohort. 
 
Note:  The total number of participants enrolled in the RHAS study was 448.  The totals reported above 
only included those that were; a) sent for genotyping, and b) passed the genotyping experiment.  It should 
also be noted that samples were sent only from consensual participants.  European frequency data was 
that generated from the variant frequency table in section 3.6.1 (Table 3.6). 
 
It is interesting to note the frequencies of the 3 variants in the larger RHAS cohort 
group.  Both T16189C and T16519C were found to be present at very high levels, 88% 
and 96% respectively.  In this group the variants greatly outnumber the globally 
common mtDNA alleles, suggesting that there is minimal European mtDNA admixture 
within the RHAS Maori.  It is also interesting to note the frequency of variant A4769G, 
the A allele appears to reside in 25% of RHAS Maori which in contrast to non-Maori 
sequences is magnitudes higher.  Due to the 16519T frequency being so low (4.2%) it 
was not possible to use it in further statistical analysis.  This left two variants, T16189C 
and A4769G, for disease association and hypothesis generating analysis.    
SNP Allele Frequency Percentage Frequency Percentage
A (CRS) 92 25 1 1
G (variant) 274 75 100 99
Total 366 100 101 100
T (CRS) 42 12 105 97
C (variant) 314 88 3 3
Total 356 100 107 100
T (CRS) 15 4 28 26
C (variant) 345 96 80 74
Total 360 100 108 100
16519
RHAS Maori European
4769
16189
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OBJECTIVE 5: Correlate the validated mtDNA signature with metabolic 
traits (e.g.BMI and Diabetes). 
 
3.9.1 16189 and Diabetes 
As the information entered into the SPSS database for several traits was categorical, a t-
test of means was not always the appropriate analysis.  This was the case for the 
diabetes trait.  In the database each individual had an entry under the variable diabetes, 
either; 0 for non-diabetic, or 1 for diabetic.  To explore variant association a chi squared 
test with risk analysis was conducted using the mtDNA SNP 16189 (Table 3.10). 
 
Table 3.10:  Association statistics of mitochondrial variant 16189 and diabetes. 
 
Note:  Total number of cases investigated has been adjusted to; a) adults, those aged 18 years or older, 
and b) adult cases that have available data for both diabetes and genotyping values. 
 
 
The chi squared test statistic was χ2 = 2.20, d.f. = 1, with a p-value of 0.138.  As one of 
the cells in the chi squared analysis fell below 5% (Table 3.10), an alternative test 
statistic was adopted.  This was the Fisher’s Exact test (2 sided) which gave a p-value of 
0.217.  This test again was non-significant so no further follow up statistics were 
conducted.   
  
T C Total
non-diabetic 32 (15%) 183 (85%) 215 (100%)
diabetic 1 (4%) 24 (96%) 25 (100%)
Total     33 (14%) 207 (86%) 240 (100%)
16189
Results 
 
110 
 
3.9.2 4769 and diabetes 
As the information entered into the SPSS database for several traits was categorical, a t-
test of means was not always the appropriate analysis.  This was the case for the 
diabetes trait.  In the database each individual had an entry under the variable diabetes, 
either; 0 for non-diabetic, or 1 for diabetic.  To explore variant association a chi squared 
test with risk analysis was conducted using the mtDNA SNP 4769 (Table 3.11). 
 
Table 3.11: Association statistics of mitochondrial variant 4769 and diabetes. 
 
Note:  Total number of cases investigated has been adjusted to; a) adults, those aged 18 years or older, 
and b) adult cases that have available data for both diabetes and genotyping values. 
 
 
The chi squared test statistic was χ2 = 2.813, d.f. = 1, with a p-value of 0.094.  This test 
was non-significant; however there appeared to be a trend which was explored with risk 
analysis.  This gave an odds ratio of 2.05, which suggests that individuals with the G 
allele are 2 times less likely to be diabetic than those who have the A allele. 
 
3.9.3 Hypothesis Generating 
In addition to the specific hypotheses tested above a set of exploratory (or hypothesis 
generating) tests were run to further analyse mtDNA markers and trait correlation in the 
larger RHAS Maori database.  Both genotyped SNPs (16189 and 4769) were tested for 
significance against an extensive list of metabolic markers.  These included; BMI, 
WHR, age, disease associations, blood serum markers (vitamin, lipids, glucose, etc.), to 
name a few.  
G A Total
non-diabetic 167 (77%) 51 (23%) 218 (100%)
diabetic 16 (62%) 10 (38%) 26 (100%)
Total     183 (75%) 61 (25%) 244 (100%)
4769
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3.9.3.1  Association Testing 16189 and Metabolic Traits 
A list of metabolic traits was generated within the SPSS database.  Possible correlations 
between metabolic traits and mitochondrial variant T16189C were tested using a 
Spearman’s two-tailed bivariate test for correlation.  Results from this test were shown 
as a hypothesis generating graph by plotting each traits p-value against it correlation 
statistic (Figure 3.13).  A cut-off for significance was set at the 0.05 a conservative level 
was chosen to ensure that no relationships of interest were overlooked.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13:  Hypothesis generating graph showing metabolic associated traits and their 
statistical correlation to mitochondrial variant T16189C.  Traits below the 0.05 level of 
significance were selected for further statistical investigation. 
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An independent samples student t-test was conducted on metabolic traits which had a 
significant correlation (<p=0.05) with the T16189C variant (Table 3.12).  It should be 
noted that several of the traits showing significant correlation were nominal in nature 
and were unable to be analysed using the student t-test.  These traits were analysed 
separately using appropriate tests.  BMI and WHR were also included in the t-test as 
traits of interest to investigate whether any associated trends may be worth further 
investigation. 
 
Table 3.12:  t-test statistics for specific clinical traits 
wt (T) variant (C)
B12 (pmol/L) 367.774 442.370 3.016 58.167 0.004
**
CREA (μmol/L) 84.613 80.141 -1.310 50.779 0.196
ICIN 13.097 12.047 -1.443 54.704 0.155
AUDIT 5.333 7.596 1.744 33.250 0.090
BMI (kg/m
2
) 30.858 32.841 1.455 80.298 0.150
mean_dias (mmHg) 77.214 81.927 2.151 40.485 0.037
*
WHR 0.930 0.929 -0.037 123.335 0.970
Clinical Trait
16189
t score df p value
 
For all traits equal variances are not assumed.  
**
indicates significance at the 0.005 level.  
*
indicates 
significance at the 0.05 level.  B12 (vitamin B12), CREA (creatinine), ICIN (bilirubin levels), AUDIT 
(dangerous consumption of alcohol), BMI (body mass index), mean_dias (mean diastolic blood pressure), 
WHR (waist hip ratio). 
 
The t-test results (Table 3.12) indicated two of the metabolic traits were deemed to have 
statistically significant difference of means; B12 (p=0.004) and mean_dia (p=0.037).  
Blood serum vitamin B12 levels appear to be significantly higher in those RHAS 
individuals who carry the T16189C variant.  A similar trend was noticed in mean 
diastolic blood pressure, again significantly higher in variant groups.  Another 
interesting trend identified was that of the decreased creatinine levels in T16189C 
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Correlation Statistic
mtA4769G trait associations
BMI 
(0.24, 0.711)
Diabetes
(-0.107, 0.094)
WHR 
(-0.047, 0.476)
P = 0.05
CHHD (-0.177,0.010)
CHOL (-0.140, 0.041)
TRIG (-0.142, 0.038)
CVD (-0.157, 0.034)
Factor2 (-0.140, 0.037)
variant individuals.  While this trend was not significant, the noted difference in means 
and creatinine’s possible role in early identification of T2DM make it a prime candidate 
for follow up research. 
 
3.9.3.2  Association Testing 4769 and Metabolic Traits 
Possible correlations between metabolic traits and mitochondrial variant A4769 were 
tested using a Spearman’s two-tailed bivariate test for correlation.  Results from this test 
were shown as a hypothesis generating graph by plotting each traits p-value against it 
correlation statistic (Figure 3.14).  A cut-off for significance was set at the 0.05 level a 
conservative level was chosen to ensure that no relationships of interest were 
overlooked.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14:  Hypothesis generating graph showing metabolic associated traits and their 
statistical correlation to mitochondrial variant A4769G.  Traits below the 0.05 level of 
significance were selected for further statistical investigation.  
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It was noted that all significant correlated metabolic traits were related to blood lipids 
and cardiovascular disease.  An independent samples student t-test was conducted on 
metabolic traits which had a significant correlation (<p=0.05) with the A4769G variant 
(Table 3.13).   
 
Table 3.13:  t-test statistics for specific clinical traits 
 
For all traits equal variances are not assumed.  
*
indicates significance at the 0.05 level.  CHHD 
(composite lipid profile statistic), CHOL (cholesterol), TRIG (triglycerides), CVD (risk of cardio vascular 
disease), Factor2 (risk factor for CVD). 
 
The t-test results (Table 3.13) indicated three of the metabolic traits were deemed have 
statistically significant difference of means; CHHD (p=0.023), TRIG (p=0.038) and 
Factor2 (p=0.040).  All three traits are related to blood lipid and triglyceride levels.   
Factor2 is a composition of several traits which creates risk factor statistic for 
cardiovascular disease.  It is therefore interesting to note that the Factor2 mean for the A 
allele is more than double that of the G allele.  These trends pave the way for future 
investigation and form a group of prime candidate markers for follow up research. 
 
  
wt (A) variant (G)
CHHD 4.339 3.947 2.311 109.497 0.023
*
CHOL (mmol/L) 5.219 4.944 1.826 105.939 0.071
TRIG (mmol/L) 2.280 1.837 2.113 80.851 0.038
*
CVD 6.895 5.191 1.514 71.801 0.134
Factor2 0.507 0.218 2.076 101.406 0.040
*
Clinical Trait
4769
t score df p value
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3.10 Summary of Results 
RFLP and HVRI sequencing was used to generate a Mitochip selection group RHAS 
Maori (n=94).  Analysis of these sequences with other Maori HVRI data identified 
increased mtDNA variation.  This increased variation has lead to the discovery of larger 
Maori haplotype diversity than was once thought, including 3 unique to RHAS Maori. 
 
Using a novel high-throughput resequencing assay this study has sequenced the first 
complete Maori mitochondrial genomes (n=20).  It has also documented 7 novel 
variants, which will be added to the Mitomap database.  When compared to independent 
worldwide sequence datasets it was determined that RHAS Maori share the same 
haplogroup markers as Polynesian mtDNA; with both belonging to haplogroup B.  It 
has been identified that RHAS Maori exhibit high frequencies of three variants; 
1185>T, 4769>A, and 16126>C.  These variants reside in very low frequencies 
worldwide (>1%), and form an RHAS Maori specific mtDNA signature. 
 
Four variants discovered within RHAS Maori mtDNA sequences have previously been 
reported to have association with disease.  These were; 4769, 6261, 16189, and 16519.  
Two of these variants (4769 and 16189) were genotyped in the wider RHAS Maori 
community (n=400).  Frequencies of these variants in the community were; T16189C 
(88%) and G4769A (25%).  When correlated against metabolic traits it was found that 
RHAS Maori with T16189C showed elevated vitamin B12 levels, as well as increased 
mean diastolic blood pressure.  The variant G4769A was found to be associated with a 
group of cardiovascular disease risk factors (CHHD, TRIG, and Factor2).  An 
association between G4769A and diabetes was also explored, with indications that 
individuals with the G variant were 4 times less likely to develop diabetes. 
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Chapter 4  Discussion 
 
4.1 HVRI Analysis of 94 RHAS Maori 
 
The control region of the human mitochondrial genome (mostly HVRI) is a focus in 
many scientific fields (Poulton et al., 1998; Stoneking 2000; Lambert et al., 2002).  It 
has proved a great success in tracing mtDNA migration and structuring populations 
(Vigilant et al., 1991; Lum et al., 1994; Hagelberg 1997), as well as being a powerful 
forensic identifier (Vallone et al., 2007).  More recently specific mtDNA variants within 
the control region have been highlighted as having associations with a variety of 
disorders (Kim et al., 2002; Navaglia et al., 2006; Bhat et al., 2007).  Several of these 
disease studies involve variants within Maori HVRI sequences (Poulton et al., 1998; 
Poulton et al., 2002). 
 
In this study the Hyper Variable Segment I (HVRI) of the mtDNA control region was 
analysed in two ways.  The first involved a novel restriction assay, which analysed a 
specific Polynesian variant marker within PCR amplified HVRI products.  The second 
method employed was sequencing of 94 HVRI from New Zealand Maori individuals 
from the Rakaipaaka iwi.  Twenty one different haplotypes were identified, defined by 
22 variable positions, or SNPs.  The majority of these variants were transitions (minimal 
transversions were detected), however, there were several areas of visible heteroplasmy, 
and two sequences contained an insertion at 16295. 
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4.1.1 RFLP assay 
Restriction Fragment Length Polymorphism (RFLP) assays have been proven to be 
useful for quick identification of specific sites within segments of DNA (Introduction, 
Section 1.3.6.1).  These assays have been well established in mtDNA research as a 
means of quickly identifying specific haplotype variants (Francalacci et al., 1999).  This 
study identified a novel restriction site that resides within a large proportion of 
Polynesian mtDNA types.  The assay used the restriction enzyme Pst I to screen for the 
Polynesian specific haplotype B4a1a1a (Results, Section 3.3).  This haplotype is 
defined by the transition variant 16247>G, which is also the position that determines the 
Pst I restriction site.  New Zealand Maori have been identified to share this Polynesian 
mtDNA haplotype (Sykes et al., 1995; Murray-McIntosh et al., 1998; Whyte et al., 
2005).  As such it was hypothesised that this test would provide a means to quickly and 
cheaply screen for Maori mtDNA sequences and would detect the presence of European 
mtDNA admixture. 
 
The RFLP assay conducted showed 77% of the RHAS Maori HVRI PCR products were 
digested.  It was originally suspected that the 33% undigested HVRI products were 
European in nature.  This was proven wrong when sequencing determined that one of 
these sequences had a variant within the restriction site, meaning it did not undergo 
restriction.  While the other sequences were found to be Polynesian in origin, they 
lacked the 16247>G variant, having the previously identified ‘CCAT’ motif (Trejaut et 
al., 2005).  This was the first documented use of this RFLP assay.  It has been proven to 
be specific for haplogroup B4a1a1a.  It was useful as a quick screen of ancestry in 
RHAS Maori, and identified the B4a1a1a haplotype in 77% of the HVRI products 
tested.  Once this thesis has been submitted this RFLP assay will be entered into the 
consortium located in the Mitomap database (Ruiz-Pesini 2007).  
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4.1.2 HVRI sequencing and 16189 
Sequencing of PCR products was used to generate a database of 94 HVRI RHAS Maori 
sequences.  All but one sequence was identified as belonging to haplogroup B (Results, 
Section 3.4.2).  One of the variants that define haplogroup B is a T to C transition at 
position 16189 in the HVRI of the D-loop.  This transition creates a poly-C tract, which 
has been shown to exhibit length variation (Poulton et al., 1998).  This variant is within 
the control region of the mitochondrial genome, while it is non-coding, it does contain 
many of the controlling elements of transcription and translation.  Previous research had 
demonstrated that due to the nature of variants within the Polynesian (B4a1a1a) mtDNA 
haplotype, sequencing through the HVRI region becomes troublesome (Cann et al., 
1987; Redd et al., 1995; Whyte et al., 2005).  The problem involves the C→T transition 
at position 16189 (Figure 4.1), and two A→C transversions at 16182 and 16183.  The 
transition, along with both transversions, generates a homopolymeric C-tract which 
causes polymerase instability during sequencing, leading to blurred results after this 
point (Figure 4.1 B).   
 
 
 
 
 
 
 
 
Figure 4.1:  Chromatographs showing; A) a Taiwanese Aboriginal HVRI sequence 
(AMI011) with a T at position 16189 (indicated above), B) a Maori HVRI sequence 
(mt3) showing the T to C transition at position 16189, as well as the two A to C 
transversions (indicated by arrows).  These two events create a homoploymeric cytosine 
tract in the mitochondrial HVRI, about 200 bp into the primer selected sequence.  
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As noted in previous work  (Lum et al., 1994; Redd et al., 1995; Whyte et al., 2005) the 
additional C-tract length variation caused technical difficulty for one directional 
sequencing of the HVRI.  To overcome this, both forward and reverse primers were 
used to obtain the full HVRI sequence.  After close examination of obtained forward 
and reverse sequences, as well as other available Polynesian sequence data, the majority 
of the RHAS HVRI samples (again all but one) were found to have a C-tract length of 
12 C’s.  This was later confirmed by Mitochip analysis (Section 3.5).  Mitochip analysis 
also revealed the presence of the 9-bp deletion in the 20 RHAS Maori sequences. 
 
4.2 Variation within 20 complete RHAS Maori mt genomes 
 
Mitochip resequencing analysis of 20 NZ Rakaipaaka Maori mitochondrial genomes 
resulted in 14 different haplotypes, defined by 44 variants (SNPs) of the revised 
Cambridge Reference Sequence.  The majority of these variants were transitions, only 
two transversions were identified.  As an internal control several of the HVRI mtDNA’s 
were chosen as they contained novel variants that could be used to test the Mitochip 
array.  One of the control sequences contained an insertion at 16295.  The Mitochip 
resequencing assay confirmed this insertion of A at base 16295, as was noted in HVRI 
sequencing results (Results, Section 3.4.2).  This indicated that the Mitochip array was 
accurate and working correctly.  As all 20 sequences belonged to haplogroup B, they 
were hypothesised to contain the 9 bp deletion (Introduction, Section 1.3.6.3).  The 
array detected the 9 bp deletion in all 20 RHAS Maori.  This detection is traditionally 
analysed using separate tests (either RFLP, directed PCR and sequencing, or a 
combination of both), yet the Mitochip was able to detect its presence.  This could be 
validated by following the procedure laid out by Whyte et al., (2005).  
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4.2.1 Identification of a RHAS Maori specific mtDNA signature 
One of the specific aims of this project was to identify whether RHAS Maori exhibit a 
specific mtDNA signature.  It was hypothesised that if a RHAS Maori signature was 
present it could possibly be used to help explain the increased frequencies of metabolic 
disorders such as diabetes and obesity within the community.  If any RHAS Maori 
specific variants were found to associate with metabolic traits they could ultimately 
become part of an early diagnostic screen.  This would allow for the development of 
early intervention strategies.  
 
Three variants were identified as belonging to RHAS Maori, and were found on the 
background haplotype of Polynesian mtDNA.  The three RHAS Maori specific 
signature variants are; 1185, 4769, and 16126.  With the finding of this signature this 
project has identified that RHAS Maori do indeed exhibit a unique mtDNA background 
when compared to Polynesians.  Implications of this will be discussed further through 
this section. 
 
4.2.2 Identification of seven novel mitochondrial variants 
Of the 44 variants identified from the 20 RHAS Maori mtDNA sequences, 16% (n=7) 
were found to be undocumented.  As such they were termed novel (Results, Section 
3.5.5, Table 3.5).  As they were only present in very low frequencies, none of these 
variants were considered to be part of the RHAS Maori mtDNA signature.  They are 
however still worth documenting, as future studies could possibly screen for these in 
other Maori mtDNA.  These novel variants will be entered into the Mitomap database 
upon submission of this thesis.  
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4.2.3 Strengths and Limitations of the Affymetrix Mitochip 
The Affymetrix Mitochip array was a relatively novel technique when it was decided 
upon for the mtDNA screening in this project, and had not previously been employed 
within NZ.  However over the last 2-3 years it has seen use in many different research 
projects, including forensics (Vallone et al., 2007), early breast cancer detection 
(Jakupciak et al., 2008), and disease correlation studies (Rollins et al., 2009).  The 
Mitochip assay offers complete resequencing of mtDNA with additional probes for 
variant identification and confirmation.  It also requires a very small amount of DNA to 
be effective, having been shown to work with DNA amounts ~10-50 ng. 
 
The assay does however have limitations; it’s relatively expensive (~NZ$700 per chip), 
chips have to be analysed on Affymetrix GeneChip machinery.  Additionally due to an 
oversight in the design there are 12bps missing from each end of the mitochondrial 
genome, and due the GC rich nature of mtDNA there are many areas that consist of 
solid cytosine blocks (runs 4 or more) which interfere slightly with probe hybridisation 
and ultimately base call data surrounding the area. 
 
There were also several quirks to the Mitochip protocol that became clear during the 
analysis phase.  The first of these was that 12bp of sequence was noted to be missing 
from the beginning and end of the mtDNA sequences.  Communications with 
Affymetrix confirmed this as a known ‘oversight’ in the design of the Mitochip, 
specifically the design of the probes.  This means that all mtDNA sequences generated 
using the Mitochip protocol were missing 24bp.  However this region of the D-loop 
contains very little variation and no key markers so for the purpose of this work these 
sequences will be referred to as complete.  
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4.3 Phylogenetic Analysis 
 
Genotyping data for three SNP’s was generated primarily for disease association testing 
within the wider RHAS Maori community (Results, Section 3.9.) and is discussed 
further in this chapter.  However this frequency information also gives a good indication 
about the mtDNA haplotype composition of RHAS Maori mtDNA.  The three SNP’s 
were found in varying frequencies in RHAS Maori; G4769A = 25%, T16189C = 88%, 
and T16519C = 96%.  The presence of the T16189C variant is a good indicator of 
Polynesian, and subsequently, Maori mtDNA ancestry as it is part of the Polynesian 
‘CCGT’ motif.   It was seen in the genotype screen for this SNP that 88% of the 
enrolled RHAS individuals had the C variant.  This left 12% with mtDNA that is 
suspected to be European-like.  The variant G4769A has been identified as a possible 
RHAS Maori specific variant, and was found to be present in the wider RHAS 
community (n=~400) in proportions similar to what was identified in the Mitochip 
analysis.  Originally discovered in 7 of the 20 mtDNA’s that were resequenced via 
Mitochip, larger scale genotyping has revealed this position to be present in 25% of the 
RHAS Maori.  It should be noted that the G4769A SNP is only present on a 
Polynesian/Maori mtDNA background, meaning that markers such as the 9-bp deletion 
and the Polynesian motif have to be present for this SNP to be found in Maori.  This 
indicates that it is most likely to have originated in RHAS Maori rather than somewhere 
in Polynesia.  It should also be noted that at this stage the G4769A SNP has only be 
validated in RHAS Maori.  Further investigation in wider Maori communities would 
determine if this variant is RHAS Maori specific or indeed a marker found in other 
Maori.  As yet it has not been observed in other Polynesian populations; a database 
search discovered no sequences containing both the Polynesian ‘CCGT’ motif and 
G4769A.  This test was also run for variants C1185T and T16126C (other RHAS 
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specific signature markers) with the same results, no sequences in the available 
databases contained the specific variants.  This leads towards the possibility of the 
discovery of the first specific Maori haplotype defining variants.  
 
The C variant at 16519 was identified in all 20 RHAS Maori mtDNA sequences.  It was 
originally thought to be another ancestral Polynesian mtDNA marker.  As such it was 
genotyped and was to be employed as a secondary screen in case genotyping of the 
T16189C variant was not possible.  It was thought that the difficulties encountered 
when sequencing mtDNA with the T16189C variant might have made genotyping the 
SNP unlikely.  This however was not the case. 
 
When examined in the RHAS Maori 16519>C was present in 96% of the community.  
This was considered odd as it was expected that the variant at T16519C would be 
present at the same frequency as T16189C, if they were both markers of Polynesian 
mtDNA ancestry.  This appears to be the result of a unique mutational relationship with 
the 16189 C variant.  When the homopolymeric C-tract generating transition (16189>C) 
is present it is hypothesised that position 16519 becomes hyper-mutable, that is it is 
more likely to undergo a transition mutation (Navaglia et al., 2006).  The T16189C 
variant does appear randomly in various geographical mitochondrial haplotypes, but has 
become a mainstay in haplogroup B (van Oven et al., 2009).  So it has been noticed that 
sequences exhibiting the T16189C variant are more likely to have the T16519C variant.  
This was also demonstrated in this study when the 16519 SNP was genotyped in the 
wider RHAS Maori community.  The T16519C variant was found to be present in 96% 
of RHAS Maori (Results, Section 3.9). Therefore it looks to be moving towards fixation 
in Maori mtDNA. 
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4.3.1 Using complete mtDNA to explore RHAS Maori ancestry 
This is the first research to completely sequence the mitochondrial genome of New 
Zealand Maori individuals.  Three variants have been identified that appear to have 
arisen in Amis Taiwanese Aboriginals: T6719C, C12239T, and A15746G.  These 3 
variants are present in mitochondrial sequences from Micronesia [Kapingamarangi 
Atoll, Majuro Atoll (Pierson 2006)], Melanesia [Espiritu Santo, Maewo, Trobriand 
Islands (Pierson 2006), Bougainville (Macaulay V. 2005), PNG coast (Ingman 2003)], 
Polynesia [Tonga (Pierson 2006), Cook Islands, Samoa (Ingman 2000; Ingman 2003)], 
and now NZ Maori (this study).  Another variant has been identified that is believed to 
have occurred either in or around coastal Melanesia (PNG) or in Oceania.  This is 
A14022G, which has been identified in peoples from Micronesia, Melanesia (coastal 
PNG), and Polynesia (Trejaut et al., 2005).  The A16247G variant of the Polynesian 
motif is not found in Amis or Taiwan, but seen in high frequencies in Melanesia and 
Polynesia (Trejaut et al., 2005). 
 
Early work has suggested the region around Taiwan as the staging post for Polynesian 
migration, this has been based on linguistics (Bellwood 1991; Gray et al., 2009), 
archaeological (Kirch et al., 1988), and DNA in the form of mitochondrial control 
region sequences (Lum et al., 1994; Sykes et al., 1995; Cann 2004).  More recently this 
evidence has been supported by complete mitochondrial genome sequence data (Ingman 
2001; Trejaut et al., 2005).  The RHAS Maori mtDNA from this study seem to provide 
support to this theory as well.  There are specific markers inside of the mitochondrial 
coding region that look to have arisen in Taiwan (Results, Section 3.6.1 Table 3.6).  It 
can be seen that the variants T6719C, T10238C, C12239T, and A15746G, appear first 
in Taiwan and grow in frequency through Melanesia and into Polynesia.  These Maori 
mtDNA therefore add weight to the ongoing argument of Polynesian migration.  
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4.3.2 Haplotype Analysis  
Of the 94 HVRI sequences 93 were reported as belonging to haplogroup B; 75 were 
identified as having the ‘CCGT’ motif (haplotype B4a1a1a), while 18 were found to 
have a previously reported pre-Polynesian ‘CCAT’ motif (haplotype B4a1a1).  This 
ratio of ‘CCGT’/’CCAT’ within the Rakaipaaka Maori is an interesting one, suggesting 
possible parallel migration of separate mtDNA lineages.  It could also indicate a 
reversion mutation at position 16247.  Both motif’s have been identified previously 
within Maori populations (Murray-McIntosh et al., 1998; Whyte et al., 2005). 
 
One individual sequence lacked any Polynesian mtDNA markers and was determined to 
belong to the European haplogroup H (Helena).  Haplogroup H is the haplogroup that 
the CRS belongs to.  This was an intriguing discovery as all RHAS Maori individuals 
were chosen based upon an autosomal ancestry score (Hall 2009).  This meant that all 
94 individuals exhibited high percentage Maori ancestry, from which it was 
hypothesised that they would also therefore show Polynesian mtDNA ancestry.  
Mitochondrial HVRI sequencing confirmed this hypothesis, with the exception of this 
one individual.  This phenomenon could be explained by admixture, all it would take is 
one European female in a lineage to pass on her mtDNA and then it would move down 
through all her female descendents.   
 
4.3.2.1  RHAS Maori mtDNA Exhibits Increased Variation 
This study has built on the previous research of Murray-McIntosh et al., (1998) and 
Whyte et al., (2005).  By combining HVRI datasets from these studies with the RHAS 
Maori HVRI dataset it has been discovered that the Maori mitochondrial genome 
exhibits more variation than once believed (Results, Section 3.6.2).  The previous 
estimate of Maori mtDNA haplotypes was 7 (Whyte et al., 2005) based on 109 HVRI 
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sequences.  In the same study analysis of East Polynesian HVRI sequences revealed 24 
haplotypes.  This suggested that mtDNA variation decreased as Austronesian speaking 
Polynesians migrated through Oceania (Hertzberg 1989).  As Aotearoa was the last 
place to be inhabited, it was concluded that there is little variation within Maori 
mtDNA.  It is thought that this was due to genetic bottlenecks created by founder effects 
(Lum 2000; Whyte et al., 2005).  Due to the then apparent low haplotype diversity it 
was speculated that Maori would show no specific mtDNA haplotype, one that would 
differentiate Maori mtDNA from the Polynesian mtDNA haplotype B4a1a1a (Trejaut et 
al., 2005). 
 
Combining the RHAS Maori HVRI dataset with that of Murray-McIntosh et al., (1998) 
and Whyte et al., (2005) greatly expanded the number of identified Maori HVRI 
haplotypes from 7 to 17 (Results, Section 3.6.2).  It was noted that several Maori 
sequences in Whyte et al., (2005) contained HVRI variation outside of the region 
explored by Murray-McIntosh et al., (1998).  When the wider HVRI sequences of 
Whyte et al., (2005) was combined with RHAS Maori HVRI data the extra variation 
increased the number of mtDNA haplotypes from 17 to 25.  This analysis reveals that 
there is indeed more variation within the Maori mtDNA HVRI than was once thought.   
 
There are several possible explanations for the increased mtDNA diversity identified.  
The first explanation is that there were more Maori founders that arrived in Aotearoa 
than have been previously estimated.  Whyte et al., (2005) went on to use Maori 
haplotype number to estimate, via population simulation, the number of founding 
females that would have been required to have arrived in Aotearoa to form the present 
day Maori population.  The final number of founding females was estimated to be ~190 
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(Whyte et al., 2005).  Based on the extended haplotype diversity discovered in this 
study, it is postulated that this number could now be considered an underestimate, and 
in fact the number of founding females is actually much higher.  Future study could 
explore re-running the computer simulations to estimate the number of female founders 
based on the new HVRI diversity. 
 
Another explanation for the noticed variation in RHAS Maori HVRI sequences is that it 
is possible that the human mtDNA is acquiring mutations at a much faster rate than 
previously expected (Howell et al., 2007).  When calculating mitochondrial mutational 
rates and applying them to current molecular clocks, it has been identified that the 
mtDNA of penguins actually mutates at 2-7 times the rate that was currently accepted 
(Subramanian et al., 2009).  It is possible that this is similar in human mtDNA mutation 
rates, and the evolutionary genetics field can only benefit from accruing more complete 
mtDNA sequences to examine this trait further. 
 
4.3.2.2  Identification of Maori Specific mtDNA haplotypes 
In Results Section 3.5.2, it was identified that within the 20 RHAS mtDNA sequences 
there were 44 variants when compared to the CRS.  Of these it was determined that the 
bulk of the common RHAS variants were the same as those found in Polynesian 
mtDNA.  However it was identified that several variants appeared in higher frequency 
in some RHAS Maori sequences, suggesting the presence of extended mtDNA 
haplotypes.  Further analysis of the 20 complete Maori mtDNA sequences has revealed 
that at least 3 unique haplotypes reside within the RHAS Maori community.  These 
novel haplotypes are defined by the RHAS specific variants C1185T, G4769A, 
T16126C, and A162476G and are documented in Table 4.1. 
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Table 4.1:  RHAS Maori mtDNA haplotype markers 
 
*Previously reported Polynesian mtDNA haplotype B4a1a1a (Trejaut et al., 2005; van Oven et al., 2009).  
Positions underlined are RHAS specific haplotype markers.  Bolded positions represent Polynesian 
mtDNA motif ‘CCGT’.  Shaded positions indicate variants to the CRS, usually positions in common to 
CRS are represented as dots, however it was chosen to represent these as the respective base to portray 
haplotype motif’s. 
 
Table 4.1 details the variant positions that define 4 RHAS Maori haplotypes within the 
well document B4a1a1 haplotype (Trejaut et al., 2005).  While there are singleton 
variants (noticed in only one sequence) that further expand these haplotypes in many of 
the sequences, it is these RHAS signature variant’s that define the major haplotype 
motifs.  The 4 haplotype motifs are: RM1 (TATCCGT), RM2 (CGCCCGT), RM3 
(CGCCCAT), and RM4 (CGTCCGT).  RM1, RM2, and RM3 are novel haplotypes that 
have not been previously documented.  This was ascertained by searching for motif 
positions in several databases (mtDB and Mitomap) as well as Phylotree (van Oven et 
al., 2009).  RM4 is the haplotype more traditionally characterised by the Polynesian 
‘CCGT’ motif, as can be seen in Table 4.1.  It is interesting to note that out of the 20 
sequences, only 15% show the traditional Polynesian motif.  Haplotype RM1 displays 
the highest frequency at 35%.  This haplotype is formed by two of the three markers 
defined as RHAS Maori specific (C1185T and G4769A).  It appears that these variants 
have most likely occurred either in, or on the way to Aotearoa, or more likely, relatively 
recently within the Rakaipaaka iwi.  Evidence for this is the fact that these two variants 
exist on top of the ‘CCGT’ Polynesian motif.  This ‘CCGT’ motif is derived from the 
Haplotype f 1185 4769 16126 16189 16217 16247 16261
RM1 7 T A T C C G T
RM2 4 C G C C C G T
RM3 6 C G C C C A T
RM4* 3 C G T C C G T
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HVRI sequence only, and has been used to classify Maori haplotypes until now 
(Murray-McIntosh et al., 1998; Whyte et al., 2005).  It is highly possible that sequences 
generated in these studies show the same or similar variant positions that are important 
for haplotype analysis.  Further research into Maori mtDNA haplotypes would benefit 
from typing these specific variant sequences, as it is obvious that there are important 
areas of haplotype variation outside of the HVRI. 
 
The other two RHAS Maori specific haplotypes (RM2 and RM3) both have the RHAS 
specific marker T16126C.  These haplotypes are interesting as they are actually defined 
by the variant A16247G, which is the final evolutionary marker of the Polynesian motif.  
Haplotype RM2 has the 16247>G transition present, where as RM3 has the more 
common A allele.  It has been generally thought that the Polynesian motif was the 
dominant motif in Oceania (Polynesians and Maori), but from this study it appears that 
the ‘CCAT” motif is present in high frequencies than documented (Whyte et al., 2005).  
There are several possibilities for this. The first possibility being, two mtDNA 
populations have co-existed during the migration and population of Oceania.  The 
‘CCAT’ motif is found in very high frequencies around Taiwan/South East Asia 
(Trejaut et al., 2005; Soares et al., 2008).  As the Austronesian speaking peoples 
migrated down and out into the Pacific some of their mtDNA acquired the 16247>G 
transition thus the ‘CCGT’ motif, while others retained the ‘CCAT’ motif.  They have 
since resided within Polynesian populations, with the ‘CCGT’ motif reaching much 
higher frequencies.  Another possibility is that position 16247 is hypermutable, and it’s 
possible that there has been a reversion mutation at 16247.  After the G allele has been 
acquired along the Polynesian migration, it has reverted back to A at some point.  It’s 
hard to say whether the T16126C variant occurred twice, once on each motif, or 
whether it was present first and then there was a reversion at 16247 bringing about the 
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A allele again.  Further research trying to identify these variants in other Polynesian and 
Maori mtDNA is required. 
 
The substructure of haplogroup B is extrapolated out in Figure 4.2 to indicate where on 
the phylogenetic tree these mtDNA sequences would be placed.  It is yet to be seen if 
these RHAS Maori haplotypes exist in Polynesia, and only research generating more 
complete mtDNA data will provide the answers to this.  If these haplotype motifs were 
found to be in the wider Oceania, it would provide vital information towards finding 
Hawaiki, the original launching place for New Zealand Maori. 
 
 
 
 
 
 
 
 
 
Figure 4.2:  extended haplotype structure for B4, data obtained from Phylotree (van 
Oven et al., 2009).  Three of the HVRI Polynesian motif markers are indicated in blue 
boxes, while haplotype B4a1a1 is shown in green.  
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4.4 rRNA Secondary Structure Predictions 
 
As mentioned previously (Introduction, Section 1.3), mitochondrial proteins stem from 
two separate locations.  The majority of proteins incorporated into a mitochondrion are 
encoded by the nuclear genome and are translated in the cytoplasm, then transported via 
chaperone proteins to the mitochondrion.  There are however 13 protein coding genes in 
the mtDNA that are essential for correct mitochondrial function that are translated 
within the matrix (Wallace 2006).  This translation occurs on ribosomes encoded by the 
12S (small subunit) and 16S (large subunit) rRNA transcripts within the mtDNA.  It is 
therefore important that these ribosomes assemble and function correctly to avoid a 
decrease or mis-translation of these proteins crucial to OXPHOS (Bai et al., 2005).  
Mutations to the 12S rRNA have been found to play a significant role in several 
diseases.  The majority of the research conducted into mutations within the 12S rRNA 
gene has looked at sensorineural hearing loss and mitochondrially inherited deafness 
(Prezant et al., 1993; Ballana et al., 2008; Hobbie et al., 2008).  
 
The characteristics of ribosomal RNA are important from both a medical and an 
evolutionary point of view.  Ribosomal RNA is the target of numerous clinically 
available antibiotics; including erythromycin, streptomycin (Ballana et al., 2008).  
Many antibiotics target the ribosomal small subunit (SSU) of bacteria, exhibiting a 
bactericidal effect by interrupting protein synthesis.  Extensive research has been 
conducted into the role of 12S rRNA mutations in syndromic and nonsyndromic hearing 
impairment (Prezant et al., 1993; Ballana et al., 2008; Hobbie et al., 2008).  It is 
suggested that specific mutations in human 12S rRNA alter the secondary structure so 
that it more closely resembles a bacterial counterpart (Ballana et al., 2008).  This has 
lead to the discovery of several mutations (A1555G, C1494T, T1291C) that seem to be 
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susceptible to aminoglycoside antibiotics (Prezant et al., 1993; Ballana et al., 2008; Lu 
et al., 2009).  It has been shown that these mutations decrease the accuracy of 
translation, and render the ribosomal decoding site hypersusceptible to aminoglycosides 
(Hobbie et al., 2008).  These aminoglycosides appear to have their mode of action on 
mitochondrial ribosomes located in the inner ear hair cells of affected individuals.  
Identification of variants that pose health risks, such as susceptibility to specific 
antibiotics, could potentially be developed into a genetic screen which would allow 
health providers to decide on alternative treatments. 
 
Several areas of variation have been identified with the 20 RHAS Maori 12S rRNA 
sequences (Results, Section 3.5.2).  One of particular interest is 1185>T, which was 
identified in 35% of the complete mtDNA sequences analysed.  This variant is within 
the 12S rRNA gene.  Secondary structure predictions were made using RNAwebserver 
to explore possible ribosomal structural changes (Results, Section 3.7).  This prediction 
analysis was based on the same parameters utilised by Ballana et al., (2006).  When 
compared to the predicted consensus (wild-type) model, it was discovered that 12S 
rRNA which contained the 1185>T transition exhibited a small conformational change.  
It was seen that in these 12S models, a small hair pin seems to disassociate from a larger 
loop.  The significance of this is unknown and would no doubt benefit from in-depth 
research in the future.  No real structural changes were evident when the same analysis 
was conducted on 16S rRNA containing variants.  
Discussion 
 
133 
 
4.5 Protein Modelling Analysis 
 
While it is important to identify correlations between identified variants and disease 
traits, it is perhaps more imperative to understand the biological mechanisms that 
contribute to disease.  It is only when these mechanisms are elucidated that putative 
treatments and pharmaceuticals can be developed.  Therefore it is essential to consider 
these modelling analyses in addition to the correlation work that has been conducted in 
this study (Section 4.6).   
 
Much of the variation found within the RHAS Maori mtDNA’s protein coding genes 
resulted in synonymous SNPs (Results, Section 3.5.2).  Synonymous SNPs do not 
produce altered coding sequences, thus the same amino acid is coded for.  These are 
termed silent mutations; as such they are not expected to have an effect on protein 
function (Kimchi-Sarfaty et al., 2007).  Because silent mutations do not alter protein 
function they are often treated as though they are evolutionarily neutral.  However, 
many organisms are known to exhibit codon usage biases, suggesting that there is 
selection for the use of particular codons due to translational stability (Kimchi-Sarfaty 
et al., 2007). Silent mutations may also affect splicing, or transcriptional control 
(Komar 2007).  Recent results suggest that silent mutations can have an effect on 
subsequent protein structure and activity  (Kimchi-Sarfaty et al., 2007; Komar 2007)  It 
has been postulated that silent mutations could slow the translation machinery, which in 
turn could lead to misfolded, or differently folded proteins (Komar 2007).     
 
Cytochrome bc1 complex (Complex III) is the third enzyme in the electron transport 
chain (Hansford 2002).  It accepts electrons from reduced Coenzyme Q and passes them 
on to cytochrome c.  Complex III contains four redox centers; two b-type hemes, a c-
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type heme, and an iron-sulphur cluster.  Of the eleven protein subunits that make up 
Complex III, with cytochrome b (cyt b) is the only one that is encoded by the 
mitochondrial genome (Hansford 2002).  Cytochrome b is located in the center of the 
transmembrane region of the bc1 complex.  It contains 2 of the total 4 redox centers; 
heme bL and heme bH.  These heme groups are vital to the transport of electrons (Voet et 
al., 2004).  As such the amino acid substitution (T15014C, Phe to Leu) could possible 
interfere with this process.  Phenylalanine prefers to be buried in protein hydrophobic 
cores, is fairly non-reactive, and is rarely directly involved in protein function (Betts et 
al., 2003).  Leucine has very similar properties; as such this substitution is most likely 
neutral.  However there is a slight difference in structure between the aromatic side 
chain of phenylalanine and that of the aliphatic leucine (Betts et al., 2003).  Due to its 
location between the two b heme groups, in close proximity to both, this substitution 
could influence the surrounding structures eliciting and have some functional effect.  
Mutations in cytochrome b primarily result in exercise intolerance in human patients; 
though more rare, severe multi-system pathologies have also been reported (Blakely et 
al., 2005). 
 
Cytochrome c oxidase (Complex IV) is the terminal enzyme of the electron transport 
chain (Voet et al., 2004).  It receives an electron from each of 4 cytochrome c 
molecules, and uses these to create two water molecules (H20) from one oxygen 
molecule (O2) (Voet et al., 2004).  One of the variants discovered in this study, 
A6261G, has been associated with prostate cancer (Petros et al., 2005; M. Esther 
Gallardo 2006; Ray et al., 2009).  This variant results in a non-conservative amino acid 
substitution of threonine (encoded by the G allele) from alanine (encoded by the A 
allele) within the cytochrome c oxidase I (COI) subunit of Complex IV.  It appears to be 
a fairly harmless amino acid substitution.  In membrane proteins Ala and Thr are 
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usually the favoured AA substitutions (Betts et al., 2003).  However there have been 
cases where Ala/Thr substitutions have been associated with various disease states  
(Canter et al., 2005; Bai et al., 2007; Bhat et al., 2007; Liao et al., 2008).    This variant 
could also impact on the interactions of COXI and the other subunits that bind to form 
the complete cytochrome c oxidase complex.   
 
Protein modelling of specific RHAS Maori variants identified two common variants in 
close proximity to crucial COXI redox centres (Figure 4.3).  These variants are 
transitions that result in synonymous mutations; there is no change to the coded amino 
acid.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3:  Redox prosthetic groups within Cytochrome c oxidase subunit I (COI).  
Structures shown represent those amino acids involved in the binding of the redox 
centers of COI.  Amino acids are labelled and colour coded; yellow binding heme a, 
purple binding heme a3, light blue binding CuB, interacting Tyr shown in green, and 
identified variants shown in pink.  The Fe and Cu ions are represented by red and cyan 
spheres.  Note that the side chains of Tyr 244 and His 240 are joined by a covalent 
bond. Protein model generated in Sirius (http://sirius.sdsc.edu/index.php).   
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As previously mentioned, synonymous mutations have been found to possibly cause 
misfolding due to codon usage bias (Kimchi-Sarfaty et al., 2007).  It is possible that 
these variants could affect the surrounding structures, which in turn could affect transfer 
of electrons and ATP production.  It has been hypothesised that variants such as these 
have persisted in mtDNA as they provide functional advantages, such as uncoupling 
(Wallace 2006). 
 
The protein COIII is a subunit of cytochrome oxidase, which is involved in the binding 
of COI and COII; COII brings the final complex enzyme together (Voet et al., 2004). 
Two variants were discovered in two separate COIII RHAS Maori sequences.  
Interestingly neither of the variants have been reported previously, and so are novel to 
these mtDNA’s at time of writing.  One of the variants found was synonymous, 
T9722C.  The other variant however, is of more interest; a transition C9255T.  This 
transition results in a codon change, from CCU (proline) to UCU (serine).  Of the 20 
protein forming amino acids proline is the only one that has its α-amino group 
secondary (Betts et al., 2003).  Due to its unique structural properties proline can 
introduce kinks into α-helices in the protein.  Therefore proline does not favour 
substitution with other amino acids easily (Betts et al., 2003), this is also confirmed by 
the conservation index (100) seen in Results (Section 3.5.2, Table 3.4).  This high index 
value indicates that the variant position has extremely high evolutionary conservation 
across 37 different organisms.  With Pro17 being in close proximity to the N-terminus, 
this variant could possibly affect the position/structure this strand.  This could in turn 
affect how this binds other subunits within Complex IV.  Proline plays important roles 
in molecular recognition, particularly in intracellular signalling. Domains such as WW 
and SH3 bind to specific proline containing peptides that are key parts of many 
signalling cascades (Betts et al., 2003).  So if this proline was within a domain such as 
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these it could have adversely affect related pathways (i.e. second messenger, ROS 
signalling). 
 
The protein modelling work conducted in this study is currently hypothetical and would 
greatly benefit from extensive protein interaction simulations.  Such work could 
possibly begin to identify the effects of these variants within the protein coding genes.  
Regardless, this study has progressed significantly in providing the first examples of 
variation within the coding region of Maori mtDNA.  Several variants of interest have 
been identified, and are plausible starting points for future analysis.  
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4.6 mtDNA variants and disease association 
 
As outlined in Chapter 1 (Introduction, Section 1.4) mtDNA variation can contribute 
towards disease susceptibility and phenotype.  Due to the recent general acceptance of 
this fact, mtDNA is starting to be implemented in numerous disorders, ranging from 
insulin resistance (Poulton et al., 1998; Wiederkehr et al., 2006; Gaster 2007) to 
Alzheimer’s disease (Pericak-Vance et al., 2002; Santoro et al., 2006).  As such, 
Mitomap, a database of recorded disease associated variants is growing substantially  
(Ruiz-Pesini 2007).  With the aid of this database, specific mtDNA variants can be 
searched and any previously reported disease associations detected.  The Mitochip assay 
of 20 complete Maori mtDNA sequences revealed a profile of 44 variants compared to 
the CRS.  When queried against variants in the Mitomap database, four of these 
identified variants were found to have been previously associated with several disorders.  
These four variants were: A4769G, G6261A, T16189C, and T16519C. 
 
The variant A4769G is somewhat of a misnomer due to the fact that is actually a rare 
polymorphism found within the CRS (Andrews et al., 1999).  The A allele at 4769 is 
actually the rarer variant and not a good representation of this position in other 
mtDNA’s.  Searching this variant in mtDB (Ingman 2006) returned 30 sequences out of 
~3000 (~1%).  This becomes interesting as 35% of the 20 RHAS Maori mtDNA’s were 
found to exhibit the A allele at 4679, the other 75% having the more common G allele.  
This variant resides within the ND2 gene, a subunit of OXPHOS Complex I.  The G to 
A transition results in a synonymous mutation of the ATG(A) anticodon of methionine.  
A literature search identified that 4769>A had been recently associated with a group of 
schizophrenia patients  (Rollins et al., 2009).  There were other possible associated 
variants identified within the same study, many of which were apparently associated 
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with various mental disorders including; schizophrenia, bipolar disorder, and 
depression.  It has been hypothesised that the higher energy dependency of neural tissue 
makes it more susceptible to adverse mtDNA mutations than tissue that is less energy 
dependent (Santoro et al., 2006; Moreira et al., 2007; Rollins et al., 2009).  It was 
recently identified that Maori appear to show elevated levels of schizophrenia when 
compared to non-Maori (Kake et al., 2008).  Unfortunately schizophrenia or other 
mental disorders were not screened in the RHAS, meaning that at this time no 
association testing can be conducted.  This is however an excellent avenue for a future 
research project. 
 
Another variant identified in RHAS Maori that has previously been associated with 
disease is G6261A.  This variant has been associated with prostate cancer in several 
studies (Jeronimo et al., 2001; Petros et al., 2005).  The 6261 variant was found to be 
present in low frequency (1%) in the Mitochip RHAS Maori sequences.  It must be 
noted that this is a very small sample size (n=20).  As such this is another variant that 
could form part of a possible future screen in the wider Maori community.   
 
Specific HVRI variants have been found to have associations with metabolic disorders.  
The most documented of these is the T16189C transition, which also happens to be a 
major haplotype defining variant of haplogroup B, mentioned extensively in this thesis.  
Interestingly the 16189 variant has been associated with a wide range of metabolic 
disorders:  insulin resistance and diabetes (Poulton et al., 1998; Lin et al., 2005; Bhat et 
al., 2007; Liao et al., 2008), cancer (Liu et al., 2003), metabolic syndrome (Weng et al., 
2005), and cardiomyopathy (Khogali et al., 2001).  A study by Liao et al (2008) 
identified several mtSNP’s which showed an increased association with type-2-diabetes 
mellitus (T2DM), including the two variants T16189C and T16519C.  These two 
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variants were found in significantly higher frequencies in patients suffering T2DM than 
in individuals that didn’t (Liao et al., 2008).  Caution is advised however when 
considering all of these associations.  As the variants in question are major markers of 
mtDNA ancestry, it is possible that they are picking up diseases associated with other 
underlying genetic factors.  For example, the presence of T16189C is a very good 
indicator of mtDNA haplogroup B.  Hence any associations involving frequencies of 
this variant with disease could well be identifying the contribution of a multitude of 
ancestral genetic markers. 
 
4.6.1 Disease Association in the RHAS Maori Community 
As part of the RHAS individuals were asked to supply blood and questionnaire 
information for clinical trait profiling.  As such the final database of RHAS Maori 
adults contained ~400 individuals, with extensively documented clinical data.  Added to 
this was also genotyping screens of three mtDNA variants identified within RHAS 
Maori.  This database allowed the statistical analysis and association testing of specific 
metabolic traits such as; diabetes, BMI, lipid profiles (LDL, HDL), reactive peptide 
levels, waist hip ratio, and many more.  Of the three SNPs, only two were identified in 
frequencies that allowed for statistical correlations.  These two SNPs were 4769>A and 
16189>C.  The next section discusses possible disease association with these markers. 
 
4.6.1.1  T16189C possible disease associations in RHAS Maori 
The variant 16189>C was identified in 88% of the wider RHAS Maori community.  
Association testing with diabetes returned non-significant results, so hypothesis testing 
was used to identify any significant correlations with metabolic traits (Results, Section 
3.9.3).  Significant correlations identified included increased means between the variant 
and common allele in: vitamin B12 and mean diastolic blood pressure.  
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Vitamin B12 is directly related to energy metabolism.  Generally levels can fluctuate 
broadly, with higher levels of vitamin B not having any adverse effects.  In fact higher 
levels of vitamin B12 are possibly protective against ROS, and aging.  Lower levels of 
B vitamin however have been found to cause disease states, usually neurological in 
nature (Herrmann et al., 2008).  This could possibly be due to an interaction between 
vitamin B12 and energy metabolism of the mitochondria in neural tissue.  Lower levels 
of vitamin B12 would lower metabolism levels decreasing energy production.  
Decreased energy production in neural tissue has been thought to lead to disorder such 
as Parkinson’s, Alzheimer's, depression, and others (Ghezzi et al., 2005).  If this is the 
case then having higher vitamin B12 levels is beneficial, and could possibly be 
somewhat protective against neurological disorders in RHAS Maori. 
 
A trend towards decreased CREA (creatinine) levels was also noticed in RHAS Maori 
with the 16189>C variant.  Decreased creatinine levels have been shown to correlate 
with the presence of type-2-diabetes in Asian men (Harita et al., 2009).  It has been 
suggested that lower creatinine levels could be a good risk factor for early diabetes 
detection.  As levels of diabetes are elevated in RHAS Maori, it could be worth 
following this analysis up in a larger group to further investigate the trend of creatinine.  
A weak correlation with a general increase in mean diastolic blood pressure was also 
noticed with the variant T16189C.  This could be a possible link to cardiovascular 
disease risk, and is worth following up. 
 
4.6.1.2  A4769G possible disease associations in RHAS Maori 
In the correlation against metabolic traits, G4769A was found to associate significantly 
with five specific traits; CHHD, TRIG, Factor2, CHOL, and CVD.  It is interesting that 
all five traits are showed significant correlations with similar metabolic traits.  These 
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traits were; LDL (low-density lipoprotein), CHOL (cholesterol), CHHD (blood lipid 
ratio), TRIG (triglycerides), and Factor2 (cardiovascular risk statistic), all of which can 
be considered risk factors for cardiovascular disease.  Further testing of means found 
that three of these traits with have statistically higher means than the common allele in 
RHAS Maori.  These were CHHD, TRIG, and Factor2.  This variant has been identified 
as a RHAS specific variant, and could well be associated with metabolic disorder, 
specifically cardiovascular disease, in the Rakaipaaka community.  It has been observed 
that RHAS Maori exhibit higher than national levels of metabolic disorders.  It’s 
therefore possible that variant G4769A could help explain this and become the basis of 
early diagnostic screens.  
 
In a chi squared analysis with risk association of 4769 and diabetes, an interesting trend 
was observed.  While not quite at the p=0.05 level of significance, it is still interesting 
to document.  The risk analysis odds ratio suggests that individuals with the 4769>G 
variant are more than 2 times less likely to develop diabetes.  Again this was not 
significant, but warrants further genotyping in the wider Maori community. 
 
A recent study considered mtDNA haplogroups and individual variants and their 
possible role in susceptibility of psychiatric disorders (Rollins et al., 2009).  In this 
work the 4769A variant showed a significant allelic association with Schizophrenia.  It 
has been identified that Maori exhibit elevated incidences of Schizophrenia than non-
Maori (Kake et al., 2008).  This provides strong evidence that a possible relationship 
between mtDNA variants and mental disorders such as Schizophrenia in Maori may 
exist, which would benefit from screens in the wider Maori community. 
 
Summary and Conclusion 
 
143 
 
Chapter 5  Summary and Conclusion 
5.1 Summary 
The major findings of this thesis are summarised below in relation to the research aims 
from Introduction, Section 1.8: 
 
1) Design and optimisation of an RFLP assay and HVRI PCR to aid with subject 
selection for Mitochip array analysis. 
A total of 94 HVRI sequences were obtained from Maori individuals enrolled in the 
RHAS.  Sequences were generated using PCR and automated sequencing.  All HVRI 
sequences will be entered in to GenBank for access by the scientific community after 
this thesis has been submitted. Of the 94 HVRI sequences 93 were reported as 
belonging to haplogroup B; 75 were identified as having the ‘CCGT’ motif, while 18 
were found to have a previously reported pre-Polynesian ‘CCAT’ motif.  One individual 
sequence lacked any Polynesian mtDNA markers and was determined to belong to the 
European haplogroup H (Helena).  Several novel variants were found within these 
HVRI sequences, of note was an insertion at 16295. From the HVRI database 20 RHAS 
mtDNA specimens were selected for complete re-sequencing using the Affymetrix 
Mitochip assay.  These 20 were selected to be a representation of mtDNA diversity 
within the Maori of the Rakaipaaka iwi.  As such 14 sequences containing the ‘CCGT’ 
motif, and 6 sequences with ‘CCAT’ motif, were selected.  To further refine selection, 
HVRI sequences showing unique individual variants were chosen as internal controls 
for the Mitochip assay. 
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2) Obtain entire mtDNA sequence information from a subsample of Rakaipaaka 
individuals with Maori ancestry (n=20) using the Affymetrix Mitochip. 
The 20 complete mtDNA from Rakaipaaka Maori revealed 9 novel variants previously 
undiscovered.  Of the 20 mtDNA sequences 7 had variants 1185>T and 4769>A that 
define a unique mtDNA haplotype.  Another variant specific to RHAS Maori, 16216>C, 
also defined a unique haplotype.  These are the first Maori specific haplotypes to be 
recorded.  It is yet to be determined if these are Rakaipaaka specific haplotypes, or if 
they exist in the wider Maori community. 
 
3) Align and compare this sequence information with independent worldwide 
sequences to identify group differences, i.e. a mtDNA signature that is specific to 
Rakaipaaka Maori. 
These complete mtDNA sequences are the first documented for Maori.  Comparison 
with available Polynesian mtDNA sequences revealed extremely high similarity.  It was 
determined that Maori mtDNA shares all the same haplotype B4a1a1 markers across 
mtDNA as Polynesians, which was previously assumed but lacked proof from any 
complete Maori mtDNA analysis.  Validation of the 3 variants, C1185T, G4768A, and 
T16126C, in global databases identified these as being RHAS Maori specific.  These 
variants then define a unique mtDNA signature within the RHAS Maori community. 
 
4) Validate the signature in a larger community sample of the RHAS Maori 
population (n=400). 
Several of the variants identified have previously been associated with possible disease 
traits and susceptibility; 4769, 6261, 16189, 16519.  The previously associated diseases 
included; mental disorders (schizophrenia), prostate cancer, insulin resistance, diabetes, 
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and cardiomyopathy.  Of the four variants, the three exhibiting highest frequencies were 
genotyped in the larger RHAS Maori community. 
 
5) Correlate the validated mtDNA signature with metabolic traits (eg. BMI and 
diabetes). 
Three SNP’s of interest were genotyped in the wider RHAS cohort group; 4769, 16189, 
and 16519.  These SNP’s were present in large numbers in the extended RHAS 
database, C variant at 16189 was present in 88%, C variant at 16519 was present in 
96%, and the A variant at 4769 was present in 25%.  Hypothesis testing was conducted 
using variants 4769 and 16189, exploring possible correlations and associations with 
metabolic traits.  The A variant at 4769 was observed to associate with three 
cardiovascular disease traits (CHHD, TRIG, and Factor2), while the C variant at 16189  
appears to be associated with increased mean vitamin B12 levels as well as increased 
mean diastolic blood pressure.  In terms of disease association, neither SNP proved to 
have significant associations with metabolic traits such as waist hip ratio (WHR), BMI, 
or diabetes.  However a chi squared test indicated a possible trend between the variant 
4769>G and diabetes in the RHAS Maori community.  It appears that if the variant (G) 
is present at 4769 then it is more than 2 times less likely that an individual will develop 
diabetes.  
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5.2 Conclusion 
 
This study has answered all the specific objectives which were where laid out.  
Complete mitochondrial genome sequencing of 20 RHAS Maori has provided pioneer 
research into the mtDNA variation within New Zealand Maori.  It has been discovered 
that a unique mtDNA signature exists within RHAS Maori.  The three variants in this 
signature create the first unique Maori mtDNA haplotypes where there were originally 
thought to be none.  
 
Previously the only mitochondrial genetic information that had been extensively 
analysed in New Zealand Maori was HVRI sequences.  This study therefore documents 
the first ‘complete’ Maori mitochondrial genomes, those of 20 RHAS Maori 
individuals.  The mitochondrial variants discovered could ultimately lead to the 
development of early diagnostic and prevention of metabolic disorders, such as diabetes 
and cardiovascular disease, for New Zealand Maori.   
 
The goal now is to understand how these markers interact with environmental variables 
to increase the risk of metabolic syndrome.  Such an outcome may open the way to 
designing personalised intervention strategies (e.g. dietary) to increase the health and 
well-being of at risk individuals.  As part of RHAS program the final results from this 
research add great knowledge to both the health and ancestry aspects of the studies main 
aims. 
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Future Directions 
 
This project set out to screen the entire mtDNA of selected RHAS Maori individuals for 
unique genetic signature markers.  The screen revealed that alongside the expected 
haplogroup B4a1a1a (Polynesian) markers, RHAS Maori mtDNA contained a 
combination of signature variants.  When compared to global frequency data, the 
amount of variation within Maori mtDNA was found to be much higher than currently 
thought.  Genotyping analysis identified high frequencies of two of these variants within 
the RHAS Maori community.  Statistical correlation studies suggested that relationships 
exist between these variants and metabolic traits, such as diabetes, vitamin B12, and 
cardiovascular disease.  The identification of specific mtDNA markers and their 
possible associations with metabolic traits opens up many avenues of future research. 
 
Increase Sample Size 
There is now technology available which allows for the cheap and efficient 
resequencing of mitochondrial genomes.  By generating more sequence data the larger 
mtDNA variation noticed in this study can be testing in outside Maori communities.  
This could give information about whether mtDNA variation is different between Maori 
iwis.  This would also establish if the signature markers discovered in RHAS Maori, 
extend out in to the wider Maori community.  
 
Haplotype Simulations and Founding Population 
The finding of unique Maori mitochondrial haplotypes raises important evolutionary 
questions.  Identifying increased numbers of Maori specific haplotypes allows for 
simulations, such as that presented by Whyte et al., (2005), to be conducted.  This data 
would extrapolate on previous work, and it is likely the estimate of founding population 
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size would increase.  Applying complete Maori mtDNA in phylogenetic applications 
could also prove beneficial in population and evolutionary genetics. 
 
Variant Genotyping and Correlation 
This project investigated and identified metabolic associated mtDNA variants in a 
single Maori iwi.  Further research extending this into the wider NZ Maori community 
would be very informative.  Variants previously associated with disease were identified 
within the RHAS Maori community.  One identified variant, G4769A, has recently been 
implicated in schizophrenia.  It has also been previously noted that Maori have elevated 
incidences of schizophrenia compared to non-Maori.  This therefore presents the perfect 
opportunity to screen for mtDNA variants in Maori mental health patients. 
 
In RHAS Maori two variants, G4769A and T16189C, were found to associate with 
metabolic traits including; increased vitamin B12, increased mean diastolic blood 
pressure, and cardiovascular risk factors.  These two were the only variants genotyped 
in the wider RHAS Maori community.  There were however, several other variants of 
note that would be informative if screened.  These are two other RHAS Maori specific 
variants; 16126 and A16247G.  They appear to be in a similar linkage relationship as 
1185 and 4769.  These four SNP's together create 3 unique mtDNA haplotype that have 
not been identified previously.  From genotyping G4769A it was identified that it 
resides at a frequency of about 25% in RHAS Maori.  Having similar information for 
other variants, such as T16126C and A16247G, would prove highly beneficial.  It 
would also allow for further disease association studies, which could ultimately lead to 
the development of early diagnostic and prevention of metabolic disorders, such as 
diabetes and cardiovascular disease, for New Zealand Maori.   
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APPENDICES 
Appendix One 
 
Rakaipaaka Health and Ancestry Study fact sheet. 
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Appendix Two 
HVRI PCR Particulars 
HVRI PCR Primers: 
Forward L15975 5’-CTCCACCATTAGCACCCAAAGC-3’ 
Reverse H16517 5’-CCTGAAGTAGGAACCAGATG-3’ 
HVRI PCR Product: 
PCR product 543bps 
CTCCACCATTAGCACCCAAAGCTAAGATTCTAATTTAAACTATTCTCTGTTCTTTCATGGGGA
AGCAGATTTGGGTACCACCCAAGTATTGACTCACCCATCAACAACCGCTATGTATTTCGTAC
ATTACTGCCAGCCACCATGAATATTGTACGGTACCATAAATACTTGACCACCTGTAGTACAT
AAAAACCCAATCCACATCAAAACCCCCTCCCCATGCTTACAAGCAAGTACAGCAATCAACCC
TCAACTATCACACATCAACTGCAGCTCCAAAGCCACCCCTCACCCACTAGGATACCAACAA
ACCTACCCACCCTTAACAGTACATAGTACATAAAGCCATTTACCGTACATAGCACATTACAG
TCAAATCCCTTCTCGTCCCCATGGATGACCCCCCTCAGATAGGGGTCCCTTGACCACCATCCT
CCGTGAAATCAATATCCCGCACAAGAGTGCTACTCTCCTCGCTCCGGGCCCATAACACTTGG
GGGTAGCTAAAGTGAACTGTATCCGACATCTGGTTCCTACTTCAGG 
   NB: seq is from CRS, changed A to G to highlight Pst I restriction site 
 
Appendix Three 
1Kb Plus DNA Ladder from Invitrogen 
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Appendix Four 
 
Pico Green Standards 
 To make 1 ml of each standard: 
Add 100 μl DNA from Invitrogen kit to 4900 μl TE buffer = 2 μg/ml 
Add 100 μl of the above 2 μg/ml solution to 900 μl TE buffer = 0.2 μg/ml 
 
200 ng = 1000 μl of 2 μg/ml solution 
100 ng = 500 μl of 2 μg/ml solution + 500 μl TE buffer 
50 ng = 250 μl of 2 μg/ml solution + 750 μl TE buffer 
25 ng = 125 μl of 2 μg/ml solution + 875 μl TE buffer 
12.5 ng = 62.5 μl of 2 μg/ml solution + 937.5 μl TE buffer 
2.5 ng = 125 μl of 0.2 μg/ml solution + 875 μl TE buffer 
1 ng = 50 μl of 0.2 μg/ml solution + 950 μl TE buffer 
0.5 ng = 25 μl of 0.2 μg/ml solution + 975 μl TE buffer 
 
 
Appendix Five 
Long range PCR primers for Mitochip analysis 
Mito1-2 
Forward Primer Total Bp 
ACATAGCACATTACAGTCAAATCCCTTCTCGTCCC 
9307 Reverse Primer 
ATTGCTAGGGTGGCGCTTCCAATTAGGTGC 
Mito3 
Forward Primer Total Bp 
TCATTTTTATTGCCACAACTAACCTCCTCGGACTC 
7814 Reverse Primer 
CGTGATGTCTTATTTAAGGGGAACGTGTGGGCTAT 
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Testname: ENVGPICO
ID 1,2,3: Miles 15 RHAS samples    
Content Sample 
ID
Well Raw data Avg of 
replicates
SD of 
replicates
%CV Calculated conc. 
(ng/μl)
Blank H01 226 217 10 4.4 -0.230
Blank H02 207 -0.263
S1 Std A01 58534 55165 3369 6.1 100.538
S1 Std A02 51796 88.893
S2 Std B01 49098 50670 1572 3.1 84.230
S2 Std B02 52242 89.664
S3 Std C01 34199 35066 867 2.5 58.482
S3 Std C02 35933 61.479
S4 Std D01 16934 17341 407 2.3 28.644
S4 Std D02 17748 30.051
S5 Std E01 5947 5911 37 0.6 9.657
S5 Std E02 5874 9.530
S6 Std F01 2729 2977 248 8.3 4.095
S6 Std F02 3225 4.952
S7 Std G01 802 876 74 8.4 0.765
S7 Std G02 949 1.019
X1 mt41 A03 8067 8324 257 3.1 13.320
X1 mt41 A04 8581 14.209
X2 mt42 B03 9222 8894 328 3.7 15.317
X2 mt42 B04 8566 14.183
X3 mt43 C03 8703 8970 267 3.0 14.420
X3 mt43 C04 9236 15.341
X4 mt44 D03 8970 8948 23 0.3 14.881
X4 mt44 D04 8925 14.803
X5 mt45 E03 8990 9344 354 3.8 14.916
X5 mt45 E04 9697 16.137
X6 mt46 F03 7960 8167 207 2.5 13.136
X6 mt46 F04 8373 13.849
X7 mt47 G03 8166 8582 416 4.8 13.492
X7 mt47 G04 8998 14.929
X8 mt50 H03 7481 7483 2 0.0 12.308
X8 mt50 H04 7485 12.315
X9 mt51 A05 3638 4097 459 11.2 5.666
X9 mt51 A06 4556 7.253
X10 mt52 B05 7850 7800 51 0.6 12.945
X10 mt52 B06 7749 12.771
X11 mt53 C05 6124 7396 1272 17.2 9.963
X11 mt53 C06 8667 14.357
X12 mt54 D05 5165 5520 355 6.4 8.305
X12 mt54 D06 5874 9.530
X13 mt55 E05 4421 4564 143 3.1 7.019
X13 mt55 E06 4706 7.512
X14 mt56 F05 7128 7433 305 4.1 11.698
X14 mt56 F06 7737 12.750
X15 mt57 G05 8021 7651 370 4.8 13.241
X15 mt57 G06 7281 11.962
12.2
8.9
7.3
12.2
12.6
15.5
13.5
14.2
12.3
6.5
12.9
2008/12/19   14:54:18
Avg Conc 
(ng/μl)
13.8
14.7
14.9
14.8
Appendix Six 
 
Example Pico-Green assay output showing average the concentrations for 15 RHAS 
Maori HVRI PCR products. 
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Appendix Seven 
 
Sample ID’s, freezer position, and working stock concentrations for the 20 RHAS 
Maori DNA specimens selected for Mitochip array analysis. 
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AY604156 AY604141 AY604126 AY604111 AY604096 AY604081
AY604155 AY604140 AY604125 AY604110 AY604095 AY604080
AY604154 AY604139 AY604124 AY604109 AY604094 AY604079
AY604153 AY604138 AY604123 AY604108 AY604093 AY604078
AY604152 AY604137 AY604122 AY604107 AY604092 AY604077
AY604151 AY604136 AY604121 AY604106 AY604091 AY604076
AY604150 AY604135 AY604120 AY604105 AY604090 AY604075
AY604149 AY604134 AY604119 AY604104 AY604089 AY604074
AY604148 AY604133 AY604118 AY604103 AY604088 AY604073
AY604147 AY604132 AY604117 AY604102 AY604087 AY604072
AY604146 AY604131 AY604116 AY604101 AY604086 AY604071
AY604145 AY604130 AY604115 AY604100 AY604085
AY604144 AY604129 AY604114 AY604099 AY604084
AY604143 AY604128 AY604113 AY604098 AY604083
AY604142 AY604127 AY604112 AY604097 AY604082
Adele Whyte Data Set
Appendix Eight 
 
Catalogue of GENBANK Accession number’s Maori HVRI mtDNA sequences used in 
variant frequency and haplotype analyses. 
 
1. mtDNA HVRI data set from Whyte et al., (2005). 
 
 
 
 
 
 
 
 
 
 
 
2. mtDNA HVRI data set from Pierson (Unpublished Data). 
 
 
 
 
 
 
 
 
  
Maori Tongan Cook Is Samoan Solomon Is Niuean Tokelauan Fijian
EF077399 EF077401 EF077402 EF077400 EF077389 EF077386 EF077371 EF077363
EF077393 EF077398 EF077394 EF077396
EF077385 EF077397 EF077388 EF077395
EF077378 EF077392 EF077387 EF077391
EF077369 EF077384 EF077381 EF077390
EF077368 EF077375 EF077377 EF077383
EF077367 EF077374 EF077376 EF077382
EF077365 EF077370 EF077362 EF077380
EF077361 EF077379
EF077360 EF077373
EF077359 EF077372
EF077366
EF077364
EF077358
EF077357
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Appendix Nine 
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